Protein tags, ligands, and method of use thereof

Chimeric small molecules with engineered protein-tags from the Cl domain of Protein Kinase C enable efficient, non-immunogenic, and functional protein modification for CRISPR-based technologies and CAR T cell engineering.

WO2026236644A1PCT designated stage Publication Date: 2026-11-12THE BRIGHAM & WOMEN S HOSPITAL INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027329
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing protein-tags are large in size, interfere with native protein structure and function, have non-human origins leading to immunogenicity concerns, and are not suitable for emerging applications like CRISPR-based technologies and CAR T cell engineering.

Method used

Development of chimeric small molecules that undergo group transfer reactions with engineered protein-tags derived from the Cl domain of Protein Kinase C, allowing for covalent attachment of transfer moieties while maintaining translational entropy, with a size of less than 150 amino acids and human origin.

Benefits of technology

The engineered protein-tags facilitate site-specific labeling, modification, and functional screening of proteins without altering their native functions, enabling applications in CRISPR-based technologies and reducing immunogenicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027329_12112026_PF_FP_ABST
    Figure US2026027329_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to chimeric small molecules comprising a protein-tag binding moiety, transfer moiety, linker, and an electrophilic reactive group, wherein the chimeric small molecule undergoes a group transfer reaction with the protein-tag, resulting in electrophilic transfer of the transfer moiety to the protein-tag and elimination of the protein-tag binding moiety. The present disclosure also relates to an engineered protein-tag and elimination of the protein-tag binding moiety. The present disclosure also relates to an engineered protein-tag, comprising a C1 domain of Protein Kinase C, wherein the C1 domain comprises a benzolactam binding pocket comprising a cysteine residue. The chimeric small molecules and protein-tags, according to the disclosure, find use in various methods such as substrate modification and screening.
Need to check novelty before this filing date? Find Prior Art

Description

PROTEIN TAGS, LIGANDS, AND METHODS OF USE THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 803,282 filed May 9, 2025. The entire contents of the above-identified applications are hereby fully incorporated herein by reference.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The contents of the electronic sequence listing (“BROD-6100WP_ST26.xml”; Size is 2,903 bytes and it was created on April 27, 2026) is herein incorporated by reference in its entirety.TECHNICAL FIELD

[0003] The subject matter disclosed herein is generally directed to protein-tags and chemical ligand compounds.BACKGROUND

[0004] Protein-tags and their small molecule ligands are valuable tools for studying functions of a given protein-of-interest (POI). However, most contemporary tags suffer from several limitations, such as their large size which may interfere with the POI’s native structure and / or function. Emerging applications such as CRTSPR-based technologies and chimeras for post-translational modifications require significantly smaller protein-tags with ligands possessing druglike properties. Another limitation of contemporary tags is their non-human origin, which limits their applications in fields such as CAR T cell engineering, due to concerns for immunogenicity. Accordingly, a need exists for new and improved protein-tags.

[0005] Citation or identification of any document in this application is not an admission that such a document is available as prior art to the present disclosure.SUMMARY

[0006] In an aspect, the present disclosure provides a chimeric small molecule according to a formula: A-Ll-E-T, A-E-Ll-T, or A-L1-E-L2-T; wherein A is a protein-tag binding moiety; T is a transfer moiety; LI and L2 are each a linker; and E is an electrophilic reactive group , whereinthe chimeric small molecule undergoes a group transfer reaction with the protein-tag resulting in electrophilic transfer of the transfer moiety to the protein-tag and elimination of the protein-tag binding moiety.

[0007] In an embodiment, the protein-tag bound by the protein-tag binding moiety is derived from a Cl domain of Protein Kinase C (PKC). In an embodiment, the Cl domain of PKC is a human Cl domain of PKC.

[0008] In an embodiment, the protein-tag binding moiety is 12-O-Tetradecanoylphorbol-13-acetate (TP A) or a benzolactam analog. In an embodiment, the protein-tag binding moiety is:

[0009] In an embodiment, the transfer moiety binds a substrate of interest. The substrate of interest may be a protein, optionally wherein the protein is BRD4, BRD2, BRD3, FKBP12F36V, tau, alpha-synuclein, HSP27, alphaAC, alphaBC, NF-L, CREB, DDX3X, PFK1, PFKFB3, PGK1, G6PD, KRAS, PKM2, MDH1, FH, KRT18, RRM1, PRPS1, Pol eta, AND-1, FEN1, TOP2A, RAD 18, PARG, NRF1, MTA1, YTHDC1, YTHDF1, YTHDF2, MITF, FBL, YAP, LATS2,GLI2, RACK1, HDAC1, M0RC2, STAT3, SLC7A11, FTH, TRFC, c-Jun, ZEB1, TAB3, MEK2, CHK2, PLK1, HGS, SKP2, p27, ZNF263, 0TX2, BMI1, S0X2, F0XA1, DOT1L, p65, STAT5, FOXK1, PDLIM7, FOXO1, CRTC2, PGC-lalpha, ERRgamma, ChREBP, p53, CaMKIdelta, AKT, SAMHD1, STING, IRF5, MAVS, vimentin, STAT6, IKKB, S6K1, RIPK1, RIPK3, GSDMD, or streptavidin.

[0010] In an embodiment, the transfer moiety is:J O .C!, or analogs thereof.

[0011] In an embodiment, the transfer moiety is a detectable label or an affinity label. In an embodiment, the transfer moiety is an azide, alkyne, biotin, or a cyanine dye.

[0012] In an embodiment, LI and L2 are independently selected from alkane, alkene, alkyne, amine, ether, thiol, sulfone, carbonyl, acyl, ketone, carboxylate ester, amide, enone, anhydride, imide, PEG, and combinations thereof. LI and L2 optionally are rigid molecules.

[0013] In an embodiment, the electrophilic reactive group is selected from N-acyl-N-alkyl sulfonamide (NASA), dibromophenyl benzoate, orN-sulfonyl pyridone.

[0014] In an embodiment, the electrophilic reactive group is selected fromOo i ° il ... A ,xS AzhL A "'T V< ~ \ ^ 6}ON , and ON

[0015] In an embodiment, the electrophilic reactive group has the formula:owherein Ri is selected from C-O, SO2, Me-C-O, or Me-SCh, R2 is selected from H, alkane, alkene, alkyne, amine, nitrile, nitro, ether, alcohol, thiol, sulfone, sulfonate, halogen, carbonyl, acyl, ketone, carboxylate ester, amide, enone, anhydride, imide, cyclic hydrocarbon, an unsaturated cyclic hydrocarbon, a heterocycle, one or more fused rings thereof; an aliphatic halide such as -OCF2CI or any combination thereof, and the benzene ring is optionally substituted at any position.

[0016] In an embodiment, the electrophilic reactive group is selected from the group consisting of:

[0017] In an embodiment, the amino acid is cysteine, and the electrophilic reactive group is selected from the group consisting of:

[0018] In an embodiment, the amino acid is lysine, and the electrophilic reactive group is:Ox ZO “fR< 'N Mewherein Ri is selected from the group consisting of:wherein R2 is selected from the group consisting of:

[0019] In an embodiment, the amino acid is lysine, and the electrophilic reactive group is selected from the group consisting of:A' -A A’ A®W~3fle • 31 »■ 3t b 3^-32$ 34a J4c

[0020] In an embodiment, the electrophilic reactive group iswherein X is selected from the group consisting of:O~S=O HN=S=Oi R 3R2R2wherein Rl, R2, R3 each independently of an alkyl group, aryl group, or a heteroatom optionally O, N, or S.

[0021] In an embodiment, the electrophilic reactive group isPh'^^'S'N'A^IRwherein R is selected from the group consisting of:

[0022] In an embodiment, the electrophilic reactive group islo — s — oIPh or analog thereof.

[0023] In an embodiment, the electrophilic reactive group is

[0024] In an embodiment, the electrophilic reactive group isL1 £L2R N'!iH , wherein R is selected from the group consisting of:"N"' H O=P~OMe 0=4=0 i T O CF3 oXN'"1"'S' O=?=O O-S-O 0CF3

[0025] In an embodiment, the electrophilic reactive group isB 1 .A My J",;^* ,oranalog thereof.

[0026] In an embodiment, the protein-tag binding moiety, the transfer moiety, or at least one of LI and L2 comprises a bio-orthogonal group. The bio-orthogonal group may optionally be selected from:

[0028] In an aspect, the present disclosure provides an engineered protein-tag, comprising a Cl domain of Protein Kinase C, wherein the Cl domain comprises a benzolactam binding pocket comprising a cysteine residue. In an embodiment, the cysteine residue is located on a surface of the benzolactam binding pocket. In an embodiment, the C 1 domain comprises an L254C mutation.

[0029] In an embodiment, the protein-tag comprises no more than 150 amino acids. In an embodiment, the protein-tag comprises about 150 amino acids, 145 amino acids, 140 amino acids, 135 amino acids, 130 amino acids, 125 amino acids, 120 amino acids, 115 amino acids, 110 amino acids, 105 amino acids, 100 amino acids, 95 amino acids, 90 amino acids, 85 amino acids, 80 amino acids, 75 amino acids, 70 amino acids, 65 amino acids, 60 amino acids, 55 amino acids, 50 amino acids, 45 amino acids, 40 amino acids, 35 amino acids, 30 amino acids, 25 amino acids, or 20 amino acids. In an embodiment, the protein-tag comprises about 50 amino acids.

[0030] In an embodiment, the protein-tag comprises an amino acid sequence of SEQ ID NO: 1. In an embodiment, the protein-tag is encoded by a nucleic acid sequence of SEQ ID NO: 2.

[0031] In an embodiment, the cysteine is capable of undergoing group transfer reaction with a ligand comprising a protein-tag binding moiety, an electrophilic linker, and a transfer moiety, whereby the transfer moiety is electrophilically transferred to the protein-tag and the protein-tag binding moiety is eliminated.

[0032] In an embodiment, the ligand is the chimeric small molecules of the present disclosure.

[0033] In an embodiment, the present disclosure provides a protein comprising the protein-tag of the present disclosure, wherein the engineered protein-tag is connected to the protein by chemogenetic fusion or chemical conjugation. The protein may optionally be a kinase, a methyltransferase, an acetyltransferase, a glycosyltransferase, an aminotransferase, a phosphatase, a peptidase or protease, a glycosidase, a lipase, a nuclease, an esterase, an amylase, aphosphodiesterase, a dehydrogenase, an oxidase, a reductase, a peroxidase, a hydroxylase, a monooxygenase, a catalase, a decarboxylase, an aldolase, a dehydratase, a synthase, a hyaluronate lyase, an epimerase, a racemase, a mutase, a topoisomerase, a protein disulfide isomerase, a ligase, an aminoacyl-tRNA synthetase, a carboxylase, a synthetase, or a ubiquitin ligase.

[0034] In an embodiment, the protein-tag does not alter the native functions of the protein.

[0035] In an aspect, the present disclosure provides a method of labeling a protein-tag comprising: delivering the chimeric small molecule of the present disclosure to a protein-tag; and transferring the transfer moiety to the protein-tag via a group transfer reaction that results in elimination of the protein-tag binding moiety, whereby the protein-tag is labeled with the transfer moiety. In an embodiment, the group transfer reaction occurs between the chimeric small molecule of the present disclosure and a cysteine or lysine residue of a protein-tag of the present disclosure.

[0036] In an aspect, the present disclosure provides a method of modifying a protein comprising: expressing a protein comprising the protein-tag of the present disclosure; delivering the chimeric small molecule comprising a protein-tag binding moiety capable of binding the protein-tag, an electrophilic linker, and a transfer moiety; labeling the protein-tag with the transfer moiety via a group transfer reaction that results in elimination of the protein-tag binding moiety. In an embodiment, the protein-tag is connected to the protein via chemogenetic fusion or chemical conjugation of the protein-of-interest.

[0037] In an aspect, the present disclosure provides a method of modifying a target substrate in a cell comprising: expressing a protein comprising the protein-tag of the present disclosure in a cell; delivering a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker and a substrate binding moiety; labeling the protein with the substrate binding moiety and eliminating the protein-tag binding moiety via a group transfer reaction; inducing proximity between the protein and a target substrate via binding of the substrate binding moiety to the target substrate; and modifying the target substrate by the protein. In an embodiment, protein is a kinase, a methyltransferase, an acetyltransferase, a glycosyltransferase, an aminotransferase, a phosphatase, a peptidase or protease, a glycosidase, a lipase, a nuclease, an esterase, an amylase, a phosphodiesterase, a dehydrogenase, an oxidase, a reductase, a peroxidase, a hydroxylase, a monooxygenase, a catalase, a decarboxylase, an aldolase, a dehydratase, a synthase, a hyaluronatelyase, an epimerase, a racemase, a mutase, a topoisomerase, a protein disulfide isomerase, a ligase, an aminoacyl-tRNA synthetase, a carboxylase, a synthetase, or a ubiquitin ligase.

[0038] In an aspect, the present disclosure provides a method for site-specific protein labeling comprising expressing a protein comprising the protein-tag of the present disclosure in a cell or cell population; delivering a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker, and a detectable label or affinity label; labeling the protein with the detectable label or affinity label and eliminating the protein-tag binding moiety via a group transfer reaction; detecting the labeled protein in the cell using microscopy or affinity-based detection.

[0039] In an aspect, the present disclosure provides a method for endogenous protein degradation screening, comprising inserting a nucleic acid encoding the protein-tag of the present disclosure into one or more genomic loci encoding an endogenous protein(s) in a cell or cell population; delivering a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker, and a degradation-inducing moiety; labeling the endogenous protein(s) with the degradation-inducing moiety and eliminating the protein-tag binding moiety via a group transfer reaction; exposing the cell or cell population to a selective pressure; identifying cells displaying a phenotype change under the selective pressure; sequencing the cell or cell population to determine which tagged endogenous protein(s), when degraded, are associated with the phenotype change.

[0040] In an aspect, the present disclosure provides a method for functional screening of induced protein-substrate interactions comprising: inserting a nucleic acid encoding the proteintag of the present disclosure into one or more genomic loci encoding an endogenous protein(s) in a cell or cell population; delivering to the cell or cell population a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker, and a substrate binding moiety; labeling the endogenous protein(s) with the substrate binding moiety and eliminating the proteintag binding moiety via a group transfer reaction, thereby inducing proximity between the tagged endogenous protein(s) and the substrate; identifying cells displaying a phenotype change resulting from the induced proximity; sequencing the cell or cell population to determine which tagged endogenous protein are associated with the phenotypic change.

[0041] In an aspect, the present disclosure provides a method for functional screening of post-translational modifications comprising; inserting a nucleic acid encoding the protein-tag of any ofthose the present disclosure into one or more genomic loci encoding an endogenous protein(s) in a cell or cell population; delivering to the cell or cell population a ligand comprising a protein-tag binding moiety, an electrophilic linker, and an enzyme binding moiety; labeling the endogenous protein(s) with the enzyme binding moiety and eliminating the protein-tag binding moiety via a group transfer reaction, thereby inducing proximity between an enzyme capable of catalyzing a post-translational modification and the endogenous protein(s); identifying cells displaying a phenotypic change resulting from the induced proximity; sequencing the cell or cell population to determine which tagged endogenous protein(s), when modified, are associated with the phenotypic change.

[0042] In an aspect, the present disclosure provides a kit for protein-tagging and proximity-induced molecular transfer comprising: a nucleic acid encoding a protein-tag of the present disclosure, or one or more nucleic acids encoding one or more proteins comprising the proteintag; a chimeric small molecule comprising a protein-tag binding moiety capable of binding the protein-tag, an electrophilic linker, and a transfer moiety; and wherein the chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety.

[0043] In an aspect, the present disclosure provides a kit for conducting programmable nuclease-based protein-tagging screens comprising: a vector encoding a RNA-guided programmable nuclease; a library of guide RNA templates or vector system for expressing guide RNAs targeting a set of genomic loci encoding endogenous proteins; a donor template comprising a nucleic acid sequence encoding a protein-tag of the present disclosure; a chimeric small molecule comprising a protein-tag binding moiety capable of binding the protein-tag, an electrophilic linker, and a transfer moiety; and wherein the chimeric small molecule is configured to bind the proteintag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the proteintag binding moiety. In an embodiment, the RNA-guided programmable nuclease is a CRISPR-Cas, a prime editor, an OMEGA system, a CAST system, a TIGR system, or a non-LTR retrotransposon system.

[0044] In an aspect, the present disclosure provides a modular kit for protein-tagging and molecular transfer comprising: a nucleic acid encoding a protein-tag of the present disclosure, or one or more nucleic acids encoding one or more proteins comprising the protein-tag; a set of atleast two protein-tag binding moieties; a set of at least two electrophilic linkers; a set of at least two transfer moieties; reagents for conjugating the precursors to form chimeric small molecules, wherein each chimeric small molecule comprises: a protein-tag binding moiety; an electrophilic linker; and a transfer moiety; wherein the chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety.

[0045] In an aspect, the present disclosure provides a kit for cell-based phenotypic screening: one or more cell lines stably expressing one or more proteins comprising a protein-tag of the present disclosure; a library of chimeric small molecules, each chimeric small molecule comprising a protein-tag binding moiety; an electrophilic linker; and a transfer moiety; wherein the chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety.

[0046] In an aspect, provided the present disclosure provides electrophilic reactive linkers. In an embodiment, the electrophilic reactive linker is according to the formula Li-E, E-Li, or Li-E-L2, wherein E is an electrophilic reactive group and wherein Li and L2 are linking molecules.

[0047] In an embodiment, the E reacts with a nucleophilic reactive group. The E may be configured to facilitate attachment of the electrophilic reactive group and all or a portion of Li or L2 to a Cysteine, Serine, Threonine, Tyrosine, Glutamic Acid, Aspartic Acid, Lysine, Arginine, Histidine, or a Methionine amino acid on a polypeptide.

[0048] In an embodiment, the linking molecules Li and L2 are independently selected from alkane, alkene, alkyne, amine, ether, thiol, sulfone, carbonyl, acyl, ketone, carboxylate ester, amide, enone, anhydride, imide, PEG, or any combination thereof. The linkers Li and / or L2 may comprise rigid molecules.

[0049] In an embodiment, the electrophilic reactive group is selected from:q 9, or analogs thereof.

[0050] In an embodiment, the E is configured to facilitate attachment of all or a portion of Li or L2 to a cysteine, and wherein the E is:

[0051] In an embodiment, the E is configured to facilitate attachment of all or a portion of Li or L2 to a lysine, and wherein the E is:F3CX

[0052] In an embodiment, the electrophilic reactive linker further comprises a bio-orthogonal group. The bio-orthogonal group may be selected from tetrazines, triazines, cyclooctenes, cyclopropenes and diazo. In an embodiment, the bio-orthogonal group is selected from the group consisting of:

[0053] In an embodiment, the electrophilic reactive linker is capable of covalently labeling a target polypeptide. In an embodiment, labeling comprises covalently bonding to a nucleophile disposed on the target polypeptide.

[0054] These and other aspects, objects, features, and advantages of the example embodiments will become apparent to those having ordinary skill in the art upon consideration of the following detailed description of example embodiments.BRIEF DESCRIPTION OF THE DRAWINGS

[0055] An understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention may be utilized, and the accompanying drawings of which:

[0056] FTG. 1 A-C: (A) Size of existing covalent chemogenetic tags. (B) example protein-tag based on binary complex guided group transfer labeling. (C) Example applications of protein-tags.

[0057] FIG. 2A-E: (A) Structures of TPA and benzolactam probes (12, 13 and 14). (B) Circular dichroism spectra of Cl domain in the presence or absence of zinc ions. (C) Microscale thermophoresis for TPA and 12. (D) BLI sensograms for dose dependent binding of 14. (E) Competition-based BLI experiment for 12 and 13.

[0058] FIG. 3: Improved synthetic route to access benzolactam scaffold.

[0059] FIG. 4A-E: (A) Crystal structure of Cl domain with a benzolactam analog. The grayed regions point to sites of cysteine engineering. (B) Structures for cTag probes 15 and 16 (C) Schematic of biochemical labeling of cTag by probe 15 (left) and intact mass analysis of cTag treated with DMSO and compound 15 (right). The theoretical mass adduct of labeled cTag is +194 Da. (D) Kinetic analysis of cTag labeling by 16. (E) Dose-dependent cellular labeling of cTag by 15, monitored via click reaction with DBCO-Cy5.

[0060] FIG. 5A-E: (A) Downstream MAPK signaling (measured via pERK) of cTag and HaloTag-fused KRASG12D. (B) Schematic of protein editing by recruiting PTM writers or erasers with noncovalent (top) or group transfer tags (bottom). (C) Structures of group transfer (17) and non-covalent (18) cTag-JQl probes for targeted BRD4 phosphorylation. (D-E) In-cellular phosphorylation of BRD4 with cTag fused Abl utilizing compounds 17 (D) and 18 (E), respectively.

[0061] FIG. 6A-E: (A, B)BLI competition assays for compounds 12 (A) and 13 (B). (C)MST data for compound 13. (D) Library of C1B mutants fused with MBP. All proteins were expressed in BL21(DE3) expression host and purified using Ni-NTA affinity chromatography. (E) Library of benzolactam analogs with binding pocket targeting electrophiles (compounds SI.1-1.9) or surface targeting electrophiles (S 1.10- 1.11)

[0062] FIG. 7A-E: (A) MS spectra for labeling of C l B_delta_M2_(L251C) with probes Sl.l, SI.2 and SI.4. (B) MS spectra for labeling of ClB_delta_M6_(L250C and W252H) with probes Sl.l, SI.2 and SI.4. (C) MS spectra for labeling of ClB_delta_M8_(F243H,L250C and W252H) with probes Sl.l, SI.2 and SI.4. (D,E) MS spectra for labeling of ClB_delta_L254C with compound 16.

[0063] FTG. 8A-F: MS spectra of labeling of probes SI.5 (A), SI.5 (B), SI.11 (C), SI.6 (D), SI.9 (E), and S1.7 (F) with C1B L250A, W252C mutant.

[0064] FIG. 9A-F: MS spectra of labeling of probes SI.5 (A), SI.5 (B), SI.11 (C), SI.6 (D), SI.9 (E), and S4.1 (F) with C1B L250H, W252C mutant.

[0065] FIG. 10A-F: MS spectra of labeling of probes SI.5 (A), SI.5 (B), SI.11 (C), SI.6 (D), SI.9 (E), and S4.1 (F) with C1B L250T, W252C mutant.

[0066] FIG. 11A-C: (A) Intact mass LCMS analysis of cTag treated with compound S6.1. (B) Pulldown of MBP-cTag using probe 15. (C) Western blot analysis of proteome-wide PKC substrate phosphorylation levels using anti-Phospho-PKC substrate motif after treatment with probe 15.

[0067] FIG. 12A-H. LCMS traces for exemplary intermediates and compounds.

[0068] FIG. 13A-L NMR spectra of exemplary compounds.

[0069] FIG. 14A-D: (A) An example protein-tag based on binary complex labeling. (B) Bump-hole strategy to obtain orthogonal protein-tags. (C-D) Validation approaches and applications of protein-tags.

[0070] FIG. 15A-E: (A) Structure of benzolactam bumped analogs to develop orthogonal tags. (B) cTag variants (cVl-6) with a hole in the binding pocket via sequential glycine incorporations. (C) Schematic of ABPP workflow. (D) Cellular imaging of KRAS* and halotag-fused KRAS*, * represents oncogenic variants (like, G12D) (E) Dose-dependent cellular labeling of cTag.GFP by compound 16.

[0071] FIG. 16A-C: (A) Haptenizing chimeras platform with CAR T or NK cells with exemplary protein-tags. (B, C) Constructs for CARNK (B) and T (C) cells with exemplary proteintags.

[0072] The figures herein are for illustrative purposes only and are not necessarily drawn to scale.DETAILED DESCRIPTION OF THE EXAMPLE EMBODIMENTS OVERVIEW

[0073] Protein-tags and their small molecule ligands are essential research tools, as less than to approximately 10 % of the proteome has small-molecule ligands, most of which are enzymeinhibitors. [1-2] While extant covalent protein-tags (e.g., HaloTag, SNAP-Tag, Figure 1 A)[3] have been impactful, emergent applications require significantly smaller tags with drug-like ligands. For example, studies on several high therapeutic value signaling proteins that lack ligands (e.g., transcription factors) can benefit from tags, but these proteins are nearly the same size as contemporary tags (~33 kDa, Figure 1A) and function via packed protein complexes that contemporary tags will disrupt. [4] CRISPR-based technologies are advancing towards efficient genome-wide, pooled knock-in screens, but contemporary tags are too large for both the technology and several protein-of-interest (POI).[5] While contemporary tags have enabled rapid evaluation of the efficacy of proximity induction between POI and large ubiquitin-ligase complexes for POI degradation, emergent chimeras for other post-translational modifications (e.g., phosphorylation, acetylation) involve smaller-sized complexes that require smaller tags. [6] Finally, while contemporary tags are of non-human origin, several applications of protein-tags (e.g., in CAR T cell engineering) require sequences of human origin to avert immunogenicity. [7]

[0074] The present disclosure provides novel protein-tags and chimeric small molecules that overcome the above-mentioned limitations. As used herein, a 'protein-tag' refers to a peptide, oligopeptide, polypeptide, protein domain, or protein that can be fused, attached, conjugated, expressed, or linked to a protein of interest (POI), and which specifically interacts with designated ligands to facilitate detection, purification, visualization, manipulation, modification, screening or any other relevant modification of itself and / or the POI. In particular, the protein-tags of the present disclosure can be characterized by any one or more of their small size (less than 150 amino acids), human origin, and ability to undergo group transfer reactions with specified ligand. In an embodiment, the protein-tag is a chemogenetic tag. As used herein, 'chemogenetic tags' refer to genetically encoded protein-tags with the ability to undergo group transfer reactions with their ligands, resulting in covalent attachment of a transfer moiety to the tag. In an embodiment, Applicants report an example protein-tag (cTag) of about 50 amino acids and its drug-like ligands (Figure IB).

[0075] The ligands of this tag exhibit a transferase-like reactivity and, unlike many covalent ligands, are neutral from a translational entropy standpoint. As used herein, 'transferase-type reactivity' refers to a reaction mechanism analogous to enzymatic transferase reactions, wherein a moiety is transferred from a donor molecule to an acceptor molecule. In the context of thisinvention, it specifically refers to the ability of the chimeric small molecules to transfer the transfer moiety to the protein-tag via a covalent bond formation at a reactive amino acid residue, with concurrent elimination of the protein-tag binding moiety. Covalent ligands operate by an associative mechanism, but these group transfer ligands operate by an associative-dissociative mechanism, which results in the same number of species after the reaction. In an embodiment, the tag does not perturb the activity of even small signaling proteins (21 kDa) and can be used to evaluate emergent induced proximity modalities further (Figure 1C). Furthermore, tags of similar length have been successfully used with CRISPR-based knock-in technologies

[0018] and these studies will advance efforts to develop genome-wide knock-in screens. Employing a bump-hole and directed evolution strategies can yield orthogonal protein-tags, which may have applications in synthetic biology and cell engineering.ENGINEERED PROTEIN-TAG

[0076] In an aspect, engineered protein-tags are provided herein. In an embodiment, an amino acid of an engineered protein-tag can undergo a group transfer reaction with a ligand such as the chimeric small molecules described herein. The protein-tag may be a peptide, oligopeptide, polypeptide, protein domain, or protein. The protein-tag may be fused, attached, conjugated, expressed, or linked in any relevant manner to a protein of interest (POI). The protein-tag may facilitate detection, purification, visualization, manipulation, modification, screening, or any other relevant modification of itself and / or the POI it may be connected to. For example, the protein-tag may facilitate affinity purification, immunodetection, fluorescence visualization, chemogenetic labeling, targeted degradation, and investigation of protein-protein interactions.

[0077] In an embodiment, the engineered protein-tag is derived from a Cl domain of Protein Kinase C (PKC) (“cTag”). As used herein, the 'Cl domain of Protein Kinase C (PKC)' refers to a conserved structural motif of approximately 50 amino acids that forms a compact globular domain containing two zinc finger-like structures coordinated by histidine and cysteine residues. Hurley et al. “Taxonomy and function of Cl protein kinase C homology domains." Protein Science, 6(2), 477-480. The Cl domain naturally functions as a diacylglycerol (DAG) and phorbol ester binding module in PKC isoforms and is characterized by a binding pocket lined with hydrophobic residues that accommodates the hydrophobic moieties of DAG or phorbol esters, while specific polar residues form hydrogen bonds with the polar groups of these ligands. The protein-tag may bederived from a Cl domain from any human PKC isoform, as well as variants with at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a native human Cl domain that retain the ability to fold into the characteristic zinc finger-like structure and bind to Cl domain ligands such as phorbol esters or benzolactams.

[0078] In an embodiment, the protein-tag is derived from a Cl domain of human PKC alpha, beta, gamma, or delta. In an embodiment, the Cl domain is a human PKCoc CIA (residues 37-86) or C1B (residues 102-151). In an embodiment, the protein-tag is derived from a Cl domain of human PKCb C1B. In an embodiment, the cysteine is introduced at a position located on a surface proximal to the binding pocket and positioned to enable the group transfer location when the protein-tag moiety is bound. In an embodiment, the cysteine is engineered into a position within or proximal to (within about 10 A of) the binding pocket of the Cl domain, where the thiol side chain (-SH) is oriented such that it can participate in nucleophilic attack on an electrophilic group presented by a ligand bound in the binding pocket. The cysteine residue may be located within the binding pocket or on a surface region adjacent to the binding pocket, positioned to enable the group transfer reaction when a ligand is bound. The positioning of this cysteine creates a microenvironment that enhances its nucleophilicity and reactivity compared to other cysteine residues in the protein. In an embodiment, the Cl domain comprises an L254C mutation in the C1B domain of human PKC5.

[0079] In an embodiment, the protein-tag comprises no more than 150 amino acids. In an embodiment, the protein-tag comprises about 150 amino acids, 145 amino acids, 140 amino acids, 135 amino acids, 130 amino acids, 125 amino acids, 120 amino acids, 115 amino acids, 110 amino acids, 105 amino acids, 100 amino acids, 95 amino acids, 90 amino acids, 85 amino acids, 80 amino acids, 75 amino acids, 70 amino acids, 65 amino acids, 60 amino acids, 55 amino acids, 50 amino acids, 45 amino acids, 40 amino acids, 35 amino acids, 30 amino acids, 25 amino acids, or 20 amino acids. In an embodiment, the protein-tag comprises about 50 amino acids.

[0080] In an embodiment, the protein-tag comprises the sequences shown below:Table 1.SEQIDNO 1 HRFKVYNYMSPTFCDHCGSLLWGCVKQGLKCEDCGMNVHHKCREKVANLCSEQ ID NO 2 caccgattcaaggtttataactacatgagccccaccttctgtgaccactgtggcagtttgctctggggatgtgtgaa gcagggattaaagtgtgaagattgtggcatgaatgtgcaccacaaatgccgggagaaggtggccaacctgtgt

[0081] In an embodiment, the protein-tag comprises an amino acid sequence of SEQ ID NO: 1. In an embodiment, the protein-tag is encoded by a nucleic acid sequence of SEQ ID NO: 2. PROTEIN COMPRISING A PROTEIN-TAG

[0082] In an aspect, proteins are provided herein comprising any engineered protein-tag disclosed herein. The protein-tag may be fused, attached, conjugated, expressed, or linked in any relevant manner to the protein. For example, the protein-tag and protein may be linked or connected by genetic fusion, cloning, expression vectors, or chemical conjugation. In an embodiment, the protein-tag is connected to the protein by chemogenetic fusion or chemical conjugation. In an embodiment, chemical conjugation can include sortase-mediated ligation, maleimide-thiol coupling, azide-alkyne cycloaddition (including copper-catalyzed and strain-promoted variants), NHS-ester amine coupling, or other bioconjugation chemistries known in the art. In an embodiment, a reactive handle can be installed on the protein-tag, on the protein, or on both, to enable chemical conjugation under physiologically compatible conditions or other suitable conjugation conditions. In an embodiment, the protein-tag is connected to the protein at the N-terminus or C-terminus.

[0083] The protein comprising the protein-tag may be any protein of interest (POI). For example the protein may be a kinase, a methyltransferase, an acetyltransferase, a glycosyltransferase, an aminotransferase, a phosphatase, a peptidase or protease, a glycosidase, a lipase, a nuclease, an esterase, an amylase, a phosphodiesterase, a dehydrogenase, an oxidase, a reductase, a peroxidase, a hydroxylase, a monooxygenase, a catalase, a decarboxylase, an aldolase, a dehydratase, a synthase, a hyaluronate lyase, an epimerase, a racemase, a mutase, a topoisomerase, a protein disulfide isomerase, a ligase, an aminoacyl -tRNA synthetase, a carboxylase, a synthetase, or a ubiquitin ligase.

[0084] In an embodiment, the protein-tag does not interfere, alter, or modify the native functions and / or structure of the protein it is connected to.

[0085] In an embodiment, the protein is ABL Kinase, Maltose Binding Protein (MBP), GFP, luciferase, KRAS, or variants thereof.

[0086] In an embodiment, the protein-tag is chemogenetically fused to ABL Kinase, Maltose Binding Protein (MBP), GFP, luciferase, KRAS, or variants thereof.

[0087] In an embodiment, the protein-tag is chemogenetically fused to KRASG12D, and the cTag does not perturb the native signaling functions of KRASG12D.CHIMERIC SMALL MOLECULES

[0088] In an aspect, provided herein are chimeric small molecules according to a formula:A-Li-E-T, A-E-Li-T, or A-L1-E-L2-T;wherein A is a protein-tag binding moiety; T is a transfer moiety; Li and L2 are each a linker; and E is an electrophilic reactive group, wherein the chimeric small molecule undergoes a group transfer reaction with the protein-tag. As used herein, a 'group transfer reaction' refers to a chemical process wherein a defined molecular fragment (the 'transfer moiety') is translocated from a donor molecule to an acceptor molecule via a reactive intermediate. In the context of this invention, the group transfer reaction specifically involves the electrophilic transfer of the transfer moiety (T) from the chimeric small molecule to a nucleophilic amino acid residue (e.g., cysteine, lysine, or methionine) of the engineered protein-tag, concurrent with the elimination of the protein-tag binding moiety (A). This process results in the covalent labeling of the protein-tag with the transfer moiety while simultaneously releasing the protein-tag binding moiety, thus maintaining translational entropy. The reaction proceeds through an associative-dissociative mechanism, distinguished from typical covalent ligand chemistry, which proceeds through a purely associative mechanism.Protein-Tag Binding Moiety

[0089] The chimeric small molecules described herein comprise a protein-tag binding moiety. As used herein, a 'protein-tag binding moiety' refers to a structural component of the chimeric small molecule that selectively and non-covalently associates with a specific protein-tag. In an embodiment, the protein-tag moiety may selectively and non-covalently associate with a particular protein-tag with a binding affinity (Kd) of between 1 pM and 10 pM (e.g., 10 pM, 100 pM, 1 nM, 10 nM, 100 nM, 1 pM) under physiological conditions. The protein-tag binding moiety comprises a recognition element that interacts with specific amino acid residues or structural motifs within the protein-tag binding pocket, allowing for specific molecular recognition. Protein-tag binding moieties include, but are not limited to, small molecules, peptides, and peptidomimetics that canform hydrogen bonds, electrostatic interactions, 7i-stacking, hydrophobic interactions, or combinations thereof with the protein-tag.

[0090] The protein-tag binding moiety may be designed to bind to any protein-tag. In an embodiment, the protein-tag binding moiety may be a chloroalkane derivative, benzylguanine derivative, benzylcytosine, trimethoprim derivatives, hydroxybenzylidene rhodamine derivatives, lipoic acid derivatives, 4-hydroxycinnamic acid derivatives, biotin derivative, biotin-phenol derivatives, 4-hydroxy-3 -methylbenzylidene rhodamine derivatives, biarsenical fluorescein and biarsenical resorufin derivatives, cyclopropene-tetrazine derivatives, or primary amine substrates.

[0091] In an embodiment, the protein-tag binding moiety may be 12-O-Tetradecanoylphorbol-13-acetate (TP A), or an analog thereof.

[0092] In an embodiment, the protein-tag binding moiety is configured to bind a protein-tag derived from a Cl domain of a human PKC as described herein.

[0093] In an embodiment, the protein-tag binding moiety may be a benzolactam analog. In an embodiment, the benzolactam analog comprises an electrophilic moiety capable of reacting with a nucleophilic amino acid, such as cysteine, lysine, or histidine. In an embodiment, the benzolactam analog comprises a benzyl moiety. In an embodiment, the protein-tag binding moiety

[0094] In an embodiment, the protein-tag binding moiety is a benzolactam analog which binds to a Cl domain of human PKC as described herein.Transfer Moiety

[0095] The chimeric small molecules described herein comprise a transfer moiety. As used herein, a 'transfer moiety' refers to the structural component of the chimeric molecule that becomes covalently attached to the protein-tag during the group transfer reaction. The transfer moiety carries the desired functionality to be conferred upon the protein-tag or its associated protein of interest. Following the group transfer reaction, this moiety remains permanently linked to the protein-tag via a covalent bond formed with a reactive amino acid residue (such as cysteine, lysine, or methionine), while the protein-tag binding moiety is eliminated. Transfer moieties can include, but are not limited to: (1) detectable labels such as fluorophores, affinity tags, or bioorthogonal handles; (2) substrate-binding moieties that facilitate proximity-induced interactions; (3) degradation-inducing moieties; (4) post-translational modification inducers; or (5) any other functional group designed to impart specific properties to the tagged protein.Detectable Label

[0096] In an embodiment, the transfer moiety is a detectable label. The detectable label may be a fluorescent dye such as fluorescein derivatives or rhodamine derivatives or cyanine dyes or Alexa Fluor dyes or BODIPY dyes or Atto dyes or Dy Light dyes or Oregon Green or JOE or ROX or TAMRA.

[0097] In an embodiment, the detectable label is a quantum dot such as CdSe / ZnS quantum dots or InP quantum dots or non-heavy metal quantum dots.

[0098] In an embodiment, the detectable label is an enzyme label such as horseradish peroxidase (HRP) or alkaline phosphatase (AP) or 0-galactosidase or luciferase.

[0099] In an embodiment, the detectable label is a radioactive label such as32P or35S or14C or3H or125I isotopes.

[0100] In an embodiment, the detectable label is metal-based, such as lanthanide chelates or gold nanoparticles.

[0101] In an embodiment, the detectable label is a biotin-based label such as biotin / streptavidin systems or biotin-PEG conjugates.

[0102] In an embodiment, the detectable label is a photoactivatable label such as photoconvertible fluorescent proteins, caged fluorophores, or photoactivatable dyes.

[0103] In an embodiment, the detectable label is a chemiluminescent label such as acridinium esters, luminol derivatives, CSPD, or CDP-Star.

[0104] In an embodiment, the detectable label is an infrared dye such as IRDye series or indocyanine green (ICG).

[0105] In an embodiment, the detectable label is a clickable reactive group for bioorthogonal chemistry, such as azides, alkynes, tetrazines, trans-cyclooctenes, or cyclopropenes.

[0106] In an embodiment, the detectable label is multi-functional, such as FRET pairs, BRET systems, or quencher-fluorophore pairs.Affinity Label

[0107] In an embodiment, the transfer moiety is an affinity label. In an embodiment, the affinity label is a small molecule binding partner such as biotin, fluorescein, digoxigenin, DNP (dinitrophenyl), desthiobiotin, azobenzene, or dexamethasone.

[0108] In an embodiment, the affinity label is a peptide-based affinity tag such as FLAG peptide or HA peptide, Myc peptide, V 5 peptide, S-tag peptide, Strep-tag peptide, SBP-tag peptide, CBP peptide, or antigenic epitopes.

[0109] In an embodiment, the affinity label is a protein binding partner such as streptavidin or avidin, NeutrA vidin, protein A, protein G, protein L, glutathione, maltose, calmodulin, GST, MBP, antibody, antibody fragment, or nanobody.

[0110] In an embodiment, the affinity label is a metal affinity label such as polyhistidine or nickel-NTA, cobalt-NTA, zinc finger motifs, Fe-catechol groups, lanthanide-binding tags, a carbohydrate binding partner such as lectins, mannose, fructose, galactose, glucose, chitin or heparin.

[0111] In an embodiment, the affinity label is a nucleic acid binding partner, such as aptamers, poly A, polyG, polyC, polyT, antisense oligonucleotides, or DNA / RNA binding proteins.

[0112] In an embodiment, the affinity label is a polymer-based affinity label such as PEG, dextran, cellulose, sepharose derivatives, or dendrimers.

[0113] In an embodiment, the affinity label is a stimuli-responsive affinity label, such as photo-switchable groups, temperature-responsive polymers, pH-sensitive linkers or redox -responsive groups.

[0114] In an embodiment, the affinity label is a click chemistry component such as azide or alkyne or strained alkyne or dibenzocyclooctyne (DBCO) or tetrazine or trans-cyclooctene.

[0115] In an embodiment, the affinity label is a bifunctional crosslinker such as NHS-esters or maleimides or isothiocyanates or hydrazides or Sulfo-SMCC or Sulfo-SBED.

[0116] In an embodiment, the transfer moiety binds a substrate of interest. The substrate of interest may be a protein, enzyme, polynucleotide, oligosaccharide, or lipid.Degradation-inducing Moiety

[0117] In an embodiment, the transfer moiety is degradation-inducing moiety. The degradation-inducing moiety is any chemical group or structural element that, when attached to a protein, promotes its targeted degradation within a biological system.

[0118] In an embodiment, the degradation-inducing moiety is an E3 ligase-recruiting moiety such as thalidomide or lenalidomide or pomalidomide or VHL ligand or MDM2 ligand or CRBN ligand or IAP ligand or RNF114 ligand.

[0119] In an embodiment, the degradation-inducing moiety is a small molecule degrader such as PROTAC (Proteolysis Targeting Chimera) or SNIPER (Specific and Non-genetic IAP-dependent Protein Eraser) or TRIM-Away ligand or Degronomics compounds or Adamantyl-ubiquitin.

[0120] In an embodiment, the degradation-inducing moiety is a degron motif such as N-degron or PEST sequence or D-box or KEN-box or TEV-degron or auxin-inducible degron (AID) or SMASh tag or temperature-sensitive degron.

[0121] In an embodiment, the degradation-inducing moiety is a lysosome-targeting moiety such as mannose-6-phosphate or LAMP targeting sequence or glycosylation sites or tyrosine motifs or dileucine motifs or acidic cluster motifs.

[0122] In an embodiment, the degradation-inducing moiety is chemical-inducible degradation element such as destabilizing domain (DD) or HaloTag-based degrons or FKBP-based degrons or DHFR-based degrons or Shield-1 responsive elements.

[0123] In an embodiment, a targeted nuclease recruitment moiety such as CRISPR-Cas targeting components or TALEN binding elements or zinc finger nuclease recognition sequences.Polynucleotide Binding Moieties

[0124] In an embodiment, the transfer moiety is a polynucleotide binding moiety. Example polynucleotide binding moieties include small molecules. Small molecules that target polynucleotides include groove binders and intercalators, see e.g. Wang M., et al. “Recent Advances in Developing Small Molecules Targeting Nucleic Acid.” IJMS 2016, 17 (6), 779 and Warner K. D., et al. “Principles for Targeting RNA with Drug-like Small Molecules.” Nat Rev Drug Discov 2018, 17 (8), 547-558, herein incorporated by reference. Additional example polynucleotide binding moieties include polynucleotide binding proteins. Polynucleotide binding proteins can be identified from nucleotide-binding folds in the proteins, such as the Rossmann-type (see, e.g. Kleiger et al., J. of Mol. Biol. 323: 69-76) and the P-loop containing nucleotide hydrolase folds (see, e.g., Saraste et al., Trends in Bio Sci, 15: 430-434). Chauhan et al. has developed methods for the identification of ATP and GTP binding residues and Ansari et al. has designed a method specifically for NAD. Parca et al. (2012), identified nucleotide-binding sites in protein structures, and include nucleotides bound by the protein, protein name and name of organism in Table SI of DOI: 10.1371 / journal. pone.0050240, incorporated herein by reference. Accordingly, nucleotide binding moieties are known in the art and can be identified by one of skill in the art for use as a transfer moiety in the present compositions.Oligosaccharide Binding Moieties

[0125] In an embodiment, the transfer moiety is an oligosaccharide binding moiety. Oligosaccharide binding moieties include small molecules. For example, small molecules that include boronic acid are typically used to bind to oligosaccharides. See e.g. Jin S., et rz / .“Carbohydrate Recognition by Boronolectins, Small Molecules, and Lectins. Med. Res. Rev.2009, herein incorporated by reference. Other oligosaccharide binding moieties include carbohydrate binding proteins, are important targets when considering antiviral and anticancer drugs. The localizing moiety can be, for example, a lectin, facilitating interaction sites for carbohydrates. Exemplary molecules include small molecule boronolectins, nucleic acid-based boronolectins, and peptidoboronolectins. See, e.g. Jin et al., Med. Res Rev. 2010 March; 30(2): 171-257; doi: 10.1002 / med.20155, incorporated herein by reference, specifically Figures 1-50 forbinding molecules and the complexes formed. Publicly available computational methods are available using developed bioinformatics to select small molecules capable of binding carbohydrates, see, e.g. , Zhao et al., Current Protocols in Protein Science 94: 1 10.1002 / cpps.75; Shionyu-Mitsuyama C, Shirai T, Ishida H, Yamane T (2003) Protein Eng 16: 467-478; and Kulharia M, Bridgett SJ, Goody RS, Jackson RM (2009) InCa-SiteFinder: a method for structurebased prediction of inositol and carbohydrate binding sites on proteins. J Mol Graph Model 28: 297-303.

[0126] Analysis of binding site residues along with stabilizing residues in protein-carbohydrate complexes can allow for identification of folding and binding of the complexes to understand interactions in addition to non-covalent interactions of hydrogen bonding and nonpolar interactions. See, e.g., Shanmugam et al., doi.: 10.2174 / 0929866525666180221122529. Utilizing publicly available tools, carbohydrate binding moieties, including binding sites and predicted folding can be used for the design of chimeric small molecules comprising such a carbohydrate binding moiety.Lipid Binding Moieties

[0127] In an embodiment, the transfer moiety is a lipid binding moiety. As regulators of cellular stabilization and signaling, modifications in their composition, distribution or trafficking would be useful in treatment, regulation and / or modification of pathways, processes and conditions. Lipids include charged lipids, e.g. phosphatidylserine (PS), phosphatidic acid (PA), phosphatidylinositol (PI), and the Pl-phosphate, -bisphosphate, and -trisphosphate (PIPs - a family of seven anionic charged lipids), and ganglioside (GM). Zwitterionic lipids, e.g., phosphatidylcholine (PC), phosphatidylethanolamine (PE), and sphingomyelin (SM) lipids, Ceramides (CER), diacylglycerol (DAG), and lysophosphatidylcholine (LPC) lipids, sphingolipids, glycerophospholipids, cholesterol, phosphatidylglycerols.

[0128] Certain steroids are capable of targeting and binding to lipids. Other lipid binding moieties such as proteins can either bind lipids specifically, where a clear binding site for a given lipid can be identified, or nonspecifically, where lipids act as a medium, and physical properties like thickness, fluidity, or curvature regulate the protein function. Phosphoinositide binding domains such as FYVE or PX, or the FRRG motif in the P-propeller of PROPPINs are more common domains that can be used to identify lipid binding proteins. The FYVE domain, namedafter the first four proteins to contain the motif (Fabl, YOTB, Vacl EEA1) contains several conserved regions, which can also be utilized to identify related domains. See, e.g., A.H. Lystad, A. Simonsen Phosphoinositide-binding proteins in autophagy, FEBS Lett., 590 (2016), pp. 2454-2468, 10.1002 / 1873-3468.12286. Additional FYVE domain-containing proteins include SARA, FRABIN, DFCP1 FGD1, ANKFY1, EEA1 FGD1, FGD2, FGD3, FGD4, FGD5, FGD6, FYCO1, HGS MTMR3, MTMR4, PIKFYVE, PLEKHF1, PLEKHF2, RUFY1, RUFY2, WDF3, WDFY1, WDFY2, WDFY3, ZFYVE1, ZFYVE16, ZFYVE19, ZFYVE20, ZFYVE21, ZFYVE26, ZFYVE27, ZFYVE28, ZFYVE9.

[0129] Eukaryotic cells can degrade intracellular components through a lysosomal degradation pathway called macroautophagy, with pathway malfunction linked to several diseases. Dikic et al., Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol., 19 (2018), pp. 349-364, doi: 10.1038 / s41580-018-0003-4. Accordingly, autophagy related (ATG) proteins may be utilized as lipid binding moiety in the present invention, including LC3A, LC3B, LC3C, GABARAP, GABARAPL1 and GABARAPL2. De la Ballina (2019), doi.org / 10.1016 / j.jmb.2019.05.051. Lipid-binding proteins include protein HCLS1 binding protein 3 (HS1BP3) that is able to negatively regulate the activity of phospholipase DI (PLD1).Protein Binding Moiety

[0130] In an embodiment, the transfer moiety is a protein binding moiety. The protein binding moiety binds any protein of interest. The protein binding moiety may be chosen based on the desired association and modification. Accordingly, the modifications desired, which may be tailored based on a particular modification, condition, disease, treatment, or other desired effect, may be a design consideration when choosing the protein binding moiety. In an embodiment, the protein of interest is an enzyme. The enzyme may be bound by an enzyme binding moiety. In an embodiment, the transfer moiety is an enzyme binding moiety.

[0131] In an embodiment, the protein may be BRD4, BRD2, BRD3, FKBP12F36V, tau, alpha-synuclein, HSP27, alphaAC, alphaBC, NF-L, CREB, DDX3X, PFK1, PFKFB3, PGK1, G6PD, KRAS, PKM2, MDH1, FH, KRT18, RRM1, PRPS1, Pol eta, AND-1, FEN1, TOP2A, RAD18, PARG, NRF1, MTA1, YTHDC1, YTHDF1, YTHDF2, MITF, FBL, YAP, LATS2, GLI2, RACK1, HDAC1, M0RC2, STAT3, SLC7A11, FTH, TRFC, c-Jun, ZEB1, TAB3, MEK2, CHK2, PLK1, HGS, SKP2, p27, ZNF263, OTX2, BMI1, SOX2, FOXA1, DOT1L, p65, STAT5, FOXK1,PDLIM7, F0X01, CRTC2, PGC-1 alpha, ERRgamma, ChREBP, p53, CaMKIdelta, AKT, SAMHD1, STING, IRF5, MAVS, vimentin, STAT6, IKKB, S6K1, RIPK1, RIPK3, GSDMD, or streptavidin.

[0132] The protein binding moiety may be chosen for a specific protein of interest, which may be located in different localization sites of the cell, e.g. nucleus, cytoplasm, mitochondria, cell surface. Example protein binding moieties are disclosed for example in, Sun et al., Signal Transduction and Targeted Therapy, 4:64 (2019), which provides exemplary proteins and corresponding ligands (i.e. polypeptide binding moieties, see in particular Figs. 5-48, which is incorporated herein by reference). The protein binding moiety may bind to proteins which undergo conformation change upon binding.

[0133] The protein binding moiety may bind to proteins which undergo conformation change upon binding, for example, an androgen receptor (AR). In an embodiment, activation of the protein results in modification of the target substrate by the protein at one or more new modification sites that would otherwise remain unmodified by the protein when not activated by the chimeric small molecule. The target substrate is not required to be a natural substrate of the protein. The target substrate may be a protein, and discussion herein of genes includes the products of the gene expression.

[0134] In an embodiment, the protein binding moiety is capable of binding a protein that is an ATPase or GTPase. Exemplary GTPases may be from the Ras, Rho, Rab, Arf or Ran family, see, e g. Yoshimi Takai, Takuya Sasaki, and Takashi Matozaki, Small GTP -Binding Proteins, Physiological Reviews 2001 81:1, 153-208; doi: 10.1152 / ohysrev.2001.81.1.153. Exemplary molecules targeting may include molecules such as Ibrutinib (BTK), Dsatinib (BCR-ABL), MRTX (KRAS), MI- 1061 (MDM2), Gelfitinib (EGFR), Palbociclib (CDK4 / 6) and Foretinib (C-MET), or analogs thereof.

[0135] The following provides examples of further, non-limiting, protein binding moieties to various target proteins of interest.BRD2, BRD3, and BRD4 Bindins Moiety

[0136] In an embodiment, the protein binding moiety is a BRD2, BRD3, or BRD4 binding moiety. BRD2, BRD3, and BRD4 are members of the BET (Bromodomain and Extra-Terminal) family of transcriptional regulators, each containing two tandem N-terminal bromodomains (BD1and BD2) and an extra-terminal (ET) domain that recognize acetylated lysine residues on histone H3 and H4 tails, enabling recruitment to chromatin and regulation of transcriptional elongation.

[0137] BRD2 can associate with E2F transcription factors to regulate expression of cell cycle genes and has been implicated in B cell lymphoma and inflammatory gene regulation. BRD3 can interact with GATA family transcription factors to regulate erythroid gene expression and has been identified as a fusion partner in NUT carcinoma through chromosomal translocations involving NUTM1. BRD4 can promote transcriptional elongation through recruitment of the positive transcription elongation factor b (P-TEFb) complex to chromatin at super-enhancer-regulated loci and has been implicated in NUT carcinoma, hematologic malignancies, and solid tumors.

[0138] In an embodiment, the BET bromodomain binding moiety comprises JQ1, a pan-BET bromodomain inhibitor. [Filippakopoulos P, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327): 1067-73. doi:10.1038 / nature09504.]

[0139] In an embodiment, the protein binding moiety is:■ ,.-N'r-’X.r-N V-o.Ci, or analogs thereof.

[0140] In an embodiment, the protein binding moiety is a BRD4 binding moiety selected from the group consisting of

[0141] In an embodiment, the BET bromodomain binding moiety comprises I-BET762, a pan-BET bromodomain inhibitor, according to the formula:or an analog thereof. See e.g., Nicodeme E, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327): 1103-7. doi: 10.1038 / nature09589.KRAS Bindins Moiety

[0142] In an embodiment, the protein binding moiety is a KRAS binding moiety. In an embodiment, the protein binding moiety is a KRAS binder according selected from the group consisting of:wherein R is a covalent warhead; X is the formulaand Y is selected from the group consisting of: H, alkane, alkene, alkyne, amine, nitrile, nitro, ether, alcohol, thiol, sulfone, sulfonate, halogen, carbonyl, acyl, ketone, carboxylate ester, amide, enone, anhydride, imide, cyclic hydrocarbon, an unsaturated cyclic hydrocarbon, a heterocycle, one or more fused rings thereof, or an aliphatic halides such as -OCF2CI.

[0143] In an embodiment, the protein binding moiety is a KRAS binding molecule according to the formula:OH SIn an embodiment, the protein binding moiety is a KRAS binding moiety according to the formula:r v vzi i, wherein R may be H, Gly, Ala, 0-Ala, Vai, He, Pro, or any other feasible substituent known in the art. In an embodiment, the protein binding moiety is a KRAS binding moiety is an indole, phenol, sulfonamide, or any modified version thereof. See Sun et al., Angew Chem Int Ed Engl. 2012 Jun 18; 51(25): 6140-6143. doi: 10.1002 / anie.201201358, herein incorporated by reference in its entirety.

[0144] In an embodiment, the protein binding moiety is a KRAS binding molecule according to the formula:31FITC-CHD— 1FITC-CHDSos-2FITC-CHDSo8-3UnU

[0145] In an embodiment, the protein binding moiety is a KRAS binding molecule according to the formula:embodiment, R4 is an electrophilic group. In an embodiment, the R4 isBiol. 2020, 15, 6, 1604-1612, incorporated herein by reference in their entirety.FKBP12F36VBindins Moiety

[0146] In an embodiment, the protein binding moiety can be designed to bind an FK506-binding protein (FKBP). The FKBP may be FKBP 12, which binds to intracellular calcium release channels and TGF-0 type I receptor. In an embodiment, the FKBP protein binding moiety is an FKBP12F36Vbinding molecule. In an embodiment, the protein binding moiety is selected from, , , or an analog thereof.

[0147] Tyrosine phosphorylation on FGFR1 can trigger signaling cascade to induce PI3K / AKT / mT0R signaling and increased transcription of G-CSF, a blood growth factor. See, e.g. Turner et al, Nature Reviews Cancer 2010.EGFR Binding Moiety

[0148] In an embodiment, the protein binding moiety is an EGFR binding moiety. EGFR is a tyrosine kinase receptor belonging to the ErbB family of receptors that mediates cell growth, differentiation and repair in cells, especially non-cancerous cells, but EGF is overexpressed in certain cells such as many solid tumors, including colorectal, non-small-cell lung cancer, squamous cell carcinoma of the ovary, kidney, head, pancreas, neck and prostate, and especially breast cancer.

[0149] In an embodiment, the protein binding molecule is an EGFR binding molecule of the formula,, or an analog thereof.HSP90 Bindins Moiety

[0150] Heat Shock Protein 90 (Hsp90) is an ATP dependent molecular chaperone that with its co-chaperones modulates proteins involved in cell cycle control and signal transduction. Like many ATP dependent proteins, the protein undergoes a functional cycle that is linked to its ATPase cycle.

[0151] In an embodiment, the HSP90 binding molecule isor analog thereof.

[0152] Additional HSP90 binders include geldanamycin and derivatives thereof, including Tanespimycin (IC50 of 5nM in cell free assay), according to the formula:Alvespimycin (IC50 of 62nM in cell-free assay), according to the formula:EC141 according to the formula:Novobiocin according to the formula:Hsooj...0a _"A Y A o X -G 6 CB.(IC50=700uM).Novobiocin analogs can also be utilized and as described in Hall et al., J Med Chem. 2016 Feb 11; 59(3): 925-933; doi: 10.1021 / acs.jmedchem.5b01354, incorporated by reference, which can be used as a MAPK signaling disruptor.BTK Bindins Moiety

[0153] Bruton’s Tyrosine Kinase (BTK) is a protein involved in multiple signaling cascades and is widely expressed in B cells. First, BTK is a cytoplasmic protein and thus available for interactions with cytoplasmic kinases, such as AMPK.

[0154] In an embodiment, the BTK binding moiety selected from the group consisting of:and or an analog thereof.MDM2 Bindins Moiety

[0155] In an embodiment, the protein binding moiety is an MDM2 binding moiety according, or a derivative or analog thereof.FGFR1 Binding Moiety

[0156] In an embodiment, the protein binding moiety is an FGFR1 binding moiety. In an embodiment, the protein binding moiety inhibits FGFR1 fusion proteins. In an embodiment, the FGFR1 fusion protein inhibitor is Dovitinib, also known as TKI258, according to the formula H.-.Or o r HF NH2 / i) — fsj m —PtpA, PtpB Binding Moiety

[0157] In an embodiment, protein binding moiety is a PtpA binding moiety is according to the HO-P11* 4;OH A M^1 j - txr >iA „ \_VCFsA jformula' — , -,G Br, or any derivatives thereof.

[0158] In an, the PtpB binding moiety is according to the formulaOH / F3Qor any derivatives thereof.SapM Binding Moiety

[0159] In an embodiment, the protein binding moiety is a SapM binding moiety. In an embodiment, the SapM binding moiety contains a trihydroxy-benzene group. In an embodiment, the SapM binding moiety comprises of a benzylidenemalononitrile scaffold. In an embodiment, the SapM binding moiety has the formula:or any derivatives thereof. In an embodiment the SapM binding moiety is L-ascorbic acid (L-AC) and 2-phospho-L-ascorbic acid (2P-AC).UMPK Bin dins Moiety

[0160] In an embodiment, the protein binding moiety is a M. tb kinase inhibitor. In an embodiment, the M. tb kinase inhibitor is a UMPK inhibitor, and any derivative thereof identified in US Patent Application US US20090209022, herein incorporated by reference.Colistin Bindins Moiety

[0161] In an embodiment, the PsA associated target protein binding moiety is Colistin, which has the formula:AKT Binding Moiety

[0162] In one example embodiment, the protein binding moiety is an AKT binding moiety. In one example embodiment, the AKT binding moiety is an inhibitor or activator. RAC-alpha serine / threonine-protein kinase (AKT) in humans has three isozymes (AKT1, 2, and 3, also known as PKB-a, - and -y). Each isozyme contains an amino (N)-terminal PH domain, inter-domain linker, kinase domain and 21 -residue carboxy (C)-terminal hydrophobic motif. In an example embodiment, the ATK inhibitor is Borussertib with the formula:or a derivative thereof and the oval shape represents the remaining chimeric small molecule.

[0163] In an example embodiment, the kinase inhibitor is MK-2206 with the formula:with the following properties:Hydrogen bond acceptorsHydrogen bond donors *hoods <1Topologiaal poiar surtace area 83.07Mofecdar weight 407 J?XLogP 5.13No. Uptogte’s rules brcftenMK-2206 is an orally bioavailable allosteric inhibitor of the serine / threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. MK-2206 has pICso values of 8.3, 7.9, and 7.2 for AKT1, 2, and 3 respectively. MK-2206 is able to enhance the antitumor efficacy of standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. As of 2018, ClinicalTrilas.gov had 50 registered MK-2206 trials. Many have been withdrawn, terminated or completed. The ring fused to the pyridine may be modified to mono-, bi-, tricyclic linear fused rings, or angular tricycles. The pyridine may be modified to a pyrazine. The moiety of substituted benzene may also be modified. The strained cyclobutene may be substituted for any substituent known in the art. Furthermore, the hydrogens on the amine in the moiety may be substituted for any substituent known in the art. For further design guidance see Kettle, J. G., et al. “Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT.” J. Med. Chem. 2012, 55 (3), 1261-1273, herein incorporated by reference in its entirety.

[0164] In one example embodiment, the AKT inhibitor is any inhibitor from International Patent Application W02008070016A2, herein incorporated by reference in its entirety, and any derivative thereof. In addition, see e.g. Wu, W.-I., et al. “Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition.” PLoS ONE 2010, 5 (9), el2913, herein incorporated by reference in its entirety. In an embodiment, inhibitors of AKT or derivatives thereof can be according to:wherein R1 = H and R2 = or , where any N in the ring can be substituted with C, N, O. S, B or P;or according to , wherein R= NHMe. See, Bioorg. Med. Chem. Let.2008, 18, 4191-4194; doi: 10.1371 / journal.pone.0012913, incorporated herein by reference.Optimization of allosteric inhibition of AKT can be performed based on the following guidance:F mm ‘Wf ! N Or-tol * z- >- ** • H J * . ring amines, cyofe sis* fcteratetfWf' Strategy for combining potency and reducing hERG affinity for AKT binders can be based in whole or in part on the following:

[0165] In an example embodiment, the kinase inhibitor is AKT Inhibitor VIII, also known as compound 16h, with the formula:AKT Inhibitor VII is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit AKT (protein kinase B), with selectivity for AKT1 and 2 over AKT3. The pICso values of AKT Inhibitor VIII is 7.2, 6.7, and 5.7 for AKT1, 2, and 3 respectively. See Lindsley, C.W., et al. “Allosteric Akt (PKB) Inhibitors: Discovery and SAR of Isozyme Selective Inhibitors.” Bioorganic & Medicinal Chemistry Letters 2005, 15 (3), 761-764, herein incorporated by reference in its entirety with specific mention of Table 1 and Table 2, reproduced below:Fable X. .Structures o-;-.* £<>: / W< >«W:> 5(5 : Ki<? >5(i :.x;()

[0166] In an example embodiment, the kinase inhibitor is miransertib, also known as ARQ- 092, according to the formula:Miransertib is an orally active, selective, and potent allosteric AKT inhibitor. Miransertib has pICso values of 8.3, 8.4, and 7.8 for AKT1, 2, and 3. Miransertib has progressed to Phase 1 and 2development in solid and liquid tumors. See e.g. “Discovery of 3-(3-(4-(l- Aminocyclobutyl)Phenyl)-5-Phenyl-3H-Imidazo[4,5-b]Pyridin-2-Yl)Pyridin-2-Amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.” J. Med. Chem.2016, 59 (13), 6455-6469, herein incorporated by reference in its entirety with specific mention of Tables: 1, 2, 3, 4, 6, and 9, with Tables 2 and 4 reproduced below:Table 2. Structure— Activity Relationship for Substitution on the Pyridine Ring”R:it. AZT3'’Sdg l&pemneaUl Section ibr assay details. NT means not tested.feAS$ay conducted with unphosphorylaied enzymes.Table 4. Str»mK»~Aaivay KeUtiosslsip of s- Substituted Analogs>::N

[0167] In an example embodiment, the kinase inhibitor is ARQ 751. In one example embodiment, the kinase inhibitor is any inhibitor from Ashwell, M. A., et al. “Discovery andOptimization of a Series of 3-(3-Phenyl-3H-Tmidazo[4,5-b]Pyridin-2-Yl)Pyridin-2-Amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors.” J. Med. Chem. 2012, 55 (11), 5291-5310 or any derivative thereof with specific mention of Tables 3, 4, 6, and 8, reproduced below for reference:TaHe 4. Aktl Bfothemfoai ami Sfophyslcat Resedfo for Seaffold 24“T*W 4. AfoS foifotsaassfop for Pae*- Safotfos«foV:iifo^fos tfor IJ« ami S2)“

[0168] In an example embodiment, the kinase inhibitor is borussertib with the formula:oX ayA A-yA ABorussertib is a covalent-allosteric inhibitor of AKT, with an IC50 of 0.8 m< and a Ki of 2.2 nM for AKT"1. The EC50 values for Borussertib are 191 ± 90 nM, 48 ± 15 nM, 5 ± InM, 277 ± 90 nM, 373 ± 54 nM, 7770 ± 641 nM in AN3CA (endometrium), T47D (breast), ZR-75-1 (breast), MCF-7 (breast), BT-474 (breast), and KU-19-19 (bladder) cell lines, respectively. In an aspect, the allosteric inhibitor can be according to Table reproduced below:Varying of the scaffold can be according to the following scheme:

[0169] In an example embodiment the AKT inhibitor is Lactoquinomycin according to the formulas:or any derivative thereof, see e.g. “Lactoquinomycin C and D, Two New Medermycin Derivatives from the Marine-Derived Streptomyces Sp. SS17A.” Natural Product Research 2019, 34 (9), 1213-1218. In an example embodiment, the Lactoquinomycin is Medermycin.

[0170] In an example embodiment, the AKT inhibitor is BIND-2206, also known as MK-2206 or NSC-749607, according to the formula:i Hydrogen bcsnri acceptors i 4 = Hydrogen brand donore ; 2 i Rc-tatabfe bonds ; 3 i TbpoiogicaE petal surface area i 83.07 Afotecuisr 'Aefgfit i 407.17 ALogF : 5 13 . . i No. Upmsbfs rotes broken i t with the following properties: ;. AKT moieties can be synthesized according to the guidance and design provided herein in view of AKT binding moieties as disclosed, for example, in Panicker et al. Adv Exp Med Biol 1163:253 -278 (2019); Botello-Smith et al. PLoS Comp Biol 13(8):el005711 (2017); Mou et al. Chem BiolDrug Des 89(5):723-731 (2017); Ruiz-Carillo et al. Sci Rep 8:7365 (2018), and Budas et al. Biochem Soc Trans 35:1021-1026 (2007). Further information on AKT allosteric inhibitors may be found in Wu, W.-L, et al. “Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition.” PLoS ONE 2010, 5 (9), el2913.MEK Bindins Moiety

[0171] In one example embodiment, the protein binding moiety is a MEK binding moiety. In one example embodiment, the MEK binding moiety is an inhibitor or activator. MEK is a kinase enzyme that phosphorylates mitogen activated protein kinases (MAPK). Seven MEK subtypes have been identified, all mediate cellular responses to different growth signals. In one example embodiment, the kinase binding moiety is a MEK inhibitor. In one embodiment, the binding moiety is a Type-3 kinase inhibitor. In one embodiment, the MEK inhibitor comprises Trametinib according to the formula:\ / Trametinib has been used for the adjuvant treatment of patients with BRAF V600E or V600K mutated melanoma inhibiting MAP2K1 and MAP2K2 (aka MEK1 and 2) in the p42 / p44 MAPK pathway. Absorption / distribution of an oral dose of trametinib tablet is 72%. Trametinib is 97.4% bound to human plasma proteins, which can be utilized when determining dosage for small molecules detailed herein. See, Gilmartin, et al., GSK1120212 (JTP-74057) Is An Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition. Clin Cancer Res. 2011 Mar 1 ; 17(5):989-1000. doi: 10.1158 / 1078-0432.CCR- 10-2200. Epub 2011 Jan 18. Trametinib has aMAPKl inhibition pICso of 9 / 0-9.1 and a MAPK2 pICso inhibition of 8.7. Trametinib was shown to have sustained suppression of p-ERKl / 2 for more than 24 hours, with high potency, selectivity and long circulating half-life.

[0172] In one example embodiment, the MEK inhibitor comprises Cobimetinib, an allosteric inhibitor of MEK serine / threonine protein kinases, with a selectivity for MEK 1 and MEK2.Cobimetinib selectively inhibits the activity of the MEK serinetheronin protein kinase and is according to the formula:Hydrogen borte acceptorHydrogen send donors 3Rotate tee bonds 5Topological polar serfage aroa 34.6Molecular weight S 31 OSXLcgP 4,52No. Lipinski’s riiies broken 8with the following properties:Additional in vitro activity of cobimetinib and related analogs was explored in Rice et al., “Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)” ACS Med. Chem. Lett. 2012, 3, 5, 416-421, incorporated herein by reference in particular, at Tables 1 and 3.

[0173] In an example embodiment, the RIP1 inhibitor is according to the formula:OH QH ' t .,.N „ .iwC’Fr, or a derivative thereof and the “Linker” and “Target Binder” represents the remaining chimeric small molecule.

[0174] In an example embodiment, the MEK inhibitor comprises Pimasertib according to the formula:H H I-t>, A, ZAKPimasertib is an orally bioavailable small-molecule inhibitor of the mitogen-activated protein kinases MEK 1 and MEK2 (MEK 1 / 2) with potential antineoplastic activity. It binds to an allosteric site, distinct from the ATP binding site and as such prevents activation rather than inhibiting catalysis. Pimasertib (AS703026) is cytotoxic against CD138-purified multiple myeloma (MM) cells from patients with relapsed and refractory MM, with IC50 values ranging from 2-200nM.MEK1 / 2 (MAP2K1 / K2) are dual-specificity threonine / tyrosine kinases that play key roles in the activation of the RAS / RAF / MEK / ERK pathway and are often upregulated in a variety of tumor cell types. Selectively binds to and inhibits the activity of MEK1 / 2, preventing the activation of MEKl / 2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. See, Yoon J, Koo KH, Choi KY. MEK1 / 2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res. 2011 Jan 15;71(2):445-53. doi: 10.1158 / 0008-5472.

[0175] In an example embodiment, the MEK inhibitor comprises CI-1040 according to the formula:

[0176] In an example embodiment, the MEK1 and MEK2 inhibitor is Selumetinib (AZD6244, ARRY-142886) according to the formula:Hydrogen bend acceptorsHydrogen bond donors 3RotaiaWs bondsTopciogscai polar surface areaMolecular wefgt 4503.7No. LjpiiWs rates &.-o*en Ci : and with the following propertiesSelumietinib is an orally bioavailable non-ATP competitive inhibitor that is highly specific for MEK1 / 2. It is a negative allosteric modulator of MEK1 with a pIC50 of 7.8-7.9. Sensitivity to selmuetinib in a panel of NSCLC and CRC cell lines showed sensitivity to particular mutations of KRAS in GEO cells with amino acid change p.G12A, SW480 cells with amino acid change G12V, SW620 cells with amino acid change p.G12V, and in HCT116 cells with amino acid change G13Dand PIK3CA amino acid change p.H1047R, and in Hl 299 cells with NRAS amino acid change p.Q61K.

[0177] In an example embodiment, the allosteric MEK inhibitor is a 3,4-difluoro-2-(2-halo-4-iodo-phenylamino)-V-2-hydroxy-ethoxy)-benzamide according to the formulaHO4 lov r H mN' ' F ' ' IFwherein R and R5 are selected from the table below24 Cl IS <128 -CH / Pr F W Wa»> a 1.5 <131 -awwtt F 8.® s32 {♦KHA'HOH'OWH} a 1133 F D.4S 14734 iP» 032590L R ’ . '■ F 8.33 19835 F 02 255as described in Hartung et al., Optimization of allosteric MEK inhibitors, Part 1: Venturing into underexplored SAR territories, Bioorganic and Medicinal Chemistry Letters 23 (2013) 2384-2390, incorporated herein by reference.

[0178] In one example embodiment, the MEK inhibitor is Mirdametinib (PD 0325901) a selective and non-ATP-competitive MEK inhibitor that has been explored in advanced KRAS mutant colorectal cancer, non-small-cell lung cancer, melanoma, colonic neoplasms and breast cancer, and is according to the formula:HQHMirdametinib has a EK1 inhibition pICso value of 8.1 and has the following properties:Hydrogen bottd accepters 4cerd < (WS 4Jr. e f 8iopotogicai pesar surface am 802Metecijsarvrelgfit 482XLogP 3.4No. Lipinski’s rules broken 0

[0179] In one example embodiment, the MEK binding moiety comprises allosteric inhibitor refam etinib :or an analog thereof, for example,or a derivative thereof.

[0180] In an example embodiment, the MEK inhibitor is Binimetinib according to the formula:Hydrogen bond acceptors 4 Hydrogen send donors 3 Rotaiabfe bonds 7 Topological poiar surface area 88.41 Molecular weight 440.03 XlogP 3.23 Nd. Lipinski's rotes broken 0 and has the following properties:Binimetinib has received FDA approaval as a treatment for advanced BRAF -mutant melanoma in conjunction with the BRAF mutant kinase inhibitor encorafenib. See, Dummer et al., Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016 / 81470-2045(18)30142-6.

[0181] Additional exploration in other solid tumor types, neuroblastoma, and hematological cancers are being explored. See, e.g. Woodfield SE, Zhang L, Scorsone KA, Liu Y, Zage PE. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer. 2016 Mar 1 ; 16: 172. doi: 10.1186 / s 12885-016-2199-z. Binimetinib is a negative allosteric modulator with a MEK1 and a MEK2 pIC50 of 7.9.IKK Bindins Moiety

[0182] In one example embodiment, the kinase binding moiety is an IKK kinase binding moiety. In one example embodiment, the IKK binding moiety is an inhibitor or activator. The IKP kinase (IKK) complex comprises of three subunits: IKKa, IKKP, and IKKy / NEMO. The subunits IKKoc and IKKP are catalytic and IKKy / NEMO is regulatory. See e.g. Karin, M. “The IKB Kinase - a Bridge between Inflammation and Cancer.” Cel! Res 2008, 18 (3), 334-342. In an example embodiment, the IKK inhibitor is BMS-345541 according to the formula:RIPK Bindins Moiety

[0183] In one example embodiment, the protein binding moiety is an RIPK kinase binding moiety. In one example embodiment, the RIPK binding moiety is an inhibitor or activator. Receptor-interacting protein kinase (RIPK)-l is involved in RIPK3 -dependent and -independent signaling pathways leading to cell death and / or inflammation. See e.g. Degterev A., et al. “Targeting RIPK1 for the Treatment of Human Diseases.” Proc Natl Acad Sci USA 2019, 116 (20), 9714-9722. In an example embodiment, the RIPK inhibitor is RIPA-56 according to the formula.orrvOH 'KRIPA-56 is a highly potent, selective, and metabolically stable type III (allosteric) inhibitor of R1PK1. RIPA-56 is also known as compound 92 in patent W02016101885, herein incorporated by reference. RIPA-56 is a drug candidate for the treatment of systemic inflammatory response syndrome (SIRS). RIPA-56 is active against human and mouse RIPK1 and is efficacious in animal models. It is devoid of off-target IDO inhibiting activity. RIPA-56 has an pICso value of 7.9 for RIPK-1. See e.g. Ren, Y., et al. “Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome.” J. Med. Chem. 2017, 60 (3), 972-986, herein incorporated by reference in its entirety with specific mention of Table 5.

[0184] In an example embodiment, the RIP1 inhibitor is according to the formula:, or a derivative thereof and the “Linker” and “Target Binder” represents the remaining chimeric small molecule.

[0185] Additional Protein Binding moieties can be found in U.S. Patent Application No.19 / 552,338, which is hereby incorporated by reference in its entirety.Tau Binding Moiety

[0186] In an embodiment, the protein binding moiety is a tau binding moiety. Tau is a microtubule-associated protein encoded by the MAPT gene that stabilizes neuronal microtubules through its microtubule-binding repeat domain. In disease states, tau can become hyperphosphorylated, which can lead to its dissociation from microtubules and aggregation into paired helical filaments and neurofibrillary tangles, pathological hallmarks of Alzheimer's diseaseand related tauopathies including frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration.

[0187] In an embodiment, the tau binding moiety comprises methylthioninium chloride, or an analog thereof. See e.g., Wischik CM, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA. 1996;93(20): 11213-8. In an embodiment, the tau binding moiety comprises flortaucipir, or an analog thereof. See e.g., Xia CF, et al.[18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9(6):666-76.Alpha-Synuclein Binding Moiety

[0188] In an embodiment, the protein binding moiety is an alpha-synuclein binding moiety. Alpha-synuclein is a 140-amino-acid presynaptic protein encoded by the SNCA gene that binds to cell membranes and functions in synaptic vesicle dynamics. In disease states, alpha-synuclein can aggregate into amyloid fibrils and oligomeric species that are hallmarks of Parkinson's disease and related synucleinopathies including dementia with Lewy bodies and multiple system atrophy.

[0189] In an embodiment, the alpha-synuclein binding moiety comprises anlel38b, or an analog thereof. See e g., Wagner J, et al. Anlel38b: a novel oligomer modulator for diseasemodifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol . 2013 ; 125 (6) : 795 -813.

[0190] In an embodiment, the alpha-synuclein binding moiety comprises squalamine, or an analog thereof. See e.g., Pemi M, et al. A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci USA. 2017;l 14(6):E1009-E1017.

[0191] In an embodiment, the alpha-synuclein binding moiety comprises UCB0599, or an analog thereof. See e.g., Schwarz TC, et al. High-resolution structural information of membranebound alpha-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599. Proc Natl Acad Sci USA. 2023;120(15):e2201910120.

[0192] In an embodiment, the alpha-synuclein binding moiety comprises NPT100-18A, or an analog thereof. See e.g., Das D, et al. Computational investigation on the effect of the peptidomimetic inhibitors (NPT100-18A and NPT200-11) on the alpha-synuclein and lipid membrane interactions. J Biomol Struct Dyn. 2023 ;42(21):11471-11482.NF-L Binding Moiety

[0193] In an embodiment, the protein binding moiety is an NF-L binding moiety. Neurofilament light chain (NF-L), encoded by the NEFL gene, is the smallest of the three neurofilament subunits and serves as a structural component of the neuronal cytoskeleton, contributing to the mechanical stability and transport properties of axons. NF-L is released into peripheral circulation and cerebrospinal fluid in response to neuronal damage and is used as a biomarker for neuroaxonal injury across a spectrum of neurological diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and traumatic brain injury.HSP27 Binding Moiety

[0194] In an embodiment, the protein binding moiety is an HSP27 binding moiety. HSP27, encoded by the HSPB1 gene, is a small heat shock protein that functions as a molecular chaperone involved in protein folding and cellular stress response. HSP27 is overexpressed in many cancer types and can confer resistance to chemotherapy and radiation therapy.

[0195] In an embodiment, the HSP27 binding moiety comprises RP101 (brivudine) , or an analog thereof. See e.g., Heinrich JC, et al. RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J Cancer Res Clin Oncol. 2011 ; 137(9): 1349-61.

[0196] In an embodiment, the HSP27 binding moiety comprises zerumbone, or an analog thereof. See e.g., Choi SH, et al. Altered cross-linking of HSP27 by zerumbone as a novel strategy for overcoming HSP27-mediated radioresistance. Int J Radiat Oncol Biol Phys. 2011 ;79(4): 1196-205.

[0197] In an embodiment, the HSP27 binding moiety comprises J2, according to the formula:fH liiOill liBsiC'H,CM,or an analog thereof. See e.g., Choi B, et al. Sensitization of lung cancer cells by altered dimerization ofHSP27. Oncotarget. 2017;8(62): 105372-105382.alphaBC Binding Moiety

[0198] In an embodiment, the protein binding moiety is an alphaBC binding moiety. alphaBC, encoded by the CRY AB gene, is a small heat shock protein and member of the crystallin family that functions as a molecular chaperone involved in protein folding and cellular stress response. alphaBC is widely expressed in muscle, heart, and other tissues and can contribute to resistance to chemotherapy and other therapeutic agents in cancer cells.

[0199] In an embodiment, the alphaBC binding moiety comprises CLR01, or an analog thereof. See e.g., Xu N, et al. Inhibition of Mutant alphaB Crystallin-Induced Protein Aggregation by a Molecular Tweezer. J Am Heart Assoc. 2017;6(8):e006182.

[0200] In an embodiment, the alphaBC binding moiety comprises NCI-41356, or an analog thereof. See e.g., Chen Z, et al. Discovery of structure -based small molecular inhibitor of aB-crystallin against basal-like / triple-negative breast cancer development in vitro and in vivo. Breast Cancer Res Treat. 2014;145(l):45-59.

[0201] In an embodiment, the alphaAC binding moiety is according to the formula:, or an analog thereof.See e.g., Makley LN, et al. Pharmacological chaperone for a-cry stallin partially restores transparency in cataract models. Science. 2015;350(6261):674-7.alphaAC Bindins Moiety

[0202] In an embodiment, the protein binding moiety is an alphaAC binding moiety. alphaAC, encoded by the CRYAA gene, is a small heat shock protein and crystallin family member that functions as a molecular chaperone, preventing aggregation of lens proteins and maintaining lens transparency throughout life. Mutations in CRYAA are associated with hereditary cataracts, and alphaAC dysfunction can lead to protein misfolding and aggregation in the lens.

[0203] In an embodiment, the alphaAC binding moiety comprises lanosterol, or an analog thereof. Lanosterol is an amphipathic sterol that binds alphaAC and reverses protein aggregation in vitro and in cataract models. See e.g., Zhao L, et al. Lanosterol reverses protein aggregation in cataracts. Nature. 2015;523(7562):607-l 1. In an embodiment, the alphaAC binding moiety isaccording to the formula:or an analog thereof.See e.g., Makley LN, et al. Pharmacological chaperone for a-cry stallin partially restores transparency in cataract models. Science. 2015;350(6261):674-7, or an analog thereof.DDX3X Binding Moiet

[0204] In an embodiment, the protein binding moiety is a DDX3X binding moiety. DDX3X is a DEAD-box RNA helicase involved in translation initiation and RNA processing, and isoverexpressed in multiple cancer types including lung, breast, colorectal, and Ewing sarcoma, where it can be associated with increased proliferation and poor patient prognosis.

[0205] In an embodiment, the DDX3X binding moiety comprises RK-33, or an analog thereof. See e.g., Bol GM, et al. Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med. 2015;7(5):648-69 and Wilky B A, et al. RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma. Oncogene. 2016;35(20):2574-83.YTHDC1 Bindins Moiety

[0206] In an embodiment, the protein binding moiety is a YTHDC1 binding moiety. YTHDC1 is a nuclear m6A reader protein that recognizes N6-methyladenosine-modified RNA transcripts and regulates their fate, playing roles in pre-mRNA splicing and mRNA stability in both normal cells and disease states.

[0207] In an embodiment, the YTHDC1 binding moiety comprises YL-5092, or an analog thereof. See e.g., Zhang H, et al. Small-molecule inhibition of YTHDC1 as a strategy against acute myeloid leukemia in mouse models. Sci Transl Med. 2026; 18(835):eadu3137.

[0208] In an embodiment, the YTHDC1 binding moiety comprises N-7, or an analog thereof. See e.g., Wang C H, et al. Discovery of a new inhibitor for YTH domain-containing mA RNA readers. RSC Chem Biol. 2024;5(9):914-923.YTHDF1 and YTHDF2 Bindins Moiety

[0209] In an embodiment, the protein binding moiety is a YTHDF1 or YTHDF2 binding moiety. YTHDF1 and YTHDF2 are cytoplasmic m6A reader proteins that recognize N-methyladenosine-modified RNA transcripts and direct their translation or degradation, respectively. These proteins are overexpressed in multiple cancer types and regulate gene expression.

[0210] In an embodiment, the YTHDF1 or YTHDF2 binding moiety comprises N-7, or an analog thereof. See e.g., Wang C H, et al. Discovery of a new inhibitor for YTH domain-containing mA RNA readers. RSC Chem Biol. 2024;5(9):914-923.FBL Bindins Moiety

[0211] In an embodiment, the protein binding moiety is an FBL binding moiety. FBL encodes fibrill arin, a highly conserved nucleolar protein that catalyzes 2'-O-methylation of ribosomal RNA as part of the rRNA methyltransferase machinery essential for ribosome biogenesis and function.Fibrillarin is overexpressed in hepatocellular carcinoma and other malignancies, where it promotes cancer cell proliferation and tumorigenesis.

[0212] In an embodiment, the FBL binding moiety comprises fludarabine phosphate, or an analog thereof. See e.g., Zhi Y, et al. FBL promotes hepatocellular carcinoma tumorigenesis and progression by recruiting YY1 to enhance CAD gene expression. Cell Death Dis. 2025;16(l):348.PFK1 Bindins Moiety

[0213] In an embodiment, the protein binding moiety is a phosphofructokinase- 1 (PFK1) binding moiety. PFK1 is a key glycolytic enzyme catalyzing the phosphorylation of fructose-6-phosphate to fructose- 1,6-bisphosphate and represents a central control point in glucose metabolism. Direct small molecule inhibitors of PFK1 have been identified as potential therapeutic agents for glycolytic malignancies and parasitic infections.

[0214] In an embodiment, the PFK1 binding moiety comprises ML251, or an analog thereof. See e.g., Brimacombe KR, et al. Identification of ML251, a potent inhibitor of T. brucei and T. cruzi phosphofructokinase. ACS Medicinal Chemistry Letters. 2014;5(l): 12-17.PFKFB3 Bindins Moiety

[0215] In an embodiment, the protein binding moiety is a 6-phosphofructo-2-kinase / fructose-2,6-bisphosphatase 3 (PFKFB3) binding moiety. PFKFB3 is a bifunctional enzyme that regulates glycolytic flux through dynamic control of fructose-2,6-bisphosphate levels and represents a key metabolic node in cancer cell glucose metabolism. Direct small molecule inhibitors of PFKFB3 can suppress glucose uptake and glycolytic ATP production in cancer cells.

[0216] In an embodiment, the PFKFB3 binding moiety comprises PFK-158, or an analog thereof. See e.g., Mondal S, et al. Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. International Journal of Cancer. 2019;144(l):178-189.PGK1 Bindins Moiety

[0217] In an embodiment, the protein binding moiety is a phosphoglycerate kinase 1 (PGK1) binding moiety. PGK1 is a glycolytic enzyme catalyzing the reversible conversion of 1,3-bisphosphoglycerate to 3 -phosphoglycerate and serves as a key node in both ATP generation and metabolic regulation. Small molecule inhibitors of PGK 1 can suppress aerobic glycolysis in cancer cells and gliomas.

[0218] In an embodiment, the PGK1 binding moiety comprises NG52, or an analog thereof. See e.g., Wang WL, et al. Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta Pharmacologica Sinica. 2021;42:633-640.G6PD Binding Moiety

[0219] In an embodiment, the protein binding moiety is a glucose-6-phosphate dehydrogenase (G6PD) binding moiety. G6PD is the rate-limiting enzyme of the pentose phosphate pathway catalyzing the oxidation of glucose-6-phosphate to 6-phosphogluconolactone and controls the generation of NADPH for biosynthetic and antioxidant pathways. Direct small molecule inhibitors of G6PD can suppress NADPH production and impair metabolic processes dependent on the pentose phosphate pathway in cancer and immune cells.

[0220] In an embodiment, the G6PD binding moiety comprises G6PDi-l, or an analog thereof. See e.g., Ghergurovich JM, et al. A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway. Nature Chemical Biology. 2020;16:731-739.PKM2 Binding Moiety

[0221] Pyruvate kinase M2 (PKM2) is the tumor-associated isoform of pyruvate kinase that catalyzes the final step of glycolysis. PKM2 functions as a metabolic checkpoint in cancer cells, shifting between active tetrameric and inactive dimeric states. PKM2 is a well-established target for cancer therapeutics, with dysregulated expression and activity implicated in numerous malignancies.

[0222] In an embodiment, the PKM2 binding moiety comprises TEPP-46, or an analog thereof. See e.g., Anastasiou D, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8(10):839-847.

[0223] In an embodiment, the PKM2 binding moiety comprises shikonin, or an analog thereof. See e.g., Chen J, et al. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene. 2011;30:4297-4306.

[0224] In an embodiment, the PKM2 binding moiety comprises compound 3K, or an analog thereof. See e.g., Ning X, et al. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase. Eur J Med Chem. 2017;138:343-352.MDH1 Bindins Moiety

[0225] Malate dehydrogenase 1 (MDH1) is a cytoplasmic enzyme that catalyzes the reversible conversion of malate to oxaloacetate in the malate-aspartate shuttle. MDH1 participates in gluconeogenesis and lipogenesis and is elevated in many cancer cell lines. MDH1 is an emerging metabolic target for anticancer therapeutics.

[0226] In an embodiment, the MDH1 binding moiety comprises 4-(3,4-difluorophenyl)thiazol-2-amine, or an analog thereof. See e.g., Romero A, et al. A fragment-based approach identifies an allosteric pocket that impacts malate dehydrogenase activity. Commun Biol.2021;4:949.

[0227] In an embodiment, the MDH1 binding moiety comprises methyl 3-(3-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)propanamido)benzoate, or an analog thereof. See e.g., Ravi Naik, et. al. Journal of Medicinal Chemistry 201760 (20), 8631-8646FH Bindins Moiety

[0228] Fumarate hydratase (FH) catalyzes the reversible hydration of fumarate to malate in the citric acid cycle. FH functions as a tumor suppressor, with loss-of-function mutations associated with hereditary leiomyomatosis, renal cell carcinoma, and other malignancies. FH loss impairs cellular metabolism and activates hypoxia-inducible factor signaling, promoting tumor development.

[0229] In an embodiment, the FH binding moiety comprises 2-thiomalate, or an analog thereof. See e.g., Feliciano PR, et al. Crystal structures of fumarate hydratases from Leishmania major in a complex with inhibitor 2-thiomalate. ACS Chem Biol. 2019;14(2):266-275.

[0230] In an embodiment, the FH binding moiety comprises a pyrrolidinone inhibitor, or an analog thereof. See e.g., Takeuchi T, et al. Identification of fumarate hydratase inhibitors with nutrient-dependent cytotoxicity. J Am Chem Soc. 2015;137(2):564-567.PRPS1 Bindins Moiety

[0231] Phosphoribosyl pyrophosphate synthetase 1 (PRPS1) catalyzes the synthesis of phosphoribosyl pyrophosphate (PRPP), the universal activated ribose donor for nucleotide biosynthesis. PRPS1 contributes to purine and pyrimidine synthesis and is frequently upregulated in cancer cells. Dysregulated PRPS1 activity drives nucleotide biosynthesis and supports rapid cancer cell proliferation.RRM1 Binding Moiety

[0232] In an embodiment, the protein binding moiety is an RRM1 binding moiety. RRM1 (ribonucleotide reductase catalytic subunit Ml) is the large subunit of ribonucleotide reductase, the enzyme responsible for catalyzing the conversion of ribonucleotides to 2'-deoxyribonucleotides — a reaction essential for DNA synthesis. RRM1 is a therapeutic target in oncology, as inhibition of ribonucleotide reductase activity can suppress tumor cell proliferation.

[0233] In an embodiment, the RRM1 binding moiety comprises gemcitabine, or an analog thereof. See e.g., Chen Z, et al. Modulation of the ribonucleotide reductase Ml -gemcitabine interaction in vivo by N-ethylmaleimide. Biochemical and Biophysical Research Communications. 2011 ;413 :383— 388.

[0234] In an embodiment, the RRM1 binding moiety comprises hydroxyurea, or an analog thereof. See e.g., Zhou B, et al. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Research.2013;73(21):6484-6493.

[0235] In an embodiment, the RRM1 binding moiety comprises COH29, or an analog thereof. See e.g., Zhou B, et al. A small -molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Research. 2013;73(21):6484-6493.Pol eta Binding Moiety

[0236] In an embodiment, the protein binding moiety is a Pol eta binding moiety. Pol eta (DNA polymerase eta, encoded by POLH) is a Y-family translesion synthesis polymerase capable of bypassing DNA lesions induced by ultraviolet radiation and platinum-based chemotherapeutics. Increased POLH expression is associated with resistance to platinum and nucleoside analog chemotherapies, making it a therapeutic target.

[0237] In an embodiment, the Pol eta binding moiety comprises PNR-7-02, or an analog thereof. See e.g., Zafar MK, et al. A Small-Molecule Inhibitor of Human DNA Polymerase p Potentiates the Effects of Cisplatin in Tumor Cells. Biochemistry. 2018;57(7): 1262-1273.AND-1 Binding Moiety

[0238] In an embodiment, the protein binding moiety is an AND-1 binding moiety. AND-1 (acidic nucleoplasmic DNA-binding protein 1, encoded by WDHD1 and also known as CTF4) isa replication fork scaffold protein involved in DNA replication initiation and elongation, as well as DNA repair processes. AND-1 can regulate cell cycle progression and genome stability, making it a potential therapeutic target.

[0239] In an embodiment, the AND-1 binding moiety comprises CH-3, or an analog thereof. See e.g., Gou W, et al. Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer. Cancer Letters. 2022;530:100-109.FEN1 Binding Moiety

[0240] In an embodiment, the protein binding moiety is an FEN1 binding moiety. FEN1 (flap endonuclease 1) is a structure-specific nuclease essential for processing Okazaki fragments during DNA replication and for base excision repair. FEN1 is overexpressed in multiple cancer types and can be a therapeutic target for synthetic lethal approaches.

[0241] In an embodiment, the FEN1 binding moiety comprises NSC-281680, or an analog thereof. See e.g., Panda H, et al. Amino acid Aspl81 of 5 '-flap endonuclease 1 is a useful target for chemotherapeutic development. Biochemistry. 2009;48(42):9952-9958.TOP2A Binding Moiety

[0242] In an embodiment, the protein binding moiety is a TOP2A binding moiety. TOP2A (topoisomerase II alpha) is a critical enzyme that catalyzes the transient unwinding of DNA by creating temporary double-strand breaks, enabling processes such as DNA replication, transcription, and chromosome segregation. TOP2A is an established target for anticancer therapy, with multiple clinical drugs targeting its catalytic activity or stabilizing enzyme-DNA cleavage complexes.

[0243] In an embodiment, the TOP2A binding moiety comprises etoposide, or an analog thereof. See e.g., Ketron AC, et al. Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions. Biochemistry. 2012;51(8):1730-1739.

[0244] In an embodiment, the TOP2A binding moiety comprises amsacrine, or an analog thereof. See e g., Ketron AC, et al. Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions. Biochemistry. 2012;51(8):1730-1739.RADI 8 Binding Moiety

[0245] In an embodiment, the protein binding moiety is a RADI 8 binding moiety. RADI 8 is an E3 ubiquitin-protein ligase involved in postreplication repair of UV-damaged DNA and DNAdamage tolerance pathways. RADI 8 catalyzes the monoubiquiti nation of PCNA at lysine 164, an event that activates translesion DNA synthesis and other DNA damage tolerance mechanisms. RAD 18 activity is relevant to cell survival following DNA damage and to understanding disease states associated with impaired DNA repair capacity.

[0246] In an embodiment, the RAD18 binding moiety comprises NSC 9037, or an analog thereof. See e.g., Fenteany G, et al. A series of xanthenes inhibiting Rad6 function and Rad6-Radl8 interaction in the PCNA ubiquitination cascade. eLife. 2022;ll:e75931.PARG Binding Moiety

[0247] In an embodiment, the protein binding moiety is a PARG binding moiety. PARG (poly(ADP-ribose) glycohydrolase) is the major enzyme responsible for catabolizing poly(ADP-ribose) (PAR) polymers deposited by PARP enzymes at DNA lesions. PARG activity contributes to regulating poly(ADP-ribosyl)ation dynamics and DNA repair processes, making PARG an attractive target for cancer therapy, particularly in combination with PARP inhibitors and in DNA repair-deficient tumors.

[0248] In an embodiment, the PARG binding moiety comprises PDD00017273, or an analog thereof. See e g., Tsuda K, et al. Genomic and biological aspects of resistance to selective poly(ADP-ribose) glycohydrolase inhibitor PDD00017273 in human colorectal cancer cells. Cancer Reports. 2023;6(2):el709.

[0249] In an embodiment, the PARG binding moiety comprises COH34, or an analog thereof. See e.g., Chen SH, et al. Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies. Sci Adv. 2019;5(4):eaav4340.CHK2 Binding Moiety

[0250] In an embodiment, the protein binding moiety is a CHK2 binding moiety. CHK2 (checkpoint kinase 2) is a serine / threonine kinase activated by DNA damage that plays a central role in cell cycle checkpoint control and apoptosis. CHK2 phosphorylates critical substrates including p53, CDC25C, and HDMX, coordinating DNA damage responses and cell fate decisions. CHK2 inhibition can enhance the efficacy of DNA-damaging chemotherapies and is relevant to cancer therapeutic strategies.

[0251] In an embodiment, the CHK2 binding moiety comprises NSC 109555, or an analog thereof. See e.g., Jobson AG, et al. Cellular inhibition of checkpoint kinase 2 (Chk2) andpotentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019. J Pharmacol Exp Ther. 2009;331(3):816-826.

[0252] In an embodiment, the CHK2 binding moiety comprises PV1019, or an analog thereof. See e.g., Jobson AG, et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019. J Pharmacol Exp Ther.2009;331(3):816-826.

[0253] In an embodiment, the CHK2 binding moiety comprises BML-277, or an analog thereof. See e.g., Hsieh, Chi-Che, et al. "CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer." British Journal of Cancer 127.9 (2022): 1615-1628.PLK1 Binding Moiety

[0254] In an embodiment, the protein binding moiety is a PLK1 binding moiety. PLK1 (pololike kinase 1) is a serine / threonine kinase that regulates cell cycle progression and mitotic checkpoints. PLK1 is an established target in oncology, as its inhibition can arrest cell division and induce apoptosis in cancer cells.

[0255] In an embodiment, the PLK 1 binding moiety comprises volasertib, or an analog thereof. See e.g., den Bossche V, et al. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plkl Inhibitor. Medicinal Research Reviews. 2016;36(4):749-86.

[0256] In an embodiment, the PLK1 binding moiety comprises BI 2536, or an analog thereof. See e.g., Lenart P, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Current Biology. 2007;17(4):304-15.

[0257] In an embodiment, the PLK1 binding moiety comprises rigosertib, or an analog thereof. See e.g., Bowles DW, et al. Phase I study of oral rigosertib (ON O191O.Na), a dual inhibitor of the PI3K and Plkl pathways, in adult patients with advanced solid malignancies. Clinical Cancer Research. 2014;20(6): 1656-65.S6K1 Bindins Moiety

[0258] In an embodiment, the protein binding moiety is an S6K1 binding moiety. S6K1 (ribosomal protein S6 kinase 1, also known as RPS6KB1) is a serine / threonine kinase downstream of mTORCl that regulates protein synthesis and cell proliferation. Inhibition of S6K1 can suppress mTOR signaling and reduce cell growth.

[0259] In an embodiment, the S6K1 binding moiety comprises PF-4708671, or an analog thereof. See e.g., Pearce LR, et al. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochemical Journal. 2010;431(2):245-55.

[0260] In an embodiment, the S6K1 binding moiety comprises LY2584702, or an analog thereof. See e.g., Tolcher AW, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. European Journal of Cancer. 2014;50(5):867-75.CaMKIdelta Bindins Moiet

[0261] In an embodiment, the protein binding moiety is a CaMKIdelta binding moiety. CaMKIdelta (calcium / calmodulin-dependent protein kinase I delta, CAMKID) is a serine / threonine kinase in the calcium / calmodulin-dependent kinase cascade that regulates transcriptional activation and cellular signaling. CaMKIdelta has emerged as a therapeutic target for metabolic disease and immune regulation.

[0262] In an embodiment, the CaMKIdelta binding moiety comprises compound 9 (from the selective inhibitor series) , or an analog thereof. See e.g., Fromont M, et al. Discovery of Highly Selective Inhibitors of Calmodulin-Dependent Kinases That Restore Insulin Sensitivity in the Diet-Induced Obesity in Vivo Mouse Model. Journal of Medicinal Chemistry. 2020;63(13):6784-801.

[0263] In an embodiment, the CaMKIdelta binding moiety comprises CS587. See e.g., Grant, Paige. "The Role of CaMKID in Alzheimer's Disease." (2022)..

[0264] In an embodiment, the CaMKIdelta binding moiety comprises CS640, or an analog thereof. See e.g., Grant, Paige. "The Role of CaMKID in Alzheimer's Disease." (2022).SKP2 Bindins Moiety

[0265] In an embodiment, the protein binding moiety is an SKP2 binding moiety. SKP2 (S-phase kinase-associated protein 2) is an F-box protein and substrate-recognition component of the SCF-SKP2 E3 ubiquitin ligase complex. SKP2 mediates the degradation of cyclin-dependent kinase inhibitors including p27 and p21, and SKP2 overexpression correlates with poor prognosis in multiple human cancers.

[0266] In an embodiment, the SKP2 binding moiety comprises Cl, C2, C16, C12, or an analog thereof. See e.g., Wu L, et al. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol. 2012;19(12):1515-24.

[0267] In an embodiment, the SKP2 binding moiety comprises a 1,3 -diphenylpyrazine-based inhibitor, or an analog thereof. See e.g., Zheng Q, et al. Discovery of novel 1,3 -diphenylpyrazine derivatives as potent S-phase kinase-associated protein 2 (Skp2) inhibitors for the treatment of cancer. J Med Chem. 2023;66(l l):7221-7242.p27 Bin dins Moiety

[0268] In an embodiment, the protein binding moiety is a p27 binding moiety. p27 (CDKN IB, p27Kipl) is a cyclin-dependent kinase inhibitor that regulates cell cycle progression at the Gl / S and G2 / M transitions by binding to and inhibiting cyclin-CDK complexes. p27 functions as a tumor suppressor, and alterations in p27 expression are implicated in cancer development and progression.

[0269] In an embodiment, the p27 binding moiety comprises SJ572710, SJ572403, or an analog thereof. See e.g., Iconaru LI, et al. Discovery of small molecules that inhibit the disordered protein, p27Kipl. Sci Rep. 2015;5:15686.HGS Bindins Moiety

[0270] In an embodiment, the protein binding moiety is an HGS binding moiety. HGS (hepatocyte growth factor-regulated tyrosine kinase substrate, also known as HRS) is a component of the ESCRT-0 complex that functions in endosomal sorting and multivesicular body biogenesis. HGS contains a FYVE domain that binds to phosphatidylinositol 3 -phosphate on endosomal membranes and serves as an initiator of the ESCRT cascade by recognizing and sorting ubiquitinated cargo.RACK1 Bindins Moiety

[0271] In an embodiment, the protein binding moiety is a RACK1 binding moiety. RACK1 (receptor for activated C kinase 1, also known as GNB2L1) is a scaffold protein containing seven WD-repeat domains that functions as an anchoring protein for protein kinase C and other signaling molecules. RACK1 mediates the recruitment, assembly, and regulation of multiprotein signaling complexes and is implicated in cell proliferation, differentiation, and migration.CREB Bindins Moiety

[0272] In an embodiment, the protein binding moiety is a CREB binding moiety. CREB (cAMP response element-binding protein) is a transcription factor that functions downstream of cAMP signaling pathways and plays a central role in cellular responses to hormones,neurotransmitters, and growth factors. CREB is activated by phosphorylation and mediates gene expression in diverse contexts including cell proliferation, differentiation, and survival. CREB dysregulation is implicated in cancer, leukemia, and neurological disorders.

[0273] In an embodiment, the CREB binding moiety comprises KG-501 or an analog thereof. See e.g., Best JL, et al. Identification of small-molecule antagonists that inhibit an activator: coactivator interaction. Proc Natl Acad Sci U S A. 2004; 101(51): 17622-7.NRF1 Binding Moiety

[0274] In an embodiment, the protein binding moiety is an NRF1 binding moiety. NRF1 (nuclear respiratory factor 1) is a transcription factor that regulates the expression of nuclear-encoded mitochondrial genes including those encoding subunits of the electron transport chain and components of oxidative phosphorylation. NRF1 activity is central to the control of mitochondrial biogenesis and energy metabolism, and is dysregulated in metabolic disease, cancer, and aging-related pathologies.MTA1 Binding Moiety

[0275] In an embodiment, the protein binding moiety is an MTA1 binding moiety. MTA1 (metastasis-associated protein 1) is a component of the NuRD chromatin remodeling complex and functions as a co-repressor of nuclear receptors and other transcription factors. MTA1 is overexpressed in many human malignancies including breast cancer, prostate cancer, and hepatocellular carcinoma, where its expression correlates with increased metastatic potential and poor clinical outcome.MITF Binding Moiety

[0276] In an embodiment, the protein binding moiety is an MITF binding moiety. MITF (microphthalmia-associated transcription factor) is a basic helix-loop-helix leucine zipper transcription factor that serves as a master regulator of melanocyte development, differentiation, and survival. MITF controls the expression of genes encoding proteins for pigmentation, DNA repair, and cell cycle progression. MITF is frequently dysregulated in melanoma and other melanocytic malignancies, where its amplification or mutation drives tumorigenesis and disease progression.

[0277] In an embodiment, the MITF binding moiety comprises ML329, or an analog thereof. See e.g., Faloon, Patrick W., et al. "A small molecule inhibitor of the MITF molecular pathway." Probe Reports from the NIH Molecular Libraries Program (2014).GLI2 Bindins Moiety

[0278] In an embodiment, the protein binding moiety is a GLI2 binding moiety, or an analog thereof. GLI2 (GLI family zinc finger 2) is a transcription factor that functions as an effector of Hedgehog (Hh) signaling, a developmental pathway dysregulated in multiple human cancers including medulloblastoma, basal cell carcinoma, and rhabdomyosarcoma. GLI2 activation downstream of Hh signaling drives expression of target genes promoting cell proliferation and survival. Direct inhibition of GLI2 transcriptional activity can suppress Hh-driven tumor growth.

[0279] In an embodiment, the GLI2 binding moiety comprises GANT61, or an analog thereof. See e.g., Agyeman A, et al. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLLDNA binding. Oncotarget. 2014;5(12):4492-503.

[0280] In an embodiment, the GLI2 binding moiety comprises arsenic trioxide, or an analog thereof. See e.g., Kim J, et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010;107(30): 13432-7.HDAC1 Bindins Moiety

[0281] In an embodiment, the protein binding moiety is a histone deacetylase 1 (HDAC1) binding moiety. HDAC1 is a member of the class I family of histone deacetylases involved in chromatin remodeling and gene regulation. Small molecule inhibitors of HD AC 1 can modulate transcription and cell differentiation across multiple disease contexts.

[0282] In an embodiment, the HDAC1 binding moiety comprises vorinostat, or an analog thereof. See e.g., Marks PA, et al. Histone deacetylase inhibitors. Adv Cancer Res. 2004;91:137- 168.

[0283] In an embodiment, the HDAC1 binding moiety comprises romidepsin, or an analog thereof. See e.g., Furumai R, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002;62(17):4916-4921.

[0284] In an embodiment, the HDAC1 binding moiety comprises entinostat, or an analog thereof. See e.g., Saito A, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, withmarked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA.1999;96(8):4592-4597.M0RC2 Binding Moiety

[0285] In an embodiment, the protein binding moiety is a microrchidia family CW-type zinc finger 2 (MORC2) binding moiety. MORC2 is a chromatin-remodeling ATPase containing a GHKL-type ATPase domain that plays a role in gene silencing, DNA damage response, and cell cycle control. MORC2 is upregulated in multiple cancer types and contributes to chemotherapy resistance and metastatic potential.STAT3 Binding Moiety

[0286] In an embodiment, the protein binding moiety is a signal transducer and activator of transcription 3 (STAT3) binding moiety. STAT3 is a key signal transduction protein and transcription factor downstream of multiple receptor pathways, with constitutive activation observed in many solid tumors and hematologic malignancies. STAT3 inhibition can suppress cancer cell proliferation, induce apoptosis, and attenuate tumor-promoting inflammatory responses.

[0287] In an embodiment, the STAT3 binding moiety comprises stattic, or an analog thereof. See e.g., Schust J, et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13(l 1): 1235-1242.

[0288] In an embodiment, the STAT3 binding moiety comprises BBI608, or an analog thereof. See e.g., Li Y, et al. Suppression of cancer relapse and metastasis by inhibiting cancer sternness. Proc Natl Acad Sci USA. 2015;l 12(6): 1839-1844.

[0289] In an embodiment, the STAT3 binding moiety comprises niclosamide, or an analog thereof. See e.g., Ren X, et al. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med Chem Lett. 2010;l(9):454-459.c-Jun Binding Moiety

[0290] In an embodiment, the protein binding moiety is a c-Jun binding moiety. c-Jun is the Jun proto-oncogene protein that forms the AP-1 transcription factor complex, regulating expression of genes involved in proliferation, differentiation, apoptosis, and stress responses, c-Jun is frequently upregulated or hyperactivated in cancer and contributes to oncogenic transcriptional programs.ZEB1 Binding Moiety

[0291] In an embodiment, the protein binding moiety is a zinc finger E-box binding homeobox 1 (ZEB1) binding moiety. ZEB1 is a transcription factor that promotes epithelial -mesenchymal transition (EMT) through repression of epithelial genes and induction of mesenchymal genes. ZEB1 is upregulated in metastatic cancers and is associated with poor prognosis and therapeutic resistance.0TX2 Binding Moiety

[0292] In an embodiment, the protein binding moiety is an OTX2 binding moiety. OTX2 (orthodenticle homeobox 2) is a homeodomain transcription factor of the bicoid subfamily that plays a critical role in brain and sensory organ development. OTX2 is frequently overexpressed in medulloblastoma, particularly in Group 3 medulloblastomas, where it can drive proliferation and self-renewal of cancer stem cells.BMI1 Binding Moiety

[0293] In an embodiment, the protein binding moiety is a BMI1 binding moiety. BMI1 (B lymphoma Mo-MLV insertion region 1) is a core component of the Polycomb repressive complex 1 (PRC1), a chromatin-modifying complex involved in transcriptional silencing and epigenetic regulation. BMI1 is overexpressed in multiple cancer types and is required for leukemia stem cell self-renewal and maintenance.

[0294] In an embodiment, the BMI1 binding moiety comprises PTC -209, or an analog thereof. See e.g., Nishida Y, et al. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy. Cancer Science. 2015; 106(12): 1705-1713.

[0295] In an embodiment, the BMI1 binding moiety comprises PTC-028, or an analog thereof. See e.g., Dey, Anindya, et al. "Evaluating the mechanism and therapeutic potential of PTC-028, a novel inhibitor of BMI-1 function in ovarian cancer." Molecular cancer therapeutics}! .1 (2018): 39-49.SOX2 Binding Moiety

[0296] In an embodiment, the protein binding moiety is a SOX2 binding moiety. SOX2 (SRY-box transcription factor 2) is a transcription factor critical for stem cell pluripotency and self-renewal. S0X2 is overexpressed in multiple cancer types and has been implicated in cancer stem cell maintenance and chemotherapy resistance.

[0297] In an embodiment, the SOX2 binding moiety comprises a pyrrole-imidazole polyamide inhibitor (e.g., PIP-S2) , or an analog thereof. See e.g., Taniguchi J, et al. A synthetic DNA-binding inhibitor of SOX2 guides human induced pluripotent stem cells to differentiate into mesoderm. Nucleic Acids Research. 2017;45(16):9219-9228.F0XA1 Bindins Moiety

[0298] In an embodiment, the protein binding moiety is a FOXA1 binding moiety. FOXA1 (forkhead box Al, also known as HNF-3alpha) is a pioneer transcription factor that plays a central role in chromatin remodeling and transcriptional regulation. FOXA1 is overexpressed and functionally important in breast cancer and prostate cancer, where it can regulate endocrine receptor signaling and contribute to therapy resistance.

[0299] In an embodiment, the FOXA1 binding moiety comprises WX-02-23, or an analog thereof. See e.g., Won KJ, et al. Redirecting the pioneering function of FOXA1 with covalent small molecules. Molecular Cell. 2024;84(21):4125-4141.DOT1L Bindins Moiety

[0300] In an embodiment, the protein binding moiety is a DOT1L binding moiety. DOT1L (disruptor of telomeric silencing 1 -like) is a histone H3K79 methyltransferase involved in chromatin regulation and transcriptional control. DOT1L is implicated in the pathogenesis of mixed lineage leukemia (MLL)-rearranged acute leukemia, where its enzymatic activity can be targeted for therapeutic intervention.

[0301] In an embodiment, the DOT1L binding moiety comprises EPZ004777, or an analog thereof. See e.g., Daigle SR, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(l):53-65.

[0302] In an embodiment, the DOT1L binding moiety comprises EPZ-5676 (pinometostat), or an analog thereof. See e.g., Daigle SR, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122(6): 1017-1025.p65 Bindins Moiety

[0303] In an embodiment, the protein binding moiety is a p65 binding moiety. p65 (RELA) is the key transcriptional activator subunit of the NF-kB transcription factor complex and plays acentral role in regulating inflammatory gene expression and immune responses. Dysregulated NF -kB signaling, driven by p65 activation, is implicated in multiple disease contexts including cancer and inflammatory diseases.

[0304] In an embodiment, the p65 binding moiety comprises CRL1101, or an analog thereof. See e.g., Kanzaki H, et al. Disabling the nuclear translocalization of RelA / NF-KB by a small molecule inhibits triple-negative breast cancer growth. Breast Cancer (Auckl). 2021;13:419-430.STAT5 Binding Moiety

[0305] In an embodiment, the protein binding moiety is a STAT5 binding moiety. STAT5 (Signal transducer and activator of transcription 5) is a key transcription factor activated downstream of cytokine receptors and tyrosine kinases and contributes to hematopoietic cell survival and proliferation. STAT5 is frequently dysregulated in hematologic malignancies, particularly in acute myeloid leukemia and chronic myelogenous leukemia.

[0306] In an embodiment, the STAT5 binding moiety comprises pimozide, or an analog thereof. See e.g., Nelson EA, et al. The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations. Genes Cancer. 2012;3(7): 503-511.

[0307] In an embodiment, the STAT5 binding moiety comprises AC-4-130, or an analog thereof. See e.g., Wingelhofer B, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018;32(5):l 135-1146.

[0308] In an embodiment, the STAT5 binding moiety comprises SH-4-54, or an analog thereof. Zhang, Xu-Fan, et al. "Targeting STAT3 with SH-4-54 suppresses sternness and chemoresistance in cancer stem -like cells derived from colorectal cancer." World Journal of Clinical Oncology 16.2 (2025): 97296.F0XK1 Binding Moiety

[0309] In an embodiment, the protein binding moiety is a FOXK1 binding moiety. FOXK1 (Forkhead box KI) is a transcription factor involved in cell cycle regulation, glucose metabolism, and autophagy. FOXK1 is implicated in cancer cell growth and survival, and its inhibition has been shown to induce autophagy with antimetastatic effects in preclinical cancer models.F0X01 Binding Moiety

[0310] In an embodiment, the protein binding moiety is a FOXO1 binding moiety. FOXO1 (Forkhead box 01) is a transcription factor that regulates apoptosis, cell cycle arrest, and metabolicprocesses. F0X01 activity is suppressed through AKT-mediated phosphorylation in cancer cells, and direct inhibition of F0X01 can restore apoptotic responses in multiple cancer types.

[0311] In an embodiment, the FOXO1 binding moiety comprises AS 1842856, or an analog thereof. See e.g., Flores D, et al. The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal-like breast cancer cells. FEBS Open Bio. 2023;13(2):352-362.CRTC2 Bindins Moiety

[0312] In an embodiment, the protein binding moiety is a CRTC2 binding moiety. CRTC2 (CREB-regulated transcription coactivator 2, also known as TORC2) is a coactivator for CREB that regulates gluconeogenic gene expression and metabolic signaling in the liver. CRTC2 is a key regulator of hepatic glucose production and is inactivated through phosphorylation by saltinducible kinase (SIK) family members.PGC-lalpha Bindins Moiety

[0313] In an embodiment, the protein binding moiety is a PGC-lalpha binding moiety. PGC-lalpha (also known as PPARGC1A, peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is a transcriptional coactivator that regulates mitochondrial biogenesis and energy metabolism. PGC-lalpha is involved in metabolic adaptation, mitochondrial function, and glucose homeostasis, with dysregulation implicated in type 2 diabetes and metabolic disease.ERRsamma Bindins Moiety

[0314] In an embodiment, the protein binding moiety is an ERRgamma binding moiety. ERRgamma (estrogen-related receptor gamma, encoded by ESRRG) is an orphan nuclear receptor and constitutively active transcription factor with no identified endogenous ligand. ERRgamma regulates energy metabolism, mitochondrial function, and metabolic adaptation, with roles in glucose and lipid metabolism.

[0315] In an embodiment, the ERRgamma binding moiety comprises GSK4716, or an analog thereof. See e.g., Wang L, et al. X-ray crystal structures of the estrogen-related receptor-gamma ligand binding domain in three functional states reveal the molecular basis of small molecule regulation. J. Biol. Chem. 2006;281(49):37773-37781.

[0316] In an embodiment, the ERRgamma binding moiety comprises DY131, or an analog thereof. See e.g., Ma H, et al. Estrogen -Related Receptor gamma agonist DY131 ameliorates lipopolysaccharide-induced acute liver injury. Front. Pharmacol. 2021; 12:626166.ChREBP Binding Moiety

[0317] In an embodiment, the protein binding moiety is a ChREBP binding moiety. ChREBP (carbohydrate-responsive element-binding protein, encoded by MLXIPL) is a transcription factor activated by glucose metabolites that regulates lipogenic and glycolytic gene expression. ChREBP is involved in the regulation of metabolic gene expression in response to carbohydrate availability, with roles in lipogenesis and glucose metabolism.p53 Binding Moiety

[0318] In an embodiment, the protein binding moiety is a p53 binding moiety. p53 (tumor protein p53, encoded by TP53) is a tumor suppressor transcription factor that regulates cell cycle arrest, apoptosis, and DNA repair. p53 is frequently mutated in human cancers, with loss of function contributing to tumorigenesis and therapeutic resistance.

[0319] In an embodiment, the p53 binding moiety comprises APR-246 (also known as eprenetapopt or PRIMA-lMet), or an analog thereof. See e.g., Lambert JM, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009; 15(5):376-388.IRF5 Binding Moiety

[0320] In an embodiment, the protein binding moiety is an IRF5 binding moiety. IRF5 (interferon regulatory factor 5) is a transcription factor involved in innate immune signaling and pro-inflammatory gene expression, including regulation of cytokines such as IL-12, TNF-alpha, and IL-6 downstream of TLR signaling. IRF5 plays a central role in immune activation and is implicated in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus and other inflammatory conditions.

[0321] In an embodiment, the IRF5 binding moiety comprises YE6144, or an analog thereof. See e.g., Ban T, et al. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. Nat. Commun. 2021;12:4379.ZNF263 Binding Moiety

[0322] In an embodiment, the protein binding moiety is a ZNF263 binding moiety. ZNF263 (zinc finger protein 263) is a KRAB-domain zinc finger transcription factor that binds DNA and functions as a transcriptional repressor. The protein is upregulated in several cancer types, including non-small cell lung cancer, colorectal cancer, and glioblastoma, where it can promote cell proliferation and enhance resistance to chemotherapeutic agents.PDLJM7 Binding Moiety

[0323] In an embodiment, the protein binding moiety is a PDLIM7 binding moiety. PDLIM7 (PDZ and LIM domain protein 7), also known as Enigma, is a scaffold protein composed of an N-terminal PDZ domain and C-terminal LIM domains. The protein mediates protein-protein interactions in cellular signaling pathways, particularly in cardiac tissue and skeletal muscle, and has been implicated in cancer progression and cell proliferation.YAP Binding Moiety

[0324] In an embodiment, the protein binding moiety is a YAP binding moiety. YAP (Yes-associated protein 1, YAP1) is a transcriptional coactivator in the Hippo signaling pathway. YAP functions as a major regulator of cell proliferation, survival, and organ size control, and dysregulation of YAP signaling can contribute to tumorigenesis and cancer progression across multiple tissue types.

[0325] In an embodiment, the YAP binding moiety comprises verteporfin, or an analog thereof. See e.g., Liu-Chittenden T, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12): 1300-1305.

[0326] In an embodiment, the YAP binding moiety comprises CA3, or an analog thereof. See e.g., Song S, et al. A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol Cancer Ther. 2018;17(2):443-454.

[0327] In an embodiment, the YAP binding moiety comprises TED-347, or an analog thereof. See e.g., Bum-Erdene, Khuchtumur, et al. "Small-molecule covalent modification of conserved cysteine leads to allosteric inhibition of the TEAD- Yap protein-protein interaction." Cell chemical biology 26.3 (2019): 378-389.LATS2 Binding Moiety

[0328] In an embodiment, the protein binding moiety is a LATS2 binding moiety. LATS2 (large tumor suppressor kinase 2) is a serine / threonine kinase in the Hippo signaling pathway. LATS2 phosphorylates and inactivates YAP and TAZ, thereby suppressing their transcriptional activity and functioning as a critical brake on cell proliferation and tissue overgrowth.

[0329] In an embodiment, the LATS2 binding moiety comprises TRULI, or an analog thereof. See e.g., Kastan NR, et al. Development of an improved inhibitor of Lats kinases to promote regeneration of mammalian organs. Proc Natl Acad Sci USA. 2022;! 19(28):e2206113119.SLC7A11 Bindins Moiety

[0330] In an embodiment, the protein binding moiety is an SLC7A11 binding moiety. SLC7A11 (xCT, solute carrier family 7 member 11) is the cystine / glutamate antiporter that mediates cellular cystine uptake and is central to glutathione synthesis and ferroptosis resistance in cancer and other cell types. Modulation of SLC7A11 activity can alter cellular redox homeostasis and ferroptotic sensitivity.

[0331] In an embodiment, the SLC7A11 binding moiety comprises erastin, or an analog thereof. See e.g., Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-1072.

[0332] In an embodiment, the SLC7A11 binding moiety comprises sulfasalazine, or an analog thereof. See e.g., Qin, Q., et al. Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2 / SLC7A11 / GPX4 signaling axis. Sci Rep 15, 30197 (2025).

[0333] In an embodiment, the SLC7A11 binding moiety comprises imidazole ketone erastin (IKE), or an analog thereof. See e.g., Zhang Y, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chemical Biology. 2019;26(5):623-633. e9.FTH Bindins Moiety

[0334] In an embodiment, the protein binding moiety is an FTH binding moiety. FTH1 (ferritin heavy chain) is the ferroxidase component of the ferritin complex responsible for iron detoxification and cellular iron storage. The ferritin complex regulates intracellular iron homeostasis and ferroptosis resistance, and its activity influences cellular proliferation and metabolic regulation.TRFC Bindins Moiety

[0335] In an embodiment, the protein binding moiety is a TRFC binding moiety. TRFC (transferrin receptor 1, TfRl, CD71) is a cell surface receptor that mediates cellular iron uptake by binding and internalizing transferrin-iron complexes. TRFC is expressed on dividing cells and iron-demanding tissues, making it a target for iron homeostasis and ferroptosis-relevant therapeutic strategies.

[0336] In an embodiment, the TRFC binding moiety comprises ferristatin IT, or an analog thereof. See e.g., Byrne SL, et al. Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo. PLoS One. 2013;8(7):e70199.SAMHD1 Binding Moiety

[0337] In an embodiment, the protein binding moiety is a SAMHD1 binding moiety. SAMHD1 (SAM domain and HD domain-containing protein 1) is a dNTP triphosphohydrolase that depletes cellular deoxyribonucleoside triphosphate (dNTP) pools and functions as an innate immune restriction factor against retroviruses and DNA damage. SAMHD1 activity regulates nucleotide homeostasis and can modulate chemotherapy response and immune cell function.

[0338] In an embodiment, the SAMHD1 binding moiety comprises TH6342, or an analog thereof. See e.g., Zhang, Si Min, et al. "Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel." Iscience 27.2 (2024).STING Binding Moiety

[0339] In an embodiment, the protein binding moiety is a STING binding moiety. STING (stimulator of interferon genes, STING1, TMEM173) is a cytoplasmic pattern recognition receptor that senses cytosolic DNA and activates type I interferon signaling and innate immune responses. STING can be modulated by both agonists to enhance immune activation and antagonists to suppress inflammatory responses, making it a versatile target for cancer immunotherapy and immune-inflammatory diseases.

[0340] In an embodiment, the STINGbinding moiety comprises diABZI, or an analog thereof. See e.g., Ramanjulu JM, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564(7736):439-443.

[0341] In an embodiment, the STING binding moiety comprises 5,6-dimethylxanthenone-4-acetic acid (DMXAA) , or an analog thereof. See e.g., Conlon J, et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. Journal of Immunology. 2013;190(10):5216-5225.

[0342] In an embodiment, the STING binding moiety comprises H-151, or an analog thereof. See e.g., Haag SM, et al. Targeting STING with covalent small-molecule inhibitors. Nature.2018;559(7713):269-273.MA VS Binding Moiety

[0343] In an embodiment, the protein binding moiety is a MAVS binding moiety. MAVS is a mitochondrial-anchored adaptor protein that mediates type I interferon induction downstream of the RIG-I and MDA5 pattern recognition receptors, playing a central role in antiviral innate immunity and having application in viral infection and autoimmune disease contexts.STAT6 Binding Moiety

[0344] In an embodiment, the protein binding moiety is a STAT6 binding moiety. STAT6 is a signal transducer and activator of transcription activated by IL-4 and IL- 13 cytokine signaling, mediating T helper cell differentiation and M2 macrophage polarization in allergic inflammation and immune responses.

[0345] In an embodiment, the STAT6 binding moiety comprises AS 1517499, or an analog thereof. See e.g., Chiba Y, etal. A novel STAT6 inhibitor AS 1517499 ameliorates antigen-induced bronchial hypercontractility in mice. American Journal of Respiratory Cell and Molecular Biology.2009;41(5):516-524.TAB3 Binding Moiety

[0346] In an embodiment, the protein binding moiety is a TAB3 binding moiety. TAB3, also known as MAP3K7IP3, is a scaffold protein serving as an adaptor within the TAK1 complex that transduces inflammatory signals from TNF and IL-1 cytokine receptors to activate NF-kB and MAPK signaling cascades, with application in inflammatory disease and immune response modulation.GSDMD Binding Moiety

[0347] In an embodiment, the protein binding moiety is a GSDMD binding moiety. GSDMD is the effector protein of pyroptosis, cleaved by caspase-1, caspase-4, and caspase-11 to liberate an N-terminal pore-forming domain, with application in inflammatory disease, infection, and necrotic cell death modulation.

[0348] In an embodiment, the GSDMD binding moiety comprises disulfiram, or an analog thereof. See e.g., Hu JJ, et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nature Immunology. 2020;21(7):736-745.

[0349] In an embodiment, the GSDMD binding moiety comprises necrosulfonamide, or an analog thereof. See e.g., Rathkey JK, et al. Chemical disruption of the pyroptotic pore-formingprotein gasdermin D inhibits inflammatory cell death and sepsis. Science Immunology.2018;3(26):eaat2738.

[0350] In an embodiment, the GSDMD binding moiety comprises LDC7559, or an analog thereof. See e.g., Yu E, et al. LDC7559 exerts neuroprotective effects by inhibiting GSDMD-dependent pyroptosis of microglia in mice with traumatic brain injury. Journal of Neurotrauma.2023;40(5):405-420.

[0351] In an embodiment, the GSDMD binding moiety comprises Bay 11-7082, or an analog thereof. See e.g., Rathkey JK, et al. Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Science Immunology.2018;3(26):eaat2738.Vimentin Binding Moiety

[0352] In an embodiment, the protein binding moiety is a vimentin binding moiety. Vimentin is a type III intermediate filament protein expressed in mesenchymal cells and upregulated during epithelial-to-mesenchymal transition in cancer, making it a marker of invasive and metastatic disease.

[0353] In an embodiment, the vimentin binding moiety comprises FiVel, or an analog thereof. See e g., Bollong MJ, et al. A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers. Proceedings of the National Academy of Sciences USA.2017;l 14(46):E9903-E9912.

[0354] In an embodiment, the vimentin binding moiety comprises withaferin A, or an analog thereof. See e.g., Bargagna-Mohan P, et al. The tumor inhibitor and anti angiogenic agent withaferin A targets the intermediate filament protein vimentin. Chemistry & Biology.2007;14(6):623-634.KRT18 Binding Moiety

[0355] In an embodiment, the protein binding moiety is a keratin 18 (KRT18) binding moiety. KRT18 is a type I intermediate filament protein expressed in simple epithelial cells and serves as a biomarker for carcinomas and hepatotoxicity.Streptavidin Binding Moiety

[0356] In an embodiment, the protein binding moiety is a streptavidin binding moiety. Streptavidin is a tetrameric bacterial protein from Streptomyces avidinii that binds its ligands withamong the highest known affinities in nature, making it a canonical system for protein engineering and bioaffinity applications.

[0357] In an embodiment, the streptavidin binding moiety comprises biotin, or an analog thereof. See e.g., Hendrickson WA, et al. Crystal structure of core streptavidin determined from multiwav elength anomalous diffraction of synchrotron radiation. Proceedings of the National Academy of Sciences USA. 1989;86(7):2190-2194.

[0358] In an embodiment, the streptavidin binding moiety comprises desthiobiotin, or an analog thereof. See e.g., Hirsch JD, et al. Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-binding proteins: uses for protein labeling, detection, and isolation. Analytical Biochemistry. 2002;308(2):343-357.Substrate binding Moiety

[0359] In an embodiment, the transfer moiety is a substrate binding moiety. The substrate may be a polynucleotide, oligosaccharide, lipid, or protein. The substrate binding moiety may be a polynucleotide binding moiety, an oligosaccharide binding moiety, lipid binding moiety, or a protein binding moiety. Non-limiting examples of polynucleotide binding moieties, oligosaccharide binding moieties, lipid binding moieties, and protein binding moieties are as described above.Electrophilic Reactive Group

[0360] The chimeric small molecules disclosed herein comprise an electrophilic reactive group. As used herein, an 'electrophilic reactive group' refers to a functional group within the chimeric small molecule that is electron-deficient and capable of forming a covalent bond with a nucleophilic amino acid side chain (such as cysteine, lysine, or histidine) in the protein-tag. The electrophilic reactive group facilitates the group transfer reaction by forming an initial covalent bond with the protein-tag, followed by rearrangement that transfers the transfer moiety to the protein-tag and eliminates the protein-tag binding moiety.

[0361] In an embodiment, the electrophilic reactive group is located between a linker and a transfer moiety. In an embodiment, the electrophilic reactive group is located between a linker and a protein-tag binding moiety. In an embodiment, the electrophilic reactive group is located between two linkers, a first linker attached to the protein-tag binding moiety and a second linker attached to the transfer moiety.

[0362] An electrophilic reactive group is can be a functional group that can form a reversible or irreversible bond with a nucleophilic functional group. In an embodiment, the electrophilic reactive group is designed to react with an amino acid side chain reactive group. The amino acid side chain reactive group may be nucleophilic. The nucleophilic amino acid side chain reactive group may comprise Cysteine, Serine, Threonine, Tyrosine, Glutamic Acid, Aspartic Acid, Lysine, Arginine, and Histidine, or a Methionine. In an embodiment, the electrophilic reactive group reacts with cysteine. An exemplary database that can aid in identification for protein ligand interaction around the binding site is described in Du et al., Nucleic Acids Research, Volume 49, Issue DI, 8 January 2021, Pages D1122-D1129, incorporated herein by reference, with the database, CovalentlnDB accessible at cadd.zju.edu.cn / cidb / . The approach can be used with any design of the electrophilic reactive group for molecules as disclosed herein.Cysteine Reactive Electrophilic Reactive Group

[0363] In an embodiment, the chimeric small molecule comprises an electrophilic reactive group that functions as the acceptor site for cysteine nucleophilic addition resulting in transfer moiety release, and wherein the electrophilic reactive group is selected from the group consisting of:CH3CF3Lysine Reactive Electrophilic Reactive Group

[0364] In an embodiment, the chimeric small molecule comprises an electrophilic reactive group that functions as the acceptor site for lysine amine addition resulting in transfer moiety release, and wherein the electrophilic reactive group is selected from the group consisting of:RRVlNNAMMeR2wherein Ri is selected from the group consisting of;wherein R2 is selected from the group consisting of

[0365] In an embodiment, the chimeric small molecule comprises an electrophilic reactive group suitable for attachment to a lysine, and wherein the electrophilic reactive group is selected from the group consisting of:rz»- rn sfe -w w-w w-wiooOHi w- »? S CS X Jl < trU'* TO>t) OHMethionine Reactive Electrophilic Linkers

[0366] In an embodiment, the chimeric small molecule comprises an electrophilic reactive group that functions as the acceptor site for methionine addition, resulting in transfer moiety release, and wherein the electrophilic reactive group is selected from the group consisting of:Oxt 0x2 0x3writ ft- r.wflHft4mW - ? M< f5-*' r{~ 149 ■?-?30x4 0*5 0x8s«*»:*«o&fe*ar* w®; if®JW*$W0x8 0x3«»; ft® or^ / r*0x10 0x11; ftM 0x13wm; ft « aiwrM4SxjftlS; ft*.«r“O3 *«^w 4,S4Oxt2t #»1Suift$2; »# atgxJQ4ft4j^a&WN-acyl-N-alkyl sulfonamide (NASA)

[0367] NASA chemistry may be used to design the electrophilic reactive group by forming a reversible or irreversible bond with a nucleophilic functional group located on the modifying polypeptide. NASA chemistry is generally described in Nat Commun 9, 1870 (2018), incorporated herein by reference. In an embodiment, the modifying polypeptide binding moiety can be attached to a linker utilizing A-acyl A-alkyl sulfonamide (NASA) electrophilic reactive group, further attached to a modifying polypeptide binding moiety. In an embodiment, a NASA analogue has the formula:V 'N'z? 'Me O1 V 8 'Me rf . A V" 'N'z° 'Me t ’NO2XA ' kCF3 LJ i 'CHF2 / CH2FQ o 9 N" Me 'NE 5t st0N' A Me k CO2H<X V ,O J 9I. Et" 'N' Me A [- N N Me V 1 k.xO®uX / Ph" 'N"” Me N AFO 0 F AF2CF30.,ZO ? Ph A N A °V° t Me Et" 'Nz'MeXCF2CF30 derivative thereof.Dibromophenyl Benzoate

[0368] In an embodiment, the electrophilic reactive group is dibromophenyl benzoate (DB).The dibromophenyl group acts as the leaving group facilitating the reaction while the benzoate stabilizes the now attached moiety. DB chemistry is generally described in Takaoka et al. Chem. Sci., (2015) , 6, 3217-3224, incorporated herein by reference.N-sulfonyl pyridone

[0369] In an embodiment, the electrophilic reactive group is N-sulfonyl pyridone (SP). SP chemistry is generally described in K. Matsuo et al. Angew. Chem. Int. Ed. 2018, 57, 659 incorporated herein by reference.Photo-Reactive Group

[0370] In an embodiment, the electrophilic reactive group is a photo-reactive group. In an embodiment, the photo-reactive group is a photoactivated cell-surface reactive group. In an embodiment, the photoactivated cell-surface reactive group is a benzophenone, azide, or diazirine, wherein the group is activated to become a carbon-centered radical, nitrene, or carbene, respectively. In an embodiment, the photo-reactive group is athienyl-substituted alpha-ketoamide, see e.g. Ota, E., et al. "Thienyl-Substituted a-Ketoamide: A Less Hydrophobic Reactive Group for Photo- Affinity Labeling." ACS Chem. Biol. 2018, 13 (4), 876-880.Additional Electrophilic Reactive Linkers

[0371] In an embodiment, the electrophilic reactive group comprisesor an analog thereof.

[0372] In an embodiment, the electrophilic reactive group comprisesJI 1or an analog thereof.

[0373] In an embodiment, the electrophilic reactive group comprises one ofO

[0374] In an embodiment, the electrophilic reactive group is of the formula:or a derivative thereof.

[0375] In an embodiment, the electrophilic reactive group comprises

[0376] In an embodiment, the electrophilic reactive group has the formula:owherein Ri is selected from C-O, SO2, Me-C-O, or Me-SCh, R2 is selected from H, alkane, alkene, alkyne, amine, nitrile, nitro, ether, alcohol, thiol, sulfone, sulfonate, halogen, carbonyl, acyl, ketone, carboxylate ester, amide, enone, anhydride, imide, cyclic hydrocarbon, an unsaturated cyclic hydrocarbon, a heterocycle, one or more fused rings thereof; an aliphatic halide such as -OCF2CI or any combination thereof, and the benzene ring is optionally substituted at any position.

[0377] In an embodiment, the electrophilic reactive group comprises:wherein X is selected from the group consisting of:O=S=O HO~P=Oi*2 R2wherein Rl, R2, R3 each independently of an alkyl group, aryl group, or a heteroatom optionally O, N, or S.

[0378] In an embodiment, the electrophilic reactive group isO O 0Ph NIRwherein R is selected from the group consisting of:Y"'‘"'NO2,CN

[0379] In an embodiment, the electrophilic reactive group isN O I AN' MeO-S-OiPh

[0380] In an embodiment, the electrophilic reactive group is

[0381] In an embodiment, the electrophilic reactive group isA - , L2 R V N1 !H , wherein R is selected from the group consisting of:' M '"' 'n" 'n'" 'NCFN'ASH°T0MeO=?=OCA3 = / AN'' ' S'-' n:'N'" - ''S'-''o~s~o $ O-S-O o1CF3

[0382] In an embodiment, an electrophilic reactive group reactive with a serine hydroxyl can include an aryl phosphonate, a fluorophosphonate, or a sulfonyl fluoride, or other electrophilic groups reactive with serine.

[0383] In an embodiment, an electrophilic reactive group reactive with a threonine hydroxyl can include a sulfonyl fluoride, an aryl phosphonate, or a fluorophosphonate, with selectivity for the threonine residue that can be guided by the local environment of the binding pocket.

[0384] In an embodiment, an electrophilic reactive group reactive with a tyrosine phenol can include a sulfonyl fluoride (for example, an electrophile reactive in sulfur(VI) fluoride exchange chemistry), a diazonium salt, or a triazolinedione.

[0385] In an embodiment, an electrophilic reactive group reactive with a glutamate or aspartate side-chain carboxylate can be configured to undergo proximity-mediated acyl transfer with the carboxylate.

[0386] In an embodiment, an electrophilic reactive group reactive with an arginine guanidinium can include a vicinal dicarbonyl, for example glyoxal, methylglyoxal, or phenylglyoxal, that condenses with the guanidinium nitrogen atoms to form a cyclic adduct.

[0387] In an embodiment, an electrophilic reactive group reactive with a histidine imidazole can include a sulfonyl fluoride or an epoxide, with reactivity that can be tuned by the local pH and the protonation state of the imidazole nitrogen atoms.Linker

[0388] A linker or linking moiety is used to link one or more of the components of the chimeric small molecules disclosed herein. In an embodiment, the terms 'linker,1'linker moiety,' 'linking moiety,1'linker molecule,' and 'linking molecule' can be used interchangeably to refer to L, LI, or L2. The linker moiety may be a chemical linker moiety and represented in the formulas of thepresent invention as L, LI, or L2. Tn an embodiment, the linker moiety may comprise one or more repeats, e.g. 1, 2, 3, 4, 5, 6, 7, 8 or more repeats, which may be utilized to facilitate or improve spacing, conformation, and / or performance of the molecules. The linker described herein may refer to both LI and L2 or LI and L2 are different linkers described herein. In an embodiment, the linker has a functionality capable of reacting with the moi eties for covalent attachment.

[0389] There are many linkers that can be used to design the compounds described herein. For example, amides, esters, and amines can be created by well-known reactions and are used in medicinal chemistry. Additional linkers such as oxygen-containing linkers (e.g., ethers, ketones, esters, etc.,) are used create natural product-like molecules. Linkers can be designed to connect two or more moieties, for example, a protein-tag binding moiety and a transfer moiety. Moreover, the linkers are designed to include an electrophilic reactive group. These linkers can be advantageous for extended binding sites, such as those described herein Linkers can be taken from, for example, ChEMBL and / or ZINC databases and designed to connect two or more binding moieties and include an electrophilic reactive group. When selecting a linker, it is common to compute and compare their properties such as their topographical characteristics and / or electronic properties. For further guidance on linker selection see e.g., P. Ertl, et al., Bioorganic & Medicinal Chemistry 2023, 81, 117194, incorporated herein by reference.

[0390] In an embodiment, a linker can include an alkane, alkene, alkyne, amine, ether, thiol, sulfone, carbonyl, acyl, ketone, carboxylate ester, amide, enone, anhydride, imide, PEG, or any combination thereof.

[0391] A linker or linking moiety can be used to link a protein-tag binding moiety to the transfer moiety, and / or the electrophilic reactive group to either the protein-tag binding moiety, transfer moiety, or both. When more than one linker molecule is used in a molecule (e.g. LI and L2), the linkers may be the same or different from each other.Exit Vectors

[0392] In an embodiment, the linker may be represented with an exit vector. In an embodiment, the exit vector may be represented independently of the linker. Exit vector parameters can be identified in part based on average orientation of a substituent attached to a variation point which can be generated using chemoinformatics software. An exit vector may comprise outgoing bonds from a chemical moiety. In an embodiment, the exit vector is provided as bonds on the linker orfrom the binding moiety, providing conformation of attachment between the linker and the activator moiety and / or the localizing moiety.

[0393] One or more exit vectors may be utilized with the molecules described herein. In an embodiment, the bond is chosen to be energetically favorable, and / or increasing binding affinity. The exit vector may be adjusted depending on the linker utilized in the molecules. In embodiments, the exit vector is a chemical moiety or bond that facilitates stereochemical protrusion that may further facilitate subsequent coupling, bonding and / or accessibility.

[0394] In an embodiment, the protein-tag binding moiety and / or transfer moiety has an adapter or reactive handle, both used herein interchangeably. The reactive handle comprises the group on the protein-tag binding moiety and / or transfer moiety that attaches to the linker. In one example embodiment, the reactive handle can perform click chemistry, amide coupling chemistry, crosslinking chemistry, alkylation, or sulfonation chemistry. (See e.g., Nwe, K.; Brechbiel, M. W. Growing Applications of “Click Chemistry” for Bioconjugation in Contemporary Biomedical Research. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 289-302.)

[0395] In an embodiment, the bond is chosen to be energetically favorable, and / or increasing binding affinity. The exit vector may be adjusted depending on the linker utilized in the molecules. In an embodiment, the exit vector is a chemical moiety or bond that facilitates stereochemical protrusion that may further facilitate subsequent coupling, bonding and / or accessibility.Rigid Linker

[0396] In an embodiment, Lis a rigid linker, which may be selected from the group consisting of:; or any combination thereof; and wherein any atom in within a ring may substituted for C, N O, S; the linkers may bond to one or more PEG molecules before bonding to A and optionally B; and m and n may be independently selected from 0 to 6.

[0397] In an embodiment, the linker L has one covalent attachment point to a protein-tag binding moiety and two covalent attachment points to the other transfer moiety, or vice versa. A covalent attachment point may be any single, double, triple, or quadruple bond between one component of the chimeric small molecule and another. In an embodiment, the linker is attached to one protein-tag binding moiety, i.e. A, and the other, i.e. B, according to the formula:

[0398] In an embodiment, the PEG compounds in the previously mentioned linker can be substituted for any linker mentioned herein. In an embodiment, the previously mentioned linker isoptimized for physiochemical properties, such as solubility and / or permeability, and / or pharmacokinetic properties, such as microsomal stability or target binding.

[0399] In an embodiment, the protein-tag binding moiety has an adapter or reactive handle, both used herein interchangeably. The reactive handle comprises the group on the protein-tag binding moiety that attaches to the linker. In an embodiment, the reactive handle can perform click chemistry, amide coupling chemistry, crosslinking chemistry, alkylation, or sulfonation chemistry.

[0400] In an embodiment, the transfer moiety has an adapter or reactive handle, both used herein interchangeably. The reactive handle comprises the group on the transfer moiety that attaches to the linker. In an embodiment, the reactive handle can perform click chemistry, amide coupling chemistry, crosslinking chemistry, alkylation, or sulfonation chemistry.Orienting Adaptor

[0401] The linker may comprise one or more orienting adaptors. In embodiment, an orienting adaptor can be utilized at each instance of a localizing moiety or an activator moiety. In an embodiment, an orienting adaptor is appended on different ends of a linker molecule, with an orienting adaptor attached to protein-tag binding moiety and / or transfer moiety of the electrophilic reactive linker, and optionally, provides an orienting adaptor interconnecting the electrophilic reactive linker on a different end to the protein-tag binding moiety and / or transfer moiety.

[0402] In an embodiment, the orienting adaptor is a small molecule group that aids in the orienting of the protein-tag binding moiety and / or transfer moiety. In an embodiment, the orienting adaptors are chosen so that the small molecule compounds bind in one of their preferred, low-energy conformations. By way of example, when a protein is the substrate, a protein dissipates strain energy through small changes across its degrees of freedom more easily than for the small molecule to adopt an unfavorable conformation by straining its few rotatable bonds. Accordingly, ‘soft’ or low-energy torsion barriers are helpful when designing the small molecule compounds. The preferences can be considered when designing orienting molecules between aryl rings. Anisoles (ArOCTER) and anilines (ArNHR) prefer coplanar conformations, alkylaryls (ArCTER), arylsulfonamides and arylsulfones prefer a perpendicular conformation. Orienting adaptor atoms control both distance and direction. See, e.g. Brameld et al. J. Chem. Inf. Model. 2008, 48, 1-24.

[0403] In some instances, the orienting adaptors can be referred to in embodiments as exit vectors. Exit vector parameters can be identified in part based on average orientation of asubstituent attached to a variation point which can be generated using chemoinformatics software. An exit vector may comprise outgoing bonds from a chemical moiety. In certain embodiments, the bond is chosen to be energetically favorable, and / or increasing binding affinity. The orienting adaptor may be represented in certain embodiments with the linker, and may be adjusted depending on the linker utilized in the multifunctional molecules. In an embodiment, the orienting adaptor is a chemical moiety or bond that facilitates stereochemical protrusion that may further facilitate subsequent coupling, bonding and / or accessibility. In an embodiment, the first and second orienting adaptors are provided as bonds on the linker, providing conformation of attachment between the linker and the protein-tag binding moiety and / or transfer moiety.

[0404] In an embodiment, the orientation adaptor comprises:

[0405] In an embodiment, the first and second orienting adaptor, when present, are independently selected from Table A (Orienting Adaptor Table).Table A:O o -0- 0 & H H H3H-NH- oH0H uH H NJUBio-Orthogonal Group

[0406] The chimeric small molecules disclosed herein may comprise a biorthogonal group. In an embodiment, the protein-tag binding moiety, transfer moiety, linker, and / or electrophilic reactive group comprises a bio-orthogonal group. Bio-orthogonal chemistry comprises chemical reactions carried out in a biological environment without reacting with endogenous systems, suchas functional groups. Bio-orthogonal groups comprise moieties capable of bio-orthogonal chemistry. Non-limiting examples of bio-orthogonal groups include tetrazines, triazines, cyclooctenes, cyclopropenes and diazo groups.

[0407] In an embodiment, the bio-orthogonal group comprises one ofExample Chimeric Small Molecules

[0409] In an embodiment, the chimeric small molecule may bind with any of the protein-tags disclosed herein. In an embodiment, the chimeric small molecule binds to a protein-tag is derived from a Cl domain of Protein Kinase C (PKC). The Cl domain ofPKC may be ahuman Cl domain of PKC. In an embodiment, the chimeric small molecule binds to cTag. In an embodiment, the protein-tag may be fused to a protein of interest, enabling labeling of the fused protein.

[0410] The modular design of the chimeric small molecules allows adaptation to multiple protein-tags. The chimeric small molecule may be designed as required for a given protein-tag, and used with any protein-tag, such as HaloTag, SNAP -tag, CLIP -tag, TMP-tag, FAST tag, LAP tag, PYP tag, BioID, TurboID, miniTurbo, APEX2, SpyTag, SnoopTag, DARPin, Y-FAST, TC-FlAsH tag, ReACT tag, AcP tag, Q-tag, or SunTag.METHODS OF USE

[0411] In an aspect, the chimeric small molecules and protein-tags disclosed herein can be utilized in various methods, such as, method for labeling a protein-tag, modifying a protein comprising a protein-tag, modifying a target substrate in a cell, site-specific protein labeling, endogenous protein degradation screening, functional screening of induced protein -substrate interactions, and functional screening of post-translational modifications (PTM).

[0412] In an embodiment, chimeric small molecules and protein-tags disclosed herein may be used in methods to endow new functions to cellular proteins or to regulate the activity of cellular modifying proteins. The chimeric small molecules and protein-tags may find use for treatment in a variety of diseases and disorders. Exemplary applications include use in rewiring of cellular signaling. See, Lim et al., Nat Rev Mol Cell Biol 2010, 11(6), 393-403. For example, cell signaling can be addressed by appending phosphoryl groups to specific signaling protein of interest with dose and temporal control to allow rewiring of kinase signaling pathways in disease or health. The chimeric small molecule and protein-tag systems herein may enable targeted degradation of a target where phosphorylation sites are targets that recruit ubiquitin ligase and signal degradation. See, Toure et al., Angewandte Chemie (InterT ed. In English) 2016, 55(6), 1966-73. Similarly, preventing protein aggregation can aid in treatment in cancer treatment approaches. As described herein, addition of negatively charged phosphoryl groups using the chimeric small molecules on a protein prone to aggregation may increase solubility and reduce self-aggregation. Guo et al., FEBSLetters, 2005, 579 (17), 3574-3578; Zhang et al., Protein Expression and Purification 200436(2) 207-216. Exemplary embodiments further include regulation of nucleotide binding proteins, which may include use with orthogonally tagged nucleases such as Cas, and phosphorylation of transcription factors to affect binding. In an embodiment, the present disclosure herein relates to a method in which cells are modified ex vivo by the chimeric small molecules and / or protein-tag to modify at least one target substrate, with subsequent administration of the edited cells to a patient in need thereof.Method Of Labeling a Protein-tag

[0413] In an aspect, the chimeric small molecules and protein-tags disclosed herein can be utilized in a method for labeling of a protein-tag, comprising delivering the chimeric small molecule of the present disclosure to a protein-tag; and transferring the transfer moiety to the protein-tag via a group transfer reaction that results in elimination of the protein-tag binding moiety, whereby the protein-tag is labeled with the transfer moiety.

[0414] In an embodiment, the group transfer reaction occurs between a chimeric small molecule of the present disclosure and a cysteine or lysine residue of a protein-tag of the present disclosure.Method Of Modifying a Protein

[0415] In an aspect, the chimeric small molecules and protein-tags disclosed herein can be utilized in a method for modifying a protein comprising expressing a protein comprising the protein-tag of the present disclosure, delivering a chimeric small molecule of the present disclosure comprising a protein-tag binding moiety capable of binding the protein-tag, an electrophilic linker, and a transfer moiety, labeling the protein-tag with the transfer moiety via a group transfer reaction that results in elimination of the protein-tag binding moiety.

[0416] In an embodiment, the protein-tag is connected to the protein via chemogenetic fusion or chemical conjugation. In an embodiment, chemical conjugation can include sortase-mediated ligation, maleimide-thiol coupling, azide-alkyne cycloaddition (including copper-catalyzed and strain-promoted variants), NHS-ester amine coupling, or other bioconjugation chemistries known in the art.Methods Of Modifying a Target Substrate

[0417] In an aspect, the chimeric small molecules and protein-tags disclosed herein can be utilized in a method of modifying a target substrate in a cell comprising: expressing a protein comprising the protein-tag of the present disclosure in a cell, delivering a chimeric small molecule of the present disclosure comprising a protein-tag binding moiety, an electrophilic linker and a substrate binding moiety, labeling the protein with the substrate binding moiety and eliminating the protein-tag binding moiety via a group transfer reaction, inducing proximity between the protein and a target substrate via binding of the substrate binding moiety to the target substrate, and modifying the target substrate by the protein.

[0418] In an embodiment, the protein is a kinase, a methyltransferase, an acetyltransferase, a glycosyltransferase, an aminotransferase, a phosphatase, a peptidase or protease, a glycosidase, a lipase, a nuclease, an esterase, an amylase, a phosphodiesterase, a dehydrogenase, an oxidase, a reductase, a peroxidase, a hydroxylase, a monooxygenase, a catalase, a decarboxylase, an aldolase, a dehydratase, a synthase, a hyaluronate lyase, an epimerase, a racemase, a mutase, a topoisomerase, a protein disulfide isomerase, a ligase, an aminoacyl -tRNA synthetase, a carboxylase, a synthetase, or a ubiquitin ligase.

[0419] The chimeric small molecules disclosed herein can be utilized in methods of modifying a target substrate. Target substrates may be proteins, polynucleotides, oligosaccharides, or lipids. Methods of modifying a target substrate are provided, which may be in a cell. In an embodiment, the modifying comprises inducing post-translational modification (PTM) of a target protein. In an embodiment, the post-translational modification is phosphorylation. The method comprises delivering, contacting, or administering to a cell or cell population a chimeric small molecule and / or protein-tag of the present disclosure. Contacting can allow for bonding to, or association with the target substrate, or to a molecule in proximity to a target substrate. Modification may be by inducing a conformational change via binding, changing structural stability, phosphorylation of a target, or via another mechanisms that affects the behavior of the target substrate. By way of example, activation or inactivation of the target substrate via the binding of the chimeric small molecule results in modification of the target substrate one or more new modification sites that would otherwise remain unmodified when the chimeric small molecule is not bound to the targetsubstrate. In an embodiment, the methods comprise inducing phosphorylation of a target protein in the cell.

[0420] In an embodiment, the chimeric small molecule can label a protein comprising the protein-tag with the substrate binding moiety for the target substrate via the electrophilic reactive group moiety. Labelling of the protein comprising the protein-tag can allow for bonding to, or association with, the target substrate, or to a molecule in proximity to a target substrate, facilitating modification of the target substrate.

[0421] In an embodiment, the target substrate is not a natural substrate of the protein, or wherein activation of the protein by the binding moiety results in modification of the target substrate by the protein at one or more new modification sites that would otherwise remain unmodified by the protein when not activated by binding to the activator moiety. Modification may be by inducing a conformational change via binding, changing structural stability, phosphorylation of a target, or via other mechanisms that affects the behavior of the target substrate, e.g., removal of groups such as phosphatases, methyltransferases.

[0422] Modifying can include the post-translational modification (PTM) as disclosed herein, including, for example, phosphorylation, hydroxylation, acetylation, methylation, glycosylation, prenylation, amidation, eliminylation, lipidation, acylation, lipoylation, deacetylation, formylation, S-nitrosylation, S-sulfenylation, sulfonylation, sulfinylation, succinylation, sulfation, carbonylation, or alkylation. In an embodiment, the methods comprise inducing phosphorylation of a target protein in or on the cell. The methods may comprise contacting a target substrate with the chimeric small molecule of the present disclosure. Chimeric small molecules that induce phosphorylation can be optionally provided with adenosine monophosphate (AMP) or another molecule providing an additional phosphate group. Without being bound by theory, the addition of the AMP or other phosphate providing molecule can enhance phosphorylation.Method For Site-Specific Protein Labeling

[0423] In an aspect, the chimeric small molecules and protein-tags disclosed herein can be utilized in a method for site-specific protein labeling comprising expressing a protein comprising the protein-tag of the present disclosure in a cell or cell population, delivering a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker, and a detectable label or affinity label, labeling the protein with the detectable label or affinity label and eliminating theprotein-tag binding moiety via a group transfer reaction, detecting the labeled protein in the cell using microscopy or affinity -based detection.Method of Screening

[0424] The term “modulate” broadly denotes a qualitative and / or quantitative alteration, change or variation in that which is being modulated. Where modulation can be assessed quantitatively - for example, where modulation comprises or consists of a change in a quantifiable variable such as a quantifiable property of a cell or where a quantifiable variable provides a suitable surrogate for the modulation - modulation specifically encompasses both increase (e.g., activation) or decrease (e.g., inhibition) in the measured variable. The term encompasses any extent of such modulation, e.g., any extent of such increase or decrease, and may more particularly refer to statistically significant increase or decrease in the measured variable.

[0425] By means of example, modulation may encompass an increase in the value of the measured variable by at least about 10%, e.g., by at least about 20%, by at least about 30%, e.g., by at least about 40%, by at least about 50%, e.g., by at least about 75%, by at least about 100%, e.g., by at least about 150%, 200%, 250%, 300%, 400% or by at least about 500%, compared to a reference situation without said modulation; or modulation may encompass a decrease or reduction in the value of the measured variable by at least about 10%, e.g., by at least about 20%, by at least about 30%, e.g., by at least about 40%, by at least about 50%, e.g., by at least about 60%, by at least about 70%, e.g., by at least about 80%, by at least about 90%, e.g., by at least about 95%, such as by at least about 96%, 97%, 98%, 99% or even by 100%, compared to a reference situation without said modulation. Modulation may be specific or selective, hence, one or more desired phenotypic aspects of an immune cell or immune cell population may be modulated without substantially altering other (unintended, undesired) phenotypic aspect(s).

[0426] After the chimeric small molecule is applied, a representative cell sample can be subjected to analysis, for example at various time points, and compared to a control, such as a sample from an organism or cell, for example a cell from an organism, or a standard value. By exposing cells, or fractions thereof, tissues, or even whole animals, to different members of the chemical libraries, and performing the methods described herein, different members of a chemical library can be screened for their effect on immune phenotypes thereof simultaneously in a relatively short amount of time, for example using a high throughput method.

[0427] In an embodiment, screening of test agents involves testing a combinatorial library containing a large number of potential modulator compounds. A combinatorial chemical library may be a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide library, is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (for example the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.Method For Endogenous Protein Degradation Screening

[0428] In an aspect, the chimeric small molecules and protein-tags disclosed herein can be utilized in a method for endogenous protein degradation screening, comprising inserting a nucleic acid encoding the protein-tag of the present disclosure into one or more genomic loci encoding an endogenous protein(s) in a cell or cell population, delivering a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker, and a degradation-inducing moiety, labeling the endogenous protein(s) with the degradation-inducing moiety and eliminating the protein-tag binding moiety via a group transfer reaction, exposing the cell or cell population to a selective pressure, identifying cells displaying a phenotype change under the selective pressure, sequencing the cell or cell population to determine which tagged endogenous protein(s), when degraded, are associated with the phenotype change.Method For Functional Screening of Induced Protein-Substrate Interactions

[0429] In an aspect, the chimeric small molecules and protein-tags disclosed herein can be utilized in a method for functional screening of induced protein-substrate interactions comprising, inserting a nucleic acid encoding the protein-tag of the present disclosure into one or more genomic loci encoding an endogenous protein(s) in a cell or cell population, delivering to the cell or cell population a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker, and a substrate binding moiety, labeling the endogenous protein(s) with the substrate binding moiety and eliminating the protein-tag binding moiety via a group transfer reaction, thereby inducing proximity between the tagged endogenous protein(s) and the substrate, identifying cells displaying a phenotype change resulting from the induced proximity, sequencingthe cell or cell population to determine which tagged endogenous protein are associated with the phenotypic change.Method For Functional Screening of Post-Translational Modifications

[0430] In an aspect, the chimeric small molecules and protein-tags disclosed herein can be utilized in a method for functional screening of post-translational modifications comprising, inserting a nucleic acid encoding the protein-tag of the present disclosure into one or more genomic loci encoding an endogenous protein(s) in a cell or cell population, delivering to the cell or cell population a ligand comprising a protein-tag binding moiety, an electrophilic linker, and an enzyme binding moiety, labeling the endogenous protein(s) with the enzyme binding moiety and eliminating the protein-tag binding moiety via a group transfer reaction, thereby inducing proximity between an enzyme capable of catalyzing a post-translational modification and the endogenous protein(s), identifying cells displaying a phenotypic change resulting from the induced proximity, sequencing the cell or cell population to determine which tagged endogenous protein(s), when modified, are associated with the phenotypic change.

[0431] Methods of nucleic acid analysis can be utilized for screening of chemical libraries, and to identify chimeric small molecules for use within the context of the embodiments disclosed herein. In an embodiment, the disclosed methods can be used to screen chemical libraries for agents that bind modifying polypeptides and modulate activation or inactivation of the same. By exposing cells, or fractions thereof, tissues, or even whole animals, to different members of the chemical libraries, and performing the methods described herein, different members of a chemical library can be screened for their effect on modifying polypeptide binding and activation state. Pharmaceutical Formulations

[0432] Also described herein are pharmaceutical formulations that can contain an amount, effective amount, and / or least effective amount, and / or therapeutically effective amount of one or more compounds, molecules, compositions, vectors, vector systems, cells, or a combination thereof (which are also referred to as the primary active agent or ingredient elsewhere herein) described in greater detail elsewhere herein a pharmaceutically acceptable carrier or excipient. As used herein, “pharmaceutical formulation” refers to the combination of an active agent, compound, or ingredient with a pharmaceutically acceptable carrier or excipient, making the composition suitable for diagnostic, therapeutic, or preventive use in vitro, in vivo, or ex vivo. As used herein,“pharmaceutically acceptable carrier or excipient” refers to a carrier or excipient that is useful in preparing a pharmaceutical formulation that is generally safe, non-toxic, and is neither biologically or otherwise undesirable, and includes a carrier or excipient that is acceptable for veterinary use as well as human pharmaceutical use. A “pharmaceutically acceptable carrier or excipient” as used in the specification and claims includes both one and more than one such carrier or excipient. When present, the compound can optionally be present in the pharmaceutical formulation as a pharmaceutically acceptable salt. In an embodiment, the pharmaceutical formulation can include, such as an active ingredient, a CRISPR-Cas system or component thereof described in greater detail elsewhere herein. In an embodiment, the pharmaceutical formulation can include, such as an active ingredient, a CRISPR-Cas polynucleotide described in greater detail elsewhere herein. In an embodiment, the pharmaceutical formulation can include, such as an active ingredient one or more modified cells, such as one or more modified cells described in greater detail elsewhere herein.

[0433] In an embodiment, the active ingredient is present as a pharmaceutically acceptable salt of the active ingredient. As used herein, “pharmaceutically acceptable salt” refers to any acid or base addition salt whose counter-ions are non-toxic to the subject to which they are administered in pharmaceutical doses of the salts. Suitable salts include, hydrobromide, iodide, nitrate, bisulfate, phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, napthalenesulfonate, propionate, malonate, mandelate, malate, phthalate, and pamoate.

[0434] The pharmaceutical formulations described herein can be administered to a subject in need thereof via any suitable method or route to a subject in need thereof. Suitable administration routes can include, but are not limited to auricular (otic), buccal, conjunctival, cutaneous, dental, electro-osmosis, endocervical, endosinusial, endotracheal, enteral, epidural, extra-amniotic, extracorporeal, hemodialysis, infiltration, interstitial, intra-abdominal, intra-amniotic, intraarterial, intra-articular, intrabiliary, intrabronchial, intrabursal, intracardiac, intracartilaginous, intracaudal, intracavernous, intracavitary, intracerebral, intracisternal, intracorneal, intracoronal (dental), intracoronary, intracorporus cavemosum, intradermal, intradiscal, intraductal,intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralesional, intraluminal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraocular, intraovarian, intrapericardial, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrasinal, intraspinal, intrasynovial, intratendinous, intratesticular, intrathecal, intrathoracic, intratubular, intratumor, intratympanic, intrauterine, intravascular, intravenous, intravenous bolus, intravenous drip, intraventricular, intravesical, intravitreal, iontophoresis, irrigation, laryngeal, nasal, nasogastric, occlusive dressing technique, ophthalmic, oral, oropharyngeal, other, parenteral, percutaneous, periarticular, peridural, perineural, periodontal, rectal, respiratory (inhalation), retrobulbar, soft tissue, subarachnoid, subconjunctival, subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transplacental, transtracheal, transtympanic, ureteral, urethral, and / or vaginal administration, and / or any combination of the above administration routes, which typically depends on the disease to be treated and / or the active ingredient(s).

[0435] Where appropriate, compounds, molecules, compositions, vectors, vector systems, cells, or a combination thereof described in greater detail elsewhere herein can be provided to a subject in need thereof as an ingredient, such as an active ingredient or agent, in a pharmaceutical formulation. As such, also described are pharmaceutical formulations containing one or more of the compounds and salts thereof, or pharmaceutically acceptable salts thereof described herein. Suitable salts include, hydrobromide, iodide, nitrate, bisulfate, phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, napthalenesulfonate, propionate, malonate, mandelate, malate, phthalate, and pamoate.

[0436] In an embodiment, the subject in need thereof has or is suspected of having a cancer or a symptom thereof. In an embodiment, the subject in need thereof has or is suspected of having, a neurobiological disease or disorder, a psychiatric disease or disorder, a cancer, an autoimmune disease or disorder, a thrombosis disease, a heart disease, a kidney disease, a lung disease, or a blood vessel disease, or a combination thereof. As used herein, “agent” refers to any substance, compound, molecule, and the like, which can be biologically active or otherwise can induce a biological and / or physiological effect on a subject to which it is administered to. As used herein,“active agent” or “active ingredient” refers to a substance, compound, or molecule, which is biologically active or otherwise, induces a biological or physiological effect on a subject to which it is administered to. In other words, “active agent” or “active ingredient” refers to a component or components of a composition to which the whole or part of the effect of the composition is attributed. An agent can be a primary active agent, or in other words, the component(s) of a composition to which the whole or part of the effect of the composition is attributed. An agent can be a secondary agent, or in other words, the component(s) of a composition to which an additional part and / or other effect of the composition is attributed.Pharmaceutically Acceptable Carriers and Secondary Ingredients and Agents

[0437] The pharmaceutical formulation can include a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include, but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxy methyl cellulose, and polyvinyl pyrrolidone, which do not deleteriously react with the active composition.

[0438] The pharmaceutical formulations can be sterilized, and if desired, mixed with agents, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and / or aromatic substances, and the like which do not deleteriously react with the active compound.

[0439] In an embodiment, the pharmaceutical formulation can also include an effective amount of secondary active agents, including but not limited to, biologic agents or molecules including, but not limited to, e.g. polynucleotides, amino acids, peptides, polypeptides, antibodies, aptamers, ribozymes, hormones, immunomodulators, antipyretics, anxiolytics, antipsychotics, analgesics, antispasmodics, anti-inflammatories, anti-histamines, anti-infectives, chemotherapeutics, and combinations thereof.Effective Amounts

[0440] In an embodiment, the amount of the primary active agent and / or optional secondary agent can be an effective amount, least effective amount, and / or therapeutically effective amount. As used herein, “effective amount” refers to the amount of the primary and / or optional secondary agent included in the pharmaceutical formulation that achieve one or more therapeutic effects ordesired effect. As used herein, “least effective” amount refers to the lowest amount of the primary and / or optional secondary agent that achieves the one or more therapeutic or other desired effects. As used herein, “therapeutically effective amount” refers to the amount of the primary and / or optional secondary agent included in the pharmaceutical formulation that achieves one or more therapeutic effects.

[0441] The effective amount, least effective amount, and / or therapeutically effective amount of the primary and optional secondary active agent described elsewhere herein contained in the pharmaceutical formulation can range from about 0 to 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000 pg, ng, pg, mg, or g or be any numerical value with any of these ranges.

[0442] In an embodiment, the effective amount, least effective amount, and / or therapeutically effective amount can be an effective concentration, least effective concentration, and / or therapeutically effective concentration, which can each range from about 0 to 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000 pM, nM, pM, mM, or M or be any numerical value with any of these ranges.

[0443] In other embodiments, the effective amount, least effective amount, and / or therapeutically effective amount of the primary and optional secondary active agent can range from about 0 to 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750,760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000 IU or be any numerical value with any of these ranges.

[0444] In an embodiment, the primary and / or the optional secondary active agent present in the pharmaceutical formulation can range from about 0 to 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, 0.5, 0.51, 0.52, 0.53, 0.54, 0.55, 0.56, 0.57, 0.58, 0.59, 0.6, 0.61, 0.62, 0.63, 0.64, 0.65, 0.66, 0.67, 0.68, 0.69, 0.7, 0.71, 0.72, 0.73, 0.74, 0.75, 0.76, 0.77, 0.78, 0.79, 0.8, 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89, 0.9, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.9, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 % w / w, v / v, or w / v of the pharmaceutical formulation.

[0445] In an embodiment where a cell population is present in the pharmaceutical formulation (e.g., as a primary and / or or secondary active agent), the effective amount of cells can range from about 2 cells to IXIO' / mL, lX1020 / mL or more, such as about IXlO mL, lX102 / mL, lX103 / mL, IXIO mL, lX105 / mL, lX106 / mL, lX107 / mL, lX108 / mL, lX109 / mL, lX1010 / mL, lX10n / mL, lX1012 / mL, !X1013 / mL, !X1014 / mL, lX1015 / mL, !X1016 / mL, lX1017 / mL, lX1018 / mL, lX1019 / mL, to / or about lX102° / mL.

[0446] In an embodiment, the amount or effective amount, particularly where an infective particle is being delivered (e.g. a virus particle having the primary or secondary agent as a cargo), the effective amount of virus particles can be expressed as a titer (plaque forming units per unit of volume) or as a MOI (multiplicity of infection). In an embodiment, the effective amount can be 1X101particles per pL, nL, pL, mb, or L to 1X1O20 / particles per pL, nL, pL, mb, or L or more, such as about 1X101, 1X102, 1X103, 1X104, 1X105, 1X106, 1X107, 1X108, 1X109, 1X1010, 1X1011, 1X1012, 1X1013, 1X1014, 1X1015, 1X1016, 1X1017, 1X1018, 1X1019, to / or about 1X1O20particles per pL, nL, pL, mb, or L. In an embodiment, the effective titer can be about 1X101transforming units per pL, nL, pL, mL, or L to 1X1O20 / transforming units per pL, nL, pL, mL, or L or more,such as about 1X101, 1X102, 1X103, 1X104, 1X1O5, 1X106, 1X107, 1X108, 1X109, 1X1O10, 1X1O11, 1X1012, 1X1O13, 1X1014, 1X1O15, 1X1016, 1X1017, 1X1O18, 1X1019, to / or about 1X1O20transforming units per pL, nL, pL, mL, or L. In an embodiment, the MOI of the pharmaceutical formulation can range from about 0.1 to 10 or more, such as 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10 or more.

[0447] In an embodiment, the amount or effective amount of the one or more of the active agent(s) described herein contained in the pharmaceutical formulation can range from about 1 pg / kg to about 10 mg / kg based upon the bodyweight of the subject in need thereof or average bodyweight of the specific patient population to which the pharmaceutical formulation can be administered.

[0448] In one example embodiment where there is a secondary agent contained in the pharmaceutical formulation, the effective amount of the secondary active agent will vary depending on the secondary agent, the primary agent, the administration route, subject age, disease, stage of disease, among other things, which will be one of ordinary skill in the art.

[0449] When optionally present in the pharmaceutical formulation, the secondary active agent can be included in the pharmaceutical formulation or can exist as a stand-alone compound or pharmaceutical formulation that can be administered contemporaneously or sequentially with the compound, derivative thereof, or pharmaceutical formulation thereof.

[0450] In an embodiment, the effective amount of the secondary active agent can range from about O to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 % w / w, v / v, or w / v of the total secondary active agent in the pharmaceutical formulation. In additional embodiments, the effective amount of the secondary active agent can range from about 0 to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 % w / w, v / v, or w / v of the total pharmaceutical formulation.Dosage Forms

[0451] In an embodiment, the pharmaceutical formulations described herein can be provided in a dosage form. The dosage form can be administered to a subject in need thereof. The dosage form can be effective generate specific concentration, such as an effective concentration, at a given site in the subject in need thereof. As used herein, “dose,” “unit dose,” or “dosage” can refer to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of the primary active agent, and optionally present secondary active ingredient, and / or a pharmaceutical formulation thereof calculated to produce the desired response or responses in association with its administration. In an embodiment, the given site is proximal to the administration site. In an embodiment, the given site is distal to the administration site. In some cases, the dosage form contains a greater amount of one or more of the active ingredients present in the pharmaceutical formulation than the final intended amount needed to reach a specific region or location within the subject to account for loss of the active components such as via first and second pass metabolism.

[0452] The dosage forms can be adapted for administration by any appropriate route. Appropriate routes include, but are not limited to, oral (including buccal or sublingual), rectal, intraocular, inhaled, intranasal, topical (including buccal, sublingual, or transdermal), vaginal, parenteral, subcutaneous, intramuscular, intravenous, internasal, and intradermal. Other appropriate routes are described elsewhere herein. Such formulations can be prepared by any method known in the art.

[0453] Dosage forms adapted for oral administration can discrete dosage units such as capsules, pellets or tablets, powders or granules, solutions, or suspensions in aqueous or nonaqueous liquids; edible foams or whips, or in oil-in-water liquid emulsions or water-in-oil liquid emulsions. In an embodiment, the pharmaceutical formulations adapted for oral administration also include one or more agents which flavor, preserve, color, or help disperse the pharmaceuticalformulation. Dosage forms prepared for oral administration can also be in the form of a liquid solution that can be delivered as a foam, spray, or liquid solution. The oral dosage form can be administered to a subject in need thereof. Where appropriate, the dosage forms described herein can be microencapsulated.

[0454] The dosage form can also be prepared to prolong or sustain the release of any ingredient. In an embodiment, compounds, molecules, compositions, vectors, vector systems, cells, or a combination thereof described herein can be the ingredient whose release is delayed. In an embodiment the primary active agent is the ingredient whose release is delayed. In an embodiment, an optional secondary agent can be the ingredient whose release is delayed. Suitable methods for delaying the release of an ingredient include, but are not limited to, coating or embedding the ingredients in material in polymers, wax, gels, and the like. Delayed release dosage formulations can be prepared as described in standard references such as "Pharmaceutical dosage form tablets," eds. Liberman et. al. (New York, Marcel Dekker, Inc., 1989), "Remington - The science and practice of pharmacy", 20th ed., Lippincott Williams & Wlkins, Baltimore, MD, 2000, and "Pharmaceutical dosage forms and drug delivery systems", 6th Edition, Ansel et al., (Media, PA: Wiliams and Wlkins, 1995). These references provide information on excipients, materials, equipment, and processes for preparing tablets and capsules and delayed release dosage forms of tablets and pellets, capsules, and granules. The delayed release can be anywhere from about an hour to about 3 months or more.

[0455] Examples of suitable coating materials include, but are not limited to, cellulose polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and methacrylic resins that are commercially available under the trade name EUDRAGIT® (Roth Pharma, Westerstadt, Germany), zein, shellac, and polysaccharides.

[0456] Coatings may be formed with a different ratio of water-soluble polymer, water insoluble polymers, and / or pH dependent polymers, with or without water insoluble / water soluble non-polymeric excipient, to produce the desired release profile. The coating is either performed on the dosage form (matrix or simple) which includes, but is not limited to, tablets (compressed with or without coated beads), capsules (with or without coated beads), beads, particlecompositions, "ingredient as is" formulated as, but not limited to, suspension form or as a sprinkle dosage form.

[0457] Where appropriate, the dosage forms described herein can be a liposome. In these embodiments, primary active ingredient(s), and / or optional secondary active ingredient(s), and / or pharmaceutically acceptable salt thereof where appropriate are incorporated into a liposome. In one example embodiment where the dosage form is a liposome, the pharmaceutical formulation is thus a liposomal formulation. The liposomal formulation can be administered to a subject in need thereof.

[0458] Dosage forms adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils. In an embodiment for treatments of the eye or other external tissues, for example the mouth or the skin, the pharmaceutical formulations are applied as a topical ointment or cream. When formulated in an ointment, a primary active ingredient, optional secondary active ingredient, and / or pharmaceutically acceptable salt thereof where appropriate can be formulated with a paraffinic or water-miscible ointment base. In other embodiments, the primary and / or secondary active ingredient can be formulated in a cream with an oil-in-water cream base or a water-in-oil base. Dosage forms adapted for topical administration in the mouth include lozenges, pastilles, and mouth washes.

[0459] Dosage forms adapted for nasal or inhalation administration include aerosols, solutions, suspension drops, gels, or dry powders. In an embodiment, a primary active ingredient, optional secondary active ingredient, and / or pharmaceutically acceptable salt thereof where appropriate can be in a dosage form adapted for inhalation is in a particle-size-reduced form that is obtained or obtainable by micronization. In an embodiment, the particle size of the size reduced (e.g. micronized) compound or salt or solvate thereof, is defined by a Dso value of about 0.5 to about 10 microns as measured by an appropriate method known in the art. Dosage forms adapted for administration by inhalation also include particle dusts or mists. Suitable dosage forms wherein the carrier or excipient is a liquid for administration as a nasal spray or drops include aqueous or oil solutions / suspensions of an active (primary and / or secondary) ingredient, which may be generated by various types of metered dose pressurized aerosols, nebulizers, or insufflators. The nasal / inhalation formulations can be administered to a subject in need thereof.

[0460] In an embodiment, the dosage forms are aerosol formulations suitable for administration by inhalation. In some of these embodiments, the aerosol formulation contains a solution or fine suspension of a primary active ingredient, secondary active ingredient, and / or pharmaceutically acceptable salt thereof where appropriate and a pharmaceutically acceptable aqueous or non-aqueous solvent. Aerosol formulations can be presented in single or multi -dose quantities in sterile form in a sealed container. For some of these embodiments, the sealed container is a single dose or multi -dose nasal or an aerosol dispenser fitted with a metering valve (e g. metered dose inhaler), which is intended for disposal once the contents of the container have been exhausted.

[0461] Where the aerosol dosage form is contained in an aerosol dispenser, the dispenser contains a suitable propellant under pressure, such as compressed air, carbon dioxide, or an organic propellant, including but not limited to a hydrofluorocarbon. The aerosol formulation dosage forms in other embodiments are contained in a pump-atomizer. The pressurized aerosol formulation can also contain a solution or a suspension of a primary active ingredient, optional secondary active ingredient, and / or pharmaceutically acceptable salt thereof. In further embodiments, the aerosol formulation also contains co-solvents and / or modifiers incorporated to improve, for example, the stability and / or taste and / or fine particle mass characteristics (amount and / or profile) of the formulation. Administration of the aerosol formulation can be once daily or several times daily, for example 2, 3, 4, or 8 times daily, in which 1, 2, 3 or more doses are delivered each time. The aerosol formulations can be administered to a subject in need thereof.

[0462] For some dosage forms suitable and / or adapted for inhaled administration, the pharmaceutical formulation is a dry powder inhalable-formulations. In addition to a primary active agent, optional secondary active ingredient, and / or pharmaceutically acceptable salt thereof where appropriate, such a dosage form can contain a powder base such as lactose, glucose, trehalose, manitol, and / or starch. In some of these embodiments, a primary active agent, secondary active ingredient, and / or pharmaceutically acceptable salt thereof where appropriate is in a particle-size reduced form. In further embodiments, a performance modifier, such as L-leucine or another amino acid, cellobiose octaacetate, and / or metals salts of stearic acid, such as magnesium or calcium stearate. In an embodiment, the aerosol formulations are arranged so that each metered dose of aerosol contains a predetermined amount of an active ingredient, such as the one or moreof the compositions, compounds, vector(s), molecules, cells, and combinations thereof described herein.

[0463] Dosage forms adapted for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulations. Dosage forms adapted for rectal administration include suppositories or enemas. The vaginal formulations can be administered to a subject in need thereof.

[0464] Dosage forms adapted for parenteral administration and / or adapted for injection can include aqueous and / or non-aqueous sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, solutes that render the composition isotonic with the blood of the subject, and aqueous and non-aqueous sterile suspensions, which can include suspending agents and thickening agents. The dosage forms adapted for parenteral administration can be presented in a single-unit dose or multi-unit dose containers, including but not limited to sealed ampoules or vials. The doses can be lyophilized and re-suspended in a sterile carrier to reconstitute the dose prior to administration. Extemporaneous injection solutions and suspensions can be prepared In an embodiment, from sterile powders, granules, and tablets. The parenteral formulations can be administered to a subject in need thereof.

[0465] For some embodiments, the dosage form contains a predetermined amount of a primary active agent, secondary active ingredient, and / or pharmaceutically acceptable salt thereof where appropriate per unit dose. In an embodiment, the predetermined amount of primary active agent, secondary active ingredient, and / or pharmaceutically acceptable salt thereof where appropriate can be an effective amount, a least effect amount, and / or a therapeutically effective amount. In other embodiments, the predetermined amount of a primary active agent, secondary active agent, and / or pharmaceutically acceptable salt thereof where appropriate, can be an appropriate fraction of the effective amount of the active ingredient.Co-Therapies and Combination Therapies

[0466] In an embodiment, the pharmaceutical formulation(s) described herein can be part of a combination treatment or combination therapy. The combination treatment can include the pharmaceutical formulation described herein and an additional treatment modality. The additional treatment modality can be a chemotherapeutic, a biological therapeutic, surgery, radiation, diet modulation, environmental modulation, a physical activity modulation, and combinations thereof.

[0467] In an embodiment, the co-therapy or combination therapy can additionally include but not limited to, polynucleotides, amino acids, peptides, polypeptides, antibodies, aptamers, ribozymes, hormones, immunomodulators, antipyretics, anxiolytics, antipsychotics, analgesics, antispasmodics, anti-inflammatories, anti-histamines, anti-infectives, chemotherapeutics, and combinations thereof.Administration of the Pharmaceutical Formulations

[0468] The pharmaceutical formulations or dosage forms thereof described herein can be administered one or more times hourly, daily, monthly, or yearly (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more times hourly, daily, monthly, or yearly). In an embodiment, the pharmaceutical formulations or dosage forms thereof described herein can be administered continuously over a period of time ranging from minutes to hours to days. Devices and dosages forms are known in the art and described herein that are effective to provide continuous administration of the pharmaceutical formulations described herein. In an embodiment, the first one or a few initial amount(s) administered can be a higher dose than subsequent doses. This is typically referred to in the art as a loading dose or doses and a maintenance dose, respectively. In an embodiment, the pharmaceutical formulations can be administered such that the doses over time are tapered (increased or decreased) overtime so as to wean a subject gradually off of a pharmaceutical formulation or gradually introduce a subject to the pharmaceutical formulation.

[0469] As previously discussed, the pharmaceutical formulation can contain a predetermined amount of a primary active agent, secondary active agent, and / or pharmaceutically acceptable salt thereof where appropriate. In some of these embodiments, the predetermined amount can be an appropriate fraction of the effective amount of the active ingredient. Such unit doses may therefore be administered once or more than once a day, month, or year (e.g. 1, 2, 3, 4, 5, 6, or more times per day, month, or year). Such pharmaceutical formulations may be prepared by any of the methods well known in the art.

[0470] Where co-therapies or multiple pharmaceutical formulations are to be delivered to a subject, the different therapies or formulations can be administered sequentially or simultaneously. Sequential administration is administration where an appreciable amount of time occurs between administrations, such as more than about 15, 20, 30, 45, 60 minutes or more. The time betweenadministrations in sequential administration can be on the order of hours, days, months, or even years, depending on the active agent present in each administration. Simultaneous administration refers to administration of two or more formulations at the same time or substantially at the same time (e.g. within seconds or just a few minutes apart), where the intent is that the formulations be administered together at the same time.Delivery and Administration

[0471] Methods for modifying a target of interest comprises administering or delivering or otherwise contacting a cell via one or more methods known in the art, including without limitation, microinjection, electroporation, sonoporation, biolistics, calcium phosphate-mediated transfection, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, nucleofection transfection, magnetofection, lipofection, impalefection, optical transfection, proprietary agent-enhanced uptake of nucleic acids, and delivery via liposomes, immunoliposomes, virosomes, or artificial virions. In some methods, the composition is introduced into an embryo by microinjection. The compositions may be microinjected into the nucleus or the cytoplasm of the embryo.

[0472] An actively targeting lipid particle or nanoparticle or liposome or lipid bilayer delivery system (generally as to embodiments of the invention, “lipid entity of the invention” delivery systems) are prepared by conjugating targeting moieties, including small molecule ligands, peptides and monoclonal antibodies, on the lipid or liposomal surface; for example, certain receptors, such as folate and transferrin (Tf) receptors (TfR), are overexpressed on many cancer cells and have been used to make liposomes tumor cell specific. Liposomes that accumulate in the tumor microenvironment can be subsequently endocytosed into the cells by interacting with specific cell surface receptors. To efficiently target liposomes to cells, such as cancer cells, it is useful that the targeting moiety have an affinity for a cell surface receptor and to link the targeting moiety in sufficient quantities to have optimum affinity for the cell surface receptors; and determining these aspects are within the ambit of the skilled artisan. In the field of active targeting, there are a number of cell-, e.g., tumor-, specific targeting ligands.

[0473] Also as to active targeting, with regard to targeting cell surface receptors such as cancer cell surface receptors, targeting ligands on liposomes can provide attachment of liposomes to cells, e.g., vascular cells, via a non-internalizing epitope; and, this can increase the extracellularconcentration of that which is being delivered, thereby increasing the amount delivered to the target cells. A strategy to target cell surface receptors, such as cell surface receptors on cancer cells, such as overexpressed cell surface receptors on cancer cells, is to use receptor-specific ligands or antibodies. Many cancer cell types display upregulation of tumor-specific receptors. For example, TfRs and folate receptors (FRs) are greatly overexpressed by many tumor cell types in response to their increased metabolic demand. Folic acid can be used as a targeting ligand for specialized delivery owing to its ease of conjugation to nanocarriers, its high affinity for FRs and the relatively low frequency of FRs, in normal tissues as compared with their overexpression in activated macrophages and cancer cells, e.g., certain ovarian, breast, lung, colon, kidney and brain tumors. Overexpression of FR on macrophages is an indication of inflammatory diseases, such as psoriasis, Crohn's disease, rheumatoid arthritis and atherosclerosis; accordingly, folate-mediated targeting of the invention can also be used for studying, addressing or treating inflammatory disorders, as well as cancers. Folate-linked lipid particles or nanoparticles or liposomes or lipid bilayers of the invention (“lipid entity of the invention”) deliver their cargo intracellularly through receptor-mediated endocytosis. Intracellular trafficking can be directed to acidic compartments that facilitate cargo release, and, most importantly, release of the cargo can be altered or delayed until it reaches the cytoplasm or vicinity of target organelles. Delivery of cargo using a lipid entity of the invention having a targeting moiety, such as a folate-linked lipid entity of the invention, can be superior to nontargeted lipid entity of the invention. The attachment of folate directly to the lipid head groups may not be favorable for intracellular delivery of fol ate -conjugated lipid entity of the invention, since they may not bind as efficiently to cells as folate attached to the lipid entity of the invention surface by a spacer, which may can enter cancer cells more efficiently. A lipid entity of the invention coupled to folate can be used for the delivery of complexes of lipid, e.g., liposome, e.g., anionic liposome and virus or capsid or envelope or virus outer protein, such as those herein discussed such as adenovirus or AAV. Tf is a monomeric serum glycoprotein of approximately 80 KDa involved in the transport of iron throughout the body. Tf binds to the TfR and translocates into cells via receptor-mediated endocytosis. The expression of TfR can be higher in certain cells, such as tumor cells (as compared with normal cells and is associated with the increased iron demand in rapidly proliferating cancer cells. Accordingly, the invention comprehends a TfR-targeted lipid entity of the invention, e.g., as to liver cells, liver cancer, breastcells such as breast cancer cells, colon such as colon cancer cells, ovarian cells such as ovarian cancer cells, head, neck and lung cells, such as head, neck and non-small-cell lung cancer cells, cells of the mouth such as oral tumor cells.

[0474] Also as to active targeting, a lipid entity of the invention can be multifunctional, i.e., employ more than one targeting moiety such as CPP, along with Tf; a chimeric small system; e.g., a combination of Tf and poly-L-arginine which can provide transport across the endothelium of the blood-brain barrier. EGFR is a tyrosine kinase receptor belonging to the ErbB family of receptors that mediates cell growth, differentiation and repair in cells, especially non-cancerous cells, but EGF is overexpressed in certain cells such as many solid tumors, including colorectal, non-small-cell lung cancer, squamous cell carcinoma of the ovary, kidney, head, pancreas, neck and prostate, and especially breast cancer. The invention comprehends EGFR-targeted monoclonal antibody(ies) linked to a lipid entity of the invention. HER-2 is often overexpressed in patients with breast cancer, and is also associated with lung, bladder, prostate, brain and stomach cancers. HER-2, encoded by the ERBB2 gene. The invention comprehends a HER-2-targeting lipid entity of the invention, e.g., an anti-HER-2-antibody(or binding fragment thereof)-lipid entity of the invention, a HER-2-targeting-PEGylated lipid entity of the invention (e.g., having an anti-HER-2-antibody or binding fragment thereof), a HER-2-targeting-maleimide-PEG polymer- lipid entity of the invention (e.g., having an anti-HER-2-antibody or binding fragment thereof). Upon cellular association, the receptor- antibody complex can be internalized by formation of an endosome for delivery to the cytoplasm. With respect to receptor-mediated targeting, the skilled artisan takes into consideration ligand / target affinity and the quantity of receptors on the cell surface, and that PEGylation can act as a barrier against interaction with receptors. The use of antibody-lipid entity of the invention targeting can be advantageous. Multivalent presentation of targeting moi eties can also increase the uptake and signaling properties of antibody fragments. In practice of the invention, the skilled person takes into account ligand density (e.g., high ligand densities on a lipid entity of the invention may be advantageous for increased binding to target cells). Preventing early by macrophages can be addressed with a sterically stabilized lipid entity of the invention and linking ligands to the terminus of molecules such as PEG, which is anchored in the lipid entity of the invention (e.g., lipid particle or nanoparticle or liposome or lipid bilayer). The microenvironment of a cell mass such as a tumor microenvironment can be targeted; for instance,it may be advantageous to target cell mass vasculature, such as the tumor vasculature microenvironment. Thus, the invention comprehends targeting VEGF. VEGF and its receptors are well-known proangiogenic molecules and are well -characterized targets for antiangiogenic therapy. Many small-molecule inhibitors of receptor tyrosine kinases, such as VEGFRs or basic FGFRs, have been developed as anticancer agents and the invention comprehends coupling any one or more of these peptides to a lipid entity of the invention, e.g., phage IVO peptide(s) (e.g., via or with a PEG terminus), tumor-homing peptide APRPG such as APRPG-PEG-modified. VCAM, the vascular endothelium plays a key role in the pathogenesis of inflammation, thrombosis and atherosclerosis. CAMs are involved in inflammatory disorders, including cancer, and are a logical target, E- and P-selectins, VCAM-1 and ICAMs. Can be used to target a lipid entity of the invention., e.g., with PEGylation. Matrix metalloproteases (MMPs) belong to the family of zincdependent endopeptidases. They are involved in tissue remodeling, tumor invasiveness, resistance to apoptosis and metastasis. There are four MMP inhibitors called TIMP1-4, which determine the balance between tumor growth inhibition and metastasis; a protein involved in the angiogenesis of tumor vessels is MT1-MMP, expressed on newly formed vessels and tumor tissues. The proteolytic activity of MT1-MMP cleaves proteins, such as fibronectin, elastin, collagen and laminin, at the plasma membrane and activates soluble MMPs, such as MMP-2, which degrades the matrix. An antibody or fragment thereof such as a Fabzfragment can be used in the practice of the invention such as for an antihuman MT1-MMP monoclonal antibody linked to a lipid entity of the invention, e.g., via a spacer such as a PEG spacer, a -integrins or integrins are a group of transmembrane glycoprotein receptors that mediate attachment between a cell and its surrounding tissues or extracellular matrix. Integrins contain two distinct chains (heterodimers) called a - and 0 -subunits. The tumor tissue-specific expression of integrin receptors can be utilized for targeted delivery in the invention, e.g., whereby the targeting moiety can be an RGD peptide such as a cyclic RGD. Aptamers are ssDNA or RNA oligonucleotides that impart high affinity and specific recognition of the target molecules by electrostatic interactions, hydrogen bonding and hydrophobic interactions as opposed to the Watson-Crick base pairing, which is typical for the bonding interactions of oligonucleotides. Aptamers as a targeting moiety can have advantages over antibodies: aptamers can demonstrate higher target antigen recognition as compared withantibodies; aptamers can be more stable and smaller in size as compared with antibodies; aptamers can be easily synthesized and chemically modified for molecular conjugation; and aptamers can be changed in sequence for improved selectivity and can be developed to recognize poorly immunogenic targets. Such moieties as a sgc8 aptamer can be used as a targeting moiety (e.g., via covalent linking to the lipid entity of the invention, e g., via a spacer, such as a PEG spacer). The targeting moiety can be stimuli -sensitive, e.g., sensitive to an externally applied stimuli, such as magnetic fields, ultrasound or light; and pH-triggering can also be used, e.g., a labile linkage can be used between a hydrophilic moiety such as PEG and a hydrophobic moiety such as a lipid entity of the invention, which is cleaved only upon exposure to the relatively acidic conditions characteristic of the a particular environment or microenvironment such as an endocytic vacuole or the acidotic tumor mass. pH-sensitive copolymers can also be incorporated in example embodiments of the invention can provide shielding; diortho esters, vinyl esters, cysteine-cleavable lipopolymers, double esters and hydrazones are a few examples of pH-sensitive bonds that are quite stable at pH 7.5, but are hydrolyzed relatively rapidly at pH 6 and below, e.g., a terminally alkylated copolymer of N-isopropyl acrylamide and methacrylic acid that copolymer facilitates destabilization of a lipid entity of the invention and release in compartments with decreased pH value; or, the invention comprehends ionic polymers for generation of a pH-responsive lipid entity of the invention (e.g., poly(methacrylic acid), poly(diethylaminoethyl methacrylate), poly(acrylamide) and poly(acrylic acid)). Temperature-triggered delivery is also within the ambit of the invention. Many pathological areas, such as inflamed tissues and tumors, show a distinctive hyperthermia compared with normal tissues. Utilizing this hyperthermia is an attractive strategy in cancer therapy since hyperthermia is associated with increased tumor permeability and enhanced uptake. This technique involves local heating of the site to increase microvascular pore size and blood flow, which, in turn, can result in an increased extravasation of embodiments of the invention. Temperature-sensitive lipid entity of the invention can be prepared from thermosensitive lipids or polymers with a low critical solution temperature. Above the low critical solution temperature (e.g., at site such as tumor site or inflamed tissue site), the polymer precipitates, disrupting the liposomes to release. Lipids with a specific gel-to-liquid phase transition temperature are used to prepare these lipid entities of the invention; and a lipid for a thermosensitive embodiment can be dipalmitoylphosphatidylcholine. Thermosensitive polymerscan also facilitate destabilization followed by release, and a useful thermosensitive polymer is poly (N-isopropylacrylamide). Another temperature triggered system can employ lysolipid temperature-sensitive liposomes. The invention also comprehends redox-triggered delivery: The difference in redox potential between normal and inflamed or tumor tissues, and between the intra -and extra-cellular environments has been used for delivery, e.g., GSH is a reducing agent abundant in cells, especially in the cytosol, mitochondria and nucleus. The GSH concentrations in blood and extracellular matrix are just one out of 100 to one out of 1000 of the intracellular concentration, respectively. This high redox potential difference caused by GSH, cysteine and other reducing agents can break the reducible bonds, destabilize a lipid entity of the invention and result in release of payload. The disulfide bond can be used as the cleavable / reversible linker in a lipid entity of the invention, because it causes sensitivity to redox owing to the disulfide-to-thiol reduction reaction; a lipid entity of the invention can be made reduction sensitive by using two (e.g., two forms of a disulfide-conjugated multifunctional lipid as cleavage of the disulfide bond (e.g., via tris(2-carboxyethyljphosphine, dithiothreitol, L-cysteine or GSH), can cause removal of the hydrophilic head group of the conjugate and alter the membrane organization leading to release of payload. Calcein release from reduction-sensitive lipid entity of the invention containing a disulfide conjugate can be more useful than a reduction-insensitive embodiment. Enzymes can also be used as a trigger to release payload. Enzymes, including MMPs (e.g. MMP2), phospholipase A2, alkaline phosphatase, transglutaminase or phosphatidylinositol-specific phospholipase C, have been found to be overexpressed in certain tissues, e.g., tumor tissues. In the presence of these enzymes, specially engineered enzyme-sensitive lipid entity of the invention can be disrupted and release the payload, an MMP2-cleavable octapeptide (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln) can be incorporated into a linker, and can have antibody targeting, e.g., antibody 2C5. The invention also comprehends light-or energy-triggered delivery, e.g., the lipid entity of the invention can be lightsensitive, such that light or energy can facilitate structural and conformational changes, which lead to direct interaction of the lipid entity of the invention with the target cells via membrane fusion, photo-isomerism, photofragmentation or photopolymerization; such a moiety therefor can be benzoporphyrin photosensitizer. Ultrasound can be a form of energy to trigger delivery; a lipid entity of the invention with a small quantity of particular gas, including air or perfluorated hydrocarbon can be triggered to release with ultrasound, e.g., low-frequency ultrasound (LFUS).Magnetic delivery: A lipid entity of the invention can be magnetized by incorporation of magnetites, such as Fe3O4 or y-Fe2O3, e.g., those that are less than 10 nm in size. Targeted delivery can be then by exposure to a magnetic field.

[0475] Also as to active targeting, the invention also comprehends intracellular delivery. Since liposomes follow the endocytic pathway, they are entrapped in the endosomes (pH 6.5-6) and subsequently fuse with lysosomes (pH <5), where they undergo degradation that results in a lower therapeutic potential. The low endosomal pH can be taken advantage of to escape degradation. Fusogenic lipids or peptides, which destabilize the endosomal membrane after the conformational transition / activation at a lowered pH. Amines are protonated at an acidic pH and cause endosomal swelling and rupture by a buffer effect Unsaturated dioleoylphosphatidylethanolamine (DOPE) readily adopts an inverted hexagonal shape at a low pH, which causes fusion of liposomes to the endosomal membrane. This process destabilizes a lipid entity containing DOPE and releases the cargo into the cytoplasm; fusogenic lipid GALA, cholesteryl-GALA and PEG-GALA may show a highly efficient endosomal release; a pore-forming protein listeriolysin O may provide an endosomal escape mechanism; and histidine-rich peptides have the ability to fuse with the endosomal membrane, resulting in pore formation, and can buffer the proton pump causing membrane lysis.

[0476] Also as to active targeting, cell-penetrating peptides (CPPs) facilitate uptake of macromolecules through cellular membranes and, thus, enhance the delivery of CPP -modified molecules inside the cell. CPPs can be split into two classes: amphipathic helical peptides, such as transportan and MAP, where lysine residues are major contributors to the positive charge; and Arg-rich peptides, such as TATp, Antennapedia or penetratin. TATp is a transcription-activating factor with 86 amino acids that contains a highly basic (two Lys and six Arg among nine residues) protein transduction domain, which brings about nuclear localization and RNA binding. Other CPPs that have been used for the modification of liposomes include the following: the minimal protein transduction domain of Antennapedia, a Drosophila homeoprotein, called penetratin, which is a 16-mer peptide (residues 43-58) present in the third helix of the homeodomain; a 27-amino acid-long chimeric CPP, containing the peptide sequence from the amino terminus of the neuropeptide galanin bound via the Lys residue, multipara, a wasp venom peptide; VP22, a major structural component of HSV-1 facilitating intracellular transport and transportan (18-mer)amphipathic model peptide that translocates plasma membranes of mast cells and endothelial cells by both energy-dependent and -independent mechanisms. The invention comprehends a lipid entity of the invention modified with CPP(s), for intracellular delivery that may proceed via energy dependent micropinocytosis followed by endosomal escape. The invention further comprehends organelle-specific targeting. A lipid entity of the invention surface-functionalized with the triphenyl phosphonium (TPP) moiety or a lipid entity of the invention with a lipophilic cation, rhodamine 123 can be effective in delivery of cargo to mitochondria. DOPE / sphingomyelin / stearyl-octa-arginine can delivers cargos to the mitochondrial interior via membrane fusion. A lipid entity of the invention surface modified with a lysosomotropic ligand, octadecyl rhodamine B can deliver cargo to lysosomes. Ceramides are useful in inducing lysosomal membrane permeabilization; the invention comprehends intracellular delivery of a lipid entity of the invention having a ceramide. The invention further comprehends a lipid entity of the invention targeting the nucleus, e.g., via a DNA-intercalating moiety. The invention also comprehends multifunctional liposomes for targeting, i.e., attaching more than one functional group to the surface of the lipid entity of the invention, for instance to enhances accumulation in a desired site and / or promotes organelle-specific delivery and / or target a particular type of cell and / or respond to the local stimuli such as temperature (e.g., elevated), pH (e.g., decreased), respond to externally applied stimuli such as a magnetic field, light, energy, heat or ultrasound and / or promote intracellular delivery of the cargo. All of these are considered actively targeting moieties.

[0477] An embodiment of the system may comprise an actively targeting lipid particle or nanoparticle or liposome or lipid bilayer delivery system; or a lipid particle or nanoparticle or liposome or lipid bilayer comprising a targeting moiety whereby there is active targeting or wherein the targeting moiety is an actively targeting moiety. A targeting moiety can be one or more targeting moieties, and a targeting moiety can be for any desired type of targeting such as, e.g., to target a cell such as any herein-mentioned; or to target an organelle such as any herein-mentioned; or for targeting a response such as to a physical condition such as heat, energy, ultrasound, light, pH, chemical such as enzymatic, or magnetic stimuli; or to target to achieve a particular outcome such as delivery of payload to a particular location, such as by cell penetration.

[0478] It should be understood that as to each possible targeting or active targeting moiety herein-discussed, there is one example embodiment of the invention wherein the delivery system comprises such a targeting or active targeting moiety.KITS

[0479] In an aspect, the chimeric small molecules and protein-tags disclosed herein can be utilized in various kits, such as, kits for protein-tagging and proximity-induced molecular transfer, conducting programmable nuclease-based protein-tagging screens, protein-tagging and molecular transfer, or cell-based phenotypic screening.

[0480] In an aspect, provided herein is a kit for protein-tagging and proximity-induced molecular transfer comprising, a nucleic acid encoding a protein-tag of the present disclosure, or one or more nucleic acids encoding one or more proteins comprising the protein-tag, a chimeric small molecule comprising a protein-tag binding moiety capable of binding the protein-tag, an electrophilic linker, and a transfer moiety, and wherein the chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety.

[0481] In an aspect, provided herein is a kit for conducting programmable nuclease-based protein-tagging screens comprising a vector encoding a RNA-guided programmable nuclease, a library of guide RNA templates or vector system for expressing guide RNAs targeting a set of genomic loci encoding endogenous proteins, a donor template comprising a nucleic acid sequence encoding a protein-tag of the present disclosure, a chimeric small molecule comprising a proteintag binding moiety capable of binding the protein-tag, an electrophilic linker, and a transfer moiety, and wherein the chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety. The RNA-guided programmable nuclease may be a CRISPR-Cas, a prime editor, an OMEGA system, a CAST system, a TIGR system, or a non-LTR retrotransposon system.

[0482] In an aspect, provided herein is a modular kit for protein-tagging and molecular transfer comprising, a nucleic acid encoding a protein-tag of the present disclosure, or one or more nucleic acids encoding one or more proteins comprising the protein-tag, a set of at least two protein-tag binding moieties, a set of at least two electrophilic linkers, a set of at least two transfer moieties, reagents for conjugating the precursors to form chimeric small molecules, wherein each chimericsmall molecule comprises (i) a protein-tag binding moiety, (ii) an electrophilic linker; and (iii) a transfer moiety, wherein the chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety. In an embodiment, the reagents for conjugating the precursors to form chimeric small molecules can include any one or more of: a copper-catalyzed azide-alkyne cycloaddition (CuAAC) catalyst system; an amide coupling reagent system, for example HATU with N,N-diisopropylethylamine (DIPEA); a heterobifunctional crosslinker, for example sulfo-SMCC or an N-hydroxysuccinimide (NHS) ester crosslinker; or a strain-promoted click partner, for example a dibenzocyclooctyne (DBCO) reagent or other strained-alkyne component.

[0483] In an aspect, provided herein is a kit for cell -based phenotypic screening, comprising one or more cell lines stably expressing one or more proteins comprising a protein-tag of the present disclosure; a library of chimeric small molecules, each chimeric small molecule comprising, (i) a protein-tag binding moiety, (ii) an electrophilic linker; and (iii) a transfer moiety; wherein the chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety.

[0484] Further embodiments are illustrated in the following Examples which are given for illustrative purposes only and are not intended to limit the scope of the invention. It is considered the chimeric small molecules, protein-tags, functional moieties, and components thereof may and can be modified, both chemically and physically, to substitute, remove, or add components described herein or known in the art to arrive at the claimed subject matter. In particular, it may be that components of the claimed invention, for example, are illustrated with complete or filled valences in which there appears to be no specific connection point between one component and another component of the claimed invention. However, between the example constructs described herein and the ordinary skill in the art, one can readily assemble the compounds claimed. A lack of an open bonding position should not be construed as an intended closed system. Instead, the terminal groups of compounds described herein are considered as possible bonding positions to arrive at the claimed invention.ELECTROPHILIC REACTIVE LINKERS

[0485] In an aspect, provided herein are electrophilic reactive linkers. In an embodiment, the electrophilic reactive linker is according to the formula Li-E, E-Li, or L1-E-L2, wherein E is anelectrophilic reactive group and wherein Li and L2 are linking molecules. In an embodiment, with respect to LI and L2, the term linking molecule' can be used interchangeably with linker' or 'linking moiety.' The electrophilic reactive linkers are not limited to use and / or applications with the protein-tags and related ligands disclosed herein. The electrophilic reactive linkers may, or may not, be used for use and / or applications with the protein-tags and related ligands disclosed herein. The electrophilic reactive linkers may generally be used for any relevant purpose.

[0486] In an embodiment, the E reacts with a nucleophilic reactive group. The E may be configured to facilitate attachment of the electrophilic reactive group and all or a portion of Li or L2 to a Cysteine, Serine, Threonine, Tyrosine, Glutamic Acid, Aspartic Acid, Lysine, Arginine, Histidine, or a Methionine amino acid on a polypeptide.

[0487] In an embodiment, the linking molecules Li and L2 are independently selected from alkane, alkene, alkyne, amine, ether, thiol, sulfone, carbonyl, acyl, ketone, carboxylate ester, amide, enone, anhydride, imide, PEG, or any combination thereof. The linkers Li and / or L2 may comprise rigid molecules.

[0488] In an embodiment, the electrophilic reactive group is selected from:or analogs thereof.

[0489] In an embodiment, the E is configured to facilitate attachment of all or a portion of Li or L2 to a cysteine, and wherein the E is:

[0490] In an embodiment, the E is configured to facilitate attachment of all or a portion of Li or L2 to a lysine, and wherein the E is:

[0491] The use and / or application of the following electrophilic reactive groups:OFjC""' , or analogs thereof, are not limited in any way to the protein-tags and related ligands disclosed herein. These electrophilic reactive groups may, or may not, be used for use and / or application with the protein-tags and related ligands disclosed herein. These electrophilic reactive groups may generally be used for any relevant purpose.

[0492] In an embodiment, the electrophilic reactive linker further comprises a bio-orthogonal group, the bio-orthogonal group may be selected from tetrazines, triazines, cyclooctenes, cyclopropenes and diazo.

[0493] In an embodiment, the bio-orthogonal group is selected from the group consisting of:

[0494] In an embodiment, the electrophilic reactive linker is capable of covalently labeling a target polypeptide.

[0495] In an embodiment, labeling comprises covalently bonding to a nucleophile disposed on the target polypeptide.EXAMPLESExample 1

[0496] Applicants report an ultrasmall chemogenetic tag (cTag) of 50 amino acids (aa). This tag exhibits transferase-type reactivity with their ligands to append any moiety of interest to thetag. cTag utilizes an engineered C 1 domain-bearing cysteine that undergoes group transfer reaction with its ligand. Applicants applied the tags in the context of cell signaling and proximity induction. While the fusion of HaloTag (297 aa) to the KRASG12D(188 aa) disrupted its ability to activate the growth-signaling pathway, the fusion of cTag did not. Group transfer of BRD4 binder to cTag appended to Abelson kinase (ABL) induced proximity between ABL and BRD4, resulting in the latter’s phosphorylation. Deletion of the transferase-type reactivity reduced phosphorylation levels, suggesting that proximity-inducing chimeras with group transfer design may be more efficacious in certain scenarios. Applicants envision this ultrasmall tag to have wide-ranging applications, including in basic science, biotechnology, and medicine.cTag and Ligand

[0497] Applicants ventured to employ group transfer chemistry to generate a miniature tag from the Cl domain. Protein Kinase C (PKC) is activated by ligands such as the phorbol ester TPA that possess a polar headgroup and a lipid tail; the polar headgroup binds to the Cl domain of PKC while the lipid tail facilitates PKC’s membrane translocation (Figure 2A).

[0011] Since Cl domains are small (~50 amino acids), Applicants hypothesized that a miniature tag could be generated by grafting cysteine on the Cl domain and placing an appropriate group transfer linker on the headgroup of the PKC ligand. Applicants initiated our studies by determining if the Cl domain can fold and bind to the PKC ligands without requiring other PKC domains. Taking advantage of its miniature size, Applicants chemically synthesized the Cl domain peptide and used circular dichroism to confirm the presence of the folded state— the circular dichroism spectra showed peaks at 208 and 222 nm (Figure 2B), indicative of a folded peptide. Since the C 1 domain contains two zinc finger-like motifs, removing zinc ions from the buffer resulted in spectra resembling random coil (Figure 2B). Next, Applicants confirmed that the ligand binding pocket was preserved by quantifying the binding of PKC ligand, phorbol ester. Applicants expressed and purified the Cl domain fused to maltose-binding protein (MBP) and tested the binding using microscale thermophoresis (MST). Gratifyingly, Applicants observed a dose-dependent shift in fluorescence, indicating a Kd of 190 nM (Figure 2C). These studies confirmed that the C 1 domain, when isolated from PKC and fused to another protein, maintains its ability to fold and bind to PKC ligands.

[0498] The phorbol ester head group, while a potent PKC binder, is challenging to synthesize,

[0012] preventing deep structure-activity relationship studies necessary to identify thegroup transfer linker attachment site. Applicants focused our efforts on the benzolactam scaffold, a potent PKC binder that is synthetically more tractable, although current approaches still require 10 steps.

[0013] Applicants further improved the reported synthesis by replacing the laborious and non-scalable Negishi coupling of compounds 3 and 5 with a photochemical reaction catalyzed by iridium and nickel, providing key intermediate benzolactam in 8 steps (Figure 3). In this optimized approach, intermediate 9 is directly coupled with 5 using visible-light photoredox catalysis,

[0014] providing 10 that cyclizes to 11 during the removal of volatiles. 11 was reduced to 7, which was converted to benzolactam intermediate 8 following previous report.

[0013] Next, Applicants generated benzolactam analog 12 (Figure 2A) and tested binding to the Cl MBP fusion using MST and obtained a Kd of 230 nM that is comparable to that of phorbol ester TPA. Applicants confirmed binding in an orthogonal assay using biolayer interferometry (BLI). Here, Applicants immobilized a biotinylated analog of 12 (compound 14) on the tip of the BLI sensor and assessed its binding with the Cl domain in the solution. Applicants observed a dose dependent increase in the signal, confirming binding (Figure 2D). Applicants implemented this assay in a competition format where 12 was pre-incubated with the Cl domain and observed a decrease in BLI signal by 41 -fold (Figure 2E and Figure 6A). Applicants explored analogs of 12 lacking benzyl group (compound 13, Figure 2A) to reduce the size, but this analog decreased signal by only ~3-fold, suggesting that removing the benzyl group causes substantial loss of binding (Figure 2E and Figure 6B). Applicants further confirmed this observation using MST (Figure 6C). These studies established a highly yielding route to access the benzolactam scaffold and allowed Applicants to identify a minimalist binder of the Cl domain.

[0499] Following successful binding studies, Applicants grafted cysteines around the benzolactam binding pocket (Figure 4A, 6D), the cysteines were placed within the pocket (marked in grey) and on the surface (marked in green). Applicants also generated a library of benzolactam analogs bearing thiol-reactive warheads (e.g., acrylamides, epoxides, haloacetamides, Figure 6E) at sites that will be proximal to the engineered cysteines and studied labeling using intact mass (Figures 7-10). Intriguingly, for cysteines grafted at the base of the pocket, Applicants did not observe labeling with any of the thiol -reactive warheads on the benzolactam scaffold (Figures 7-10). Applicants’ efforts to enhance the cysteine reactivity by placing a proximal histidine also wereunsuccessful (Figure 6D and 7-10). Applicants hypothesize that these mutations potentially perturb the binding pocket and / or zinc finger.

[0500] Applicants focused efforts on engineered cysteine on the surface (green site, Figure 4A) and observed group transfer reactivity with methacrylamide 15 (Figure 4B) and yielding a protein-tag derived from the Cl domain of PKC (cTag) (Figure 4C). To confirm that cTag reactivity is proximity-driven, Applicants replaced the critical benzyl group with a piperidyl group (Figure 11 A) and observed no labeling. Furthermore, Applicants observed fast-labeling kinetics of cTag with 16, a hallmark of increased effective molarity owing to proximity induction between cysteine and the reactive group 16, attained saturating labeling within 5 minutes at low micromolar protein and ligand concentrations (Figure 4D). Using 15 (labels cTag with an azide) and click chemistry with DBCO-fluorophore,

[0015] Applicants confirmed labeling in cells at as low as 25 nM (Figure 4E). By clicking DBCO-biotin, Applicants successfully pull down MBP fused to cTag from the lysate (Figure 1 IB). To confirm that our cTag ligand was not activating PKC, Applicant used PKC motif antibody and immunoblotting to assess proteome-wide changes in the phosphorylation. Applicant did not observe significant changes in the phosphorylation status compared to DMSO at the concentrations used for the labeling studies (Figure 11C). Collectively, these studies identify a miniature tag based on an engineered Cl domain that can undergo group transfer chemistry with a benzolactam scaffold.

[0501] The amino acid sequence of cTag, and nucleic acid sequence encoding cTag, are as shown below:SEQIDNO 1 HRFKVYNYMSPTFCDHCGSLLWGCVKQGLKCEDCGMNVHHKCREKVANLC SEQIDNO2 caccgattcaaggtttataactacatgagccccaccttctgtgaccactgtggcagtttgctctgggg atgtgtgaagcagggattaaagtgtgaagattgtggcatgaatgtgcaccacaaatgccgggagaag gtggccaacctgtgtImpact of size

[0502] Applicants next examined the impact of tag size on the signaling of oncogenic KRASG12D, which, upon N-terminal myristoylation, translocates to the membrane to form nanoclusters and activate the mitogen activation protein kinase (MAPK) pathway. [4d-g] Applicants hypothesized that contemporary tags (e.g., HaloTag, 33kDa) that are larger than KRAS(21 kDa) and myristoyl group will perturb the ability of KRAS to form clusters and downstream signaling. To test this hypothesis, Applicants fused HaloTag, or cTag to the N-terminus of KRASG12Dand assessed MAPK pathway activation by measuring levels of phosphorylated ERK. While cells with transient expression of KRASG12Dor cTag fused KRASG12Dactivated the MAPK pathway, cells expression HaloTag.KRASG12Dfusion did not exhibit MAPK pathway activation (Figure 5A). These studies suggest that cTag does not perturb the native function of a small signaling protein.Compatibility with induced-proximity modalities

[0503] N ext, Applicants explored the compatibility of cTag with induced-proximity modalities for appending smaller post-translational modifications. Applicants have previously reported that chimeric small molecules induce protein-of-interest (POI) phosphorylation by bringing POI in proximity to a kinase. Since many kinases lack appropriate recruiting ligands, chemogenetic tags can be impactful. In fact, chemogenetic tags have allowed systematic evaluation of various ubiquitin ligases lacking ligands.

[0016] Applicants fused ABL kinase with cTag and synthesized probes which contain JQ1 that binds to BRIM,

[0017] to induce proximity between ABL and BRIM (Figures 5B-C). Gratifyingly, Applicants observed increased BRIM phosphorylation with cTag probe 17, which was competed out by an excess of JQ1 (Figure 5D). Intriguingly, compound 18, which lacks a group transfer reactive group, was unable to induce BRIM phosphorylation at 250 nM (the concentration used for 17) but was able to do so at 10 pM,

[0013] suggesting a 40-fold increase in potency (Figure 5E). These studies suggest that covalent recruitment of PTM writers or eraser enzymes is more efficient than non-covalent recruitment. Importantly, these studies confirm that cTag can be used for the development of induced-proximity modalities.Biological Materials and Methods

[0504] Materials and general procedures.

[0505] Plasmids: All constructs were cloned in-house, and sequences are provided.

[0506] Antibodies: Phospho-Tyrosine (P-Tyr-1000) MultiMab® (cat# 8954), Ha-Tag (6E2) (cat# 2367), Phospho-p44 / 42 MAPK (Erkl / 2) (Thr202 / Tyr204) (D13.14.4E) (cat# 4370), p44 / 42 MAPK (Erkl / 2) (L34F12) (cat# 4696), DYKDDDDK Tag (D6W5B) Rabbit mAb (cat# 14793), Phospho-PKC substrate motif (Cat# 6967S) and -Actin (Cat# 4970S, 3700S) were purchasedfrom cell signaling. Anti-Ras monoclonal antibody (Cat# ab 108602) was purchased from AbCam. Anti-nanoluciferase monoclonal antibody (Cat# N7000) was purchased from Promega.

[0507] Reagents: OptiPlate-384 (White Opaque 384-well Microplate, Cat#6007290), Corning® 96-well plates with Solid White Flat Bottom (Coming cat#3917), 96-well microplate, PS, F-Bottom (Greiner, Cat# 655900), His-Tag labeling kit REDtris-NTA 2nd Generation (Nanotemper, Cat# MO-L018), Biocytin (Millipore, Cat# B4261), TransIT®-293 transfection reagent was purchased from Mirus (MIR 2700 and MIR 2300). cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail (Cat#04693159001) and Inhibitor, Phosphatase, PhosSTOP (Cat#4906837001) were purchased from Millipore Sigma. M-PER™ Mammalian Protein Extraction Reagent (Cat#78501), Pierce™ BCA Protein Assay Kit (Cat#23225), Pierce™ Anti-HA Magnetic Beads (88837), Pierce™ Anti-DYKDDDDK Magnetic beads (A36797), and NuPAGE 4-12% Bis-Tris Protein Gels (Cat#NP0336 or Cat#NP0335), DMEM (Gibco, Cat# 11965092), Opti-MEM I (cat# 11058-021) was purchased from Life Technologies.

[0508] Cloning of cTag: Cl domain and gene blocks were designed and purchased from genewiz. Gibson assembly ligation was performed to generate the pET23a-Hisl0X-MBP-Cl domain construct. The successful clones were confirmed by sequencing and stored for future use.

[0509] Site-directed mutagenesis for rationally designed cTag variants: All mutations and combinations were created using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs, Cat# E0554S). Primers were designed for each specific cTag variant according to the desired mutations, using the wild-type plasmid as a template for generating the cTag variants. In brief, after performing the site-directed mutagenesis (SDM) PCR, the amplified template plasmid was added directly to a specialized Kinase-Ligase-Dpnl (KLD) enzyme mix, resulting in rapid circularization at room temperature within 5 minutes while also removing the template. This mixture was then transformed into high-efficiency NEB 5-alpha Competent E. coli (New England Biolabs, Cat# C2987H). The mutations were confirmed through sequencing, and the plasmids were stored for future use.

[0510] Protein expression and purification (cTag and variants): Plasmids containing various Cl domains fused with His-lOX-MBP variants in the pET23a-His6X-MBP-Cl domain were transformed into BL21(DE3) competent cells (Thermo Fischer Scientific, Cat# EC0114) using a chemical transformation method. The primary culture was inoculated using a single colonygrown overnight in 10 ml of TB media containing 50 pg / ml of ampicillin (GoldBio, Cat# A -301-5) at 37°C with shaking at 200 rpm. The secondary culture was prepared by inoculating 1% of the primary culture into 1 L of TB media with ampicillin, and the culture was allowed to grow until it reached an OD600nm of 0.6 then shifted to 18°C for 30 minutes and induced by adding 0.3 mM isopropyl -P-D-l-thiogalactosidease (Thermo Fischer Scientific, Cat# 15529019) and supplemented with filtered sterile 100 pM ZnC12 (Sigma, Cat# 208086), followed by further growth for an additional 16 hours at 200 rpm. Cells were harvested by centrifuging at 6000 rpm (Thermo Fischer Scientific, Sorvall LYNX 6000) for 10 minutes at 4°C. The supernatant was discarded, and the cell pellet was resuspended in lysis buffer (20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 100 pMZnC12, 1 mM TCEP, and 10% glycerol). All the subsequent steps were performed at 4°C in the cold room.

[0511] Cells lysis was initiated by adding 1 mg / ml of lysozyme along with 0.5 mM PMSF (Thermo Fischer Scientific, Cat# 36987), and IX protease inhibitor cocktail (Pierce, Cat# A37989) (one tablet in 1 ml of lysis buffer). The cells were incubated for 1 hour with gentle rocking. 0.5% of Triton X-100 (Sigma, Cat# X100) was then added to the lysate, and the mixture was further incubated for 15 minutes. Cells were sonicated using a 250-watt ultrasonic processor (Fischer Scientific, Cat# SFX250) with a 6 mm diameter probe, applying a cycle of 8 seconds ON and 15 seconds OFF for 30 minutes. The lysate was then centrifuged at 16000 rpm for 1 hour. The cell debris was discarded, and the clarified lysate was subjected to affinity chromatography by incubating it with 1.4 ml of preequilibrated His-Pur Nickel nitriloacetic acid (Ni-NTA) resin (Thermo Scientific, Cat# 88221) overnight. The resin was washed thrice with 15 column volumes of washing buffer (20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 100 pM ZnC12, 1 mM TCEP, 40 mM imidazole, and 10% glycerol). Histidine-tagged proteins were eluted using an elution buffer (20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 100 pM ZnC12, 1 mM TCEP, 300 mM imidazole, and 10% glycerol). The collected protein was concentrated using 10 KDa cut-off Amicon spin concentrators (Millipore, Cat#UFC901008), centrifuged at 3500 rpm for 30 min, and subjected to gel filtration chromatography using an AKTA pure system (Cytiva). The proteins were injected into a HiLoad Superdex-200 column, 120 ml PG (Cytiva, Cat# 28989335) at a flow rate of 1 ml / min using running buffer (20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 100 pM ZnC12,lmM TCEP, and 10% glycerol). The protein-containing fractions were analyzed using NuPAGE Bis-Tris gels with a 4-12% gradient (Thermo Scientific, Cat# NP0321BOX) to determine the final purity. The purified protein was quantified using BCA (Pierce Cat# A55864), snap-frozen in liquid nitrogen, and stored in aliquots at -80°C until future use.

[0512] Circular Dichroism spectroscopy for Cl domain peptide: Chemically synthesized Cl domain peptide was reconstituted in peptide buffer (25 mM Tris-Cl, pH 7.4, 100 mM NaCl, 1 mM TCEP) with a master stock of 2 mM. The peptide was dialyzed overnight in assay running buffer (2 mM Tris, 15 mM NaCl 0.1 mM TCEP). The secondary structure was examined by monitoring proteins' Far-UV circular dichroism (CD) from 198nm to 250nm on a spectropolarimeter (Jasco, J-815). The spectra were recorded with 100 pM Cl domain peptide in an assay running buffer. The wavelength scan was performed at a scan rate of 10 nm / min using a 1 mm path length cuvette (Starna, Cat# 21-G-l) at 25 DC. Each spectrum was averaged over five scans. Raw CD signal (Gobs) was converted to Mean Residue Ellipticity (GMRE) as follows:GMRE = (100*Gobs) / [d*C*(n - 1)]where Gobs is the observed ellipticity (in degrees), C is protein concentration (Molar), d is path length (in centimeters) and n is the total number of amino acids in the protein.

[0513] Microscale Thermophoresis for Cl domain binding experiments: MST measurements were conducted using a Monolith NT.115 equipment (NanoTemper Technologies) at room temperature. 1 pM purified MBP fused Cl domain was labeled with NT647 (RED) fluorophore (NanoTemper Technologies, Cat# MO-L-018) and then activated by an LED filter (650 nm). Compounds were diluted from 10 pM to 0.004 pM across 12 concentrations using a two-fold dilution method in a IX assay buffer. Each dilution was then combined with the NT647 labeled Cl domain. The mixed samples were incubated at room temperature for 10 minutes. Following incubation, the dilutions were transferred into the monolith NT automated standard capillary chips (NanoTemper Technologies, Cat# MO-AK002) via capillary action. The samples were then evaluated using Microscale Thermophoresis (MST) with the auto mode set to LED power and the medium IR laser power. The results were plotted as normalized fluorescence as a function of compound concentration using GraphPad Prism (version 10.2.3).

[0514] Biolayer-Interferometry experiments for Cl domain binding studies: All the Binding kinetics were performed in IX assay buffer (IX PBS pH 7.4, 0.1 mMZnC12 1 mM TCEP, 0.01% Tween-20) using 8-channel Octet R8 (Sartorius) at 25°C. 10 pM of biotinylated compound14 was immobilized onto SAX biosensors (Sartorius, Cat# 18-5117) for 300 sec up to a response of 0.8-1 nm. The reference biosensors were immobilized similarly except for dipping in IX assay buffer instead of substrate DNA. All biosensors were blocked with 100 pM biocytin (Millipore, Cat# B4261) supplemented in IX assay buffer for 300 seconds and a stable baseline was achieved for another 120 seconds. Sensors were dipped in the Cl domain varying from 4-0.25 pM and preincubated with either DMSO or indicated compounds at 10 pM maintaining the DMSO at 2%. The kinetics were recorded with an association of 300 seconds followed by dissociation for 500 seconds in IX assay buffer. The raw data was processed by using inbuilt Octet LI analysis 12.2 software from Sartorius. The reference biosensors were subtracted using double referencing and subtracted data were aligned with baseline for each kinetics. The aligned were further aligned by using inter-step correction and processed for Savitzky-Golay filtering. The processed data is potted using GraphPad Prism (version 10.2.3) as final binding sensograms. All binding curves for each kinetic experiment were normalized with DMSO and plotted as a relative percent binding to calculate percentage binding.

[0515] Labeling experiments for cTag using Intact mass spectroscopy: For labeling experiments, 2 pM of purified Cl domain variant L254C is incubated with 20 pM compound 5, in a 20 pl reaction containing IX PBS supplemented with ImM TCEP and 100 pM ZnC12 for 30 minutes at room temperature. The reaction was diluted 3X with 0.1% formic acid and filtered to clear any precipitation. 20 pl of filtered reaction was loaded in vials for Intact mass analysis. Intact mass analysis was performed on Waters BioAccord LC-MS System (Waters, Model #) using Acquity UPLC protein BEH C4 column, 2.1mm X 50 mm, 300 A (Waters, Cat# 186004495) with a resolution capacity of 10 KDa-150 KDa. The column temperature was set at 80 °C, and the autosampler at 10 °C. Mobile phase A was 0.1% formic acid in the water, and mobile phase B was 0.1% formic acid in acetonitrile. 5 pl of samples were injected into the column with a flow rate of 0.4 ml / min. The separation was performed using a gradient of 100% A for 2 min, increasing linearly to 90% B for 5 min. For data analysis, the Inbuilt software UNIFI (version 2.1.2.14) was used. The raw spectra were extracted and deconvoluted using a 10,000:100,000 Da window with 1 Da resolution. The data were processed and represented as intensity counts vs mass.

[0516] Biochemical labeling of cTag using In-gel fluorescence: To demonstrate the labeling of cTag biochemically, 2 pM of purified MBP-C1 domain treated with 2 pM of compound 16 andDMSO in 25 pl reaction for 30 min incubation at room temperature. 10 pl of 4x Laemmli DSsample reducing buffer (Bio-RAD, cat# 1610747) was added. Samples were heated at 99°C for 10 min. After cooling to room temperature, 15 pl of the reaction mixtures were resolved on NuPAGE 4-12% Bis-Tris gels (ThermoFisher, cat # NP0321BOX) with MOPS SDS running buffer (ThermoFisher, cat # NP0001) at 150V over 1.5 hours. Western blotting was performed by transferring the gel to the nitrocellulose membrane using the dry transfer method by iBlot2 (Invitrogen, Cat# Ib21001). The membranes were blocked with 5% BSA in TBST and incubated with primary antibodies (anti -His tag, Cell Signaling, cat# 9991) for 4 hours at room temperature on a shaker. The unbound primary antibodies were washed out 3 times with TBST buffer and membranes were incubated with a secondary antibody (IRDye800CW, Donkey anti-Mouse, cat#926-32212) for 45 minutes at room temperature. Unbound secondary antibody was washed out 3 times with TBST buffer and the blot was developed on LiCor Odyssey CLx Imaging System. All primary and secondary antibodies were used at 1:1000 and 1:10,000 dilutions, respectively.

[0517] In cellular labeling of cTag using In-gel fluorescence in HEK293T cells : Compound treatment: HEK293T cells were seeded into a 6-well plate (Falcon, Cat# 353046) at the density of 1.2 million cells per well in 2 mL of media one day before cTag transfection (1 pg of DNA in 200 pl OPTI-MEM with 6 pl of trans-IT per well). 18 hours post-transfection, the cells were treated with 15, at concentrations ranging from 100 nM to 12.5 nM in DMEM. After 4 hours of incubation with the compounds, the media was removed. The cells were washed with 2 mL of ice-cold PBS and lysed using 300 pl of MPER buffer per well (Thermo Scientific, Cat#78505) containing protease (Roche, Cat# 4693159001) and phosphatase inhibitor (Roche, Ca# 4906837001) cocktails (1 tablet each per 10 mL of MPER buffer). The total lysate was sonicated for 15 seconds and spun at 16,000 g for 10 minutes at 4 °C to separate the supernatant. Total protein concentration was estimated by BCA, and concentrations were adjusted to be equal by adding lysis buffer to samples with higher concentrations.

[0518] In-gel fluorescence: To demonstrate the labeling of cTag with alkyne-containing compound 15, a copper catalyzed click reaction with sulfoCy5.5 azide and in-gel fluorescence was performed. A click reaction was performed using 350 pM of tris(3-hydroxypropyltriazolylmethyl) amine (THPTA, Lumiprobe, cat# H4050), 100 pM solution of sulfoCy5.5 azide (BroadPharm, cat# BP-22483), 2 mM CuSO4 and 1.5 mM sodium ascorbate along with of 15ug of lysatesobtained after treatment with DMSO and 15. After 30 min incubation at room temperature, 10 pl of 4x Laemmli SDS-sample reducing buffer (Bio-RAD, cat# 1610747) was added. Samples were heated at 100 °C for 5 min. After cooling to room temperature, 20 pl of the reaction mixtures were resolved on NuPAGE 4-12% Bis-Tris gels (ThermoFisher, cat # NP0321BOX) with MOPS SDS running buffer (ThermoFisher, cat # NP0001) at 200V over 1 hour. Western blotting was performed by transferring the gel to the nitrocellulose membrane using the dry -transfer method by iBlot2 (Invitrogen, Cat# Ib21001). The membranes were blocked with 5% BSA in TBST and incubated with primary antibody (anti-HA, Cat# 2367, Cell Signaling) overnight at 4 °C on a shaker in a cold room. The unbound primary antibodies were washed out 3 times with TBST buffer and membranes were further incubated with a secondary antibody (IRDye800CW, Donkey antiMouse, Cat# 926-32212) for 1 hour at room temperature. Unbound secondary antibody was washed out 3 times with TBST buffer and blots were developed on LiCor Odyssey CLx Imaging System. All primary and secondary antibodies were used at 1:1000 and 1:10,000 dilutions, respectively.

[0519] PKC activation studies for monitoring proteome-wide phosphorylation:HEK293T cells were seeded into 12 well plates (Fisherscientific, Cat# 07-200-82) at a density of 0.75 million cells per well and grown overnight for adherence. Cells were incubated with compounds 15 for 4 hours and washed with cold PBS, harvested, and lysed using MPER buffer (Thermo Scientific, cat#78505) supplemented with protease (Roche, Cat# 4693159001) and phosphatase inhibitor (Roche, ca# 4906837001) cocktails. The total lysate was spun at 16 000 g for 10 min at 4 °C to separate the supernatant. The total protein concentration was estimated by BCA. An equal amount of total lysate (Ipg / pl) was run on the automated simple western (Jess) using all required reagents from Protein Simple. The results were analyzed using the Compass SW software. Primary antibodies: anti-Phospho-PKC substrate motif, (Cell Signaling, Cat# 6967S), anti- P-Actin, Cell Signaling, Cat# 4967). All primary antibodies were used at 1:50 dilutions. Secondary antibodies: anti-rabbit-HRP (cat# 042-206, Protein Simple), used without further dilutions, and anti-mouse-NIR (cat# 043-821, Protein Simple) used at 1:20 dilution.

[0520] Effect of miniature tags fused with KRAS on pERK / EKR level for MAPK pathways: 250ng of the KRAS fusion constructs were transfected into HEK293T cells transfection reagent TransIT LT1 (Minis Bio, Cat# 2034) and incubated for 24 hours. Cells werethen washed with IxPBS and stored at -800C until proceed further. Cells were lysed using MPER buffer (cat#78505, Thermo Scientific) supplemented with protease (cat# 4693159001, Roche) cocktail. The cell lysates were spun at 16,000 g for 10 min at 4 °C to separate the supernatant. The total protein concentration was estimated by BCA assay (cat# 23225, Thermo Scientific). An equal amount of total lysate (Ipg / pl) was run on the automated simple western (Jess) using all required reagents from Protein Simple. The results were analyzed using the Compass SW software. Primary antibodies: pERK (cat# 4370S, Cell Signaling Technology), total ERK (cat# 4696S, Cell Signaling Technology), and HA (cat# 2367S, Cell Signaling Technology). All primary antibodies were used at 1:50 dilutions. Secondary antibodies: anti-rabbit-HRP (cat# 042-206, Protein Simple), used without further dilutions, and anti-mouse-NIR (cat# 043-821, Protein Simple) used at 1:20 dilution.

[0521] Immunoblotting studies for GRIPs-mediated tyrosine phosphorylation of BRD4 by cTag fused with Abl in HEK293T cells: HEK293T cells were seeded into a 6-well plate (Falcon, Cat# 353046) at the density of 1.2 million cells per well and grown 12 hr overnight for adherence. 200ng of cTag-Abl-HA and 1 pg of BDR4-Flag were co-transfected using transfection reagent TransIT LT1 (Mirus Bio, Cat# 2034). After 24 hours, cells were treated with Abl-Chimeras at 250nM concentration in DMEM for 4 hours. Cells were washed with cold PBS, harvested, and lysed using MPER buffer (Thermo Scientific, cat#78505) supplemented with protease (Roche, Cat# 4693159001,) and phosphatase inhibitor (Roche, ca# 4906837001) cocktails. The total lysate was spun at 16000 g for 10 min at 4 °C to separate the supernatant. The total protein concentration was estimated by BCA. For Immunoprecipitation, Anti -Flag-magnetic beads (Thermo Scientific, cat#A36798) 20 pl slurry per sample were taken and equilibrated twice with MPER buffer. An equal amount of the above-prepared supernatant (total protein) was added to the equilibrated beads and incubated with gentle rotation overnight at 4 °C in a cold room. Unbound protein was washed out using TBST buffer three times, and the bound protein was eluted with 4x SDS sample buffer (20 pl per tube) by heating at 99°C for 10 min. The eluted protein was pipetted out by magnetic separation to a fresh tube. Equal volumes of pulldown samples were resolved by 4-12% Bis-Tris NuPAGE gels (Thermo Scientific, Cat#NP0321BOX) and transferred to nitrocellulose membrane using the dry-transfer method by iBlot2 (Invitrogen, Cat# Ib21001). The membranes were blocked with 5% BSA in TBST followed by incubation with primary antibodies (anti-pTyr-pan, cat#8954,Cell Signaling; anti-HA, cat#2367, Cell Signaling) overnight at 4 °C on a shaker in a cold room. The unbound primary antibodies were washed out 3 times with TBST buffer and membranes were further incubated with secondary antibodies (IRDye800CW, Donkey anti-Mouse, cat#926-32212; IRDye680RD, Donkey anti-Rabbit, cat#926-68073) for 1 hour at room temperature. Unbound secondary antibodies were washed out 3 times with TBST buffer and blots were developed on LiCor Odyssey CLx Imaging System. All primary and secondary antibodies were used at 1:1000 and 1:10,000 dilutions, respectively.

[0522] Kinetic experiments with miniature Tag binders: General procedure for the measurements of the kinetics of the reaction of alkynes with N-Ac-Cys-OMe: To a 4: 1 mixture of PBS (pH=7.4) and acetonitrile (970 pl), 10 pl solution of N-(4-methoxyphenyl)acetamide (10 mM stock in DMSO), 10 pl solution of alkyne (10 mM stock in DMSO) and 10 pl solution of N-Ac-Cys-OMe (100 mM stock in DMSO) were added and the reaction was monitored for decay in the concentration of alkyne with respect to the internal standard at 25 oC. Assuming pseudo-first-order reaction kinetics, the natural logarithm of the alkyne concentration was plotted against different time points, and the rate constant was determined from the slope of the fitted line. Each data represents a time point of n=l of the same reaction mixture.Chemical Materials and Methods

[0523] Materials: All reagents were acquired from commercial suppliers and utilized without additional purification for chemical synthesis. Reactions were conducted in round-bottom flasks, utilizing Teflon ©-coated magnetic stir bars for agitation. Environmental control was maintained for moisture and air-sensitive reactions by conducting these processes under a nitrogen or argon atmosphere. Any moisture or air sensitive liquids or solutions were transferred using syringes flushed with nitrogen. To ensure the purity of organic solvents, they were degassed by bubbling nitrogen or argon through the liquid as necessary. Flash column chromatography was executed using silica gel (60 A mesh, 20-40 pm) on a Teledyne Isco CombiFlash Rf system for purification. Additionally, HPLC purification was carried out on a Teledyne ISCO ACCQPrep equipped with an XBridge BEH Prep Column (19 mm x 250 mm). UPLCMS analysis was performed using a Waters ACQUITY UPLC I-Class 15 PLUS system and an ACQUITY SQ Detector 2 for detailed mass spectrometric evaluation. Nuclear magnetic resonance (NMR) spectroscopy was conducted at room temperature on a Bruker A VANCE III HD 400 MHz spectrometer. The spectra werecollected at 400 MHz for 1HNMR and at 101 MHz for 13C NMR. The chemical shifts for 1H and 13C are reported in parts per million (ppm), referencing residual solvent signals. The NMR solvents were sourced from Cambridge Isotope Laboratories, Inc., and data were obtained in solvents such as CDCI3, CD3OD, and DMSO-de. In the presentation of 1H NMR data, the following format is used: chemical shift value in ppm, multiplicity (denoted as s for singlet, br s for broad singlet, d for doublet, t for triplet, dd for doublet of doublets, and m for multiplet), integration value, and the coupling constant value in hertz (Hz). High-resolution mass spectrometry (HRMS) was conducted using an Agilent 6210 / 6220 ESI-TOF system.

[0524] LCMS traces and NMR spectra of exemplary compounds and intermediates are shown in Figures 12 and 13.

[0525] Synthetic procedures and compound characterization„ -- Br I j ’ _ NHBcc. $ Br _ „ jj (Sr(dF(CF3)ppyh«i®py))PF6MeO' NtCla-dtipy, (Me3Si)jSiH, MeO'6Na2CO$, DME.25 X. 14 h blue LEO. 64 % nNaBH4THFAteGH, 0~25 °C. 12 h 56%

[0526] Scheme S3. Improved synthetic route to access benzolactam scaffold 8. Compound 8 is synthesized from 7 following previously reported route.

[0013] NH,NHBOG3phoin chemistry MeO

[0527] Scheme S4. Schematic of the photochemistry -mediated cross-coupling reaction.

[0528] Compound 11: To a 40 mL vial equipped with a stir bar was added 2-bromo-5-methoxy-aniline (0.5 g, 2.47 mmol, 1 eq), methyl (2R)-3-bromo-2-(tert-butoxycarbonylamino)propanoate (0.9 g, 3.22 mmol, 1.3 eq), Ir[dF(CF3)ppy]2(dtbpy)(PFe) (27.8 mg, 24.8 pmol, 0.01 eq), NiCh-dtbpy (14.8 mg, 37.1 pmol, 0.015 eq), (MesSi^SiH (615 mg, 2.47 mmol, 763 pL, 1 eq) and Na2COa (524.58 mg, 4.95 mmol, 2 eq) in DME (25 mL). The vial was sealed and placed under nitrogen was added. The reaction was stirred and irradiated with a blue 4x50 W LED lamp (3 cm away), with cooling water to keep the reaction temperature at 25 °C for 14 hr. The reaction was run in 10 batches in parallel. LCMS showed methyl (S)-3-(2-amino-4-methoxyphenyl)-2-((tert-butoxycarbonyl)amino)propanoate (6) was the main product. On completion, each reaction mixture was quenched by H2O (30 mL), and the combined mixture was extracted with ethyl acetate (200 mL x 3). The combined organic phase was washed with saturated brine (200 mL x 3) dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography with eluent of 0-15% Ethyl acetate / Petroleum ether gradient @ 100 mL / min)) to give tert-butyl (S)-(7-methoxy-2-oxo- l,2,3,4-tetrahydroquinolin-3-yl)carbamate (11) (6 g, 15.8 mmol, 63.86% yield, 77% purity) as a brown oil.

[0529] General procedure for preparation of compound 1-4 - tert-butyl (S)-(l-(2-amino-4-methoxyphenyl)-3-hydroxypropan-2-yl)carbamate.NaBH4 (6.7 eq)THF / MeOH, 0~25 °C, 2 h7

[0530] Scheme S5. Reduction of cyclized intermediate.

[0531] Compound 7: To a solution of tert-butyl (S)-(7-methoxy-2-oxo-l, 2,3,4-tetrahydroquinolin-3-yl)carbamate (11) (6 g, 15.8 mmol, 1.00 eq) in THF (25 mL) andMeOH (25 mL) was added NaBH4 (4 g, 106 mmol, 6.7 eq) at 0 °C under N2 atmosphere. Then, the mixture was stirred at 25 °C for 2 hr under an N2 atmosphere. Upon completion, the reaction mixture was quenched by NH4CI (100 ml) at 0 °C, and then ethyl acetate (50 mL x 3)Was extracted. The combined organic phase was washed with saturated brine (30 mL x 2), dried over anhydrous sodium sulfate, fdtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography with eluent of 0-40% Ethyl acetate / Petr oleum ether gradient to give tert-butyl (S)-(l-(2-amino-4-methoxyphenyl)-3-hydroxypropan-2-yl)carbamate (7) (3 g, 8.81 mmol, 55.72% yield, 87% purity) as a brown solid. Spectroscopic data was consistent with previous reports.

[0013]

[0532] Compound 8 was synthesized as shown in scheme S3, following our established protocols!. 1H NMR (400 MHz, MeOD) 66.88 (d, J = 8.3 Hz, 1H), 6.58 (d, J = 2.5 Hz, 1H), 6.40 (dd, J = 8.2, 2.5 Hz, 1H), 4.31 (dt, J = 8.7, 4.1 Hz, 1H), 3.61 (dd, J = 11.0, 4.7 Hz, 1H), 3.49 (dt, J = 7.7, 5.5 Hz, 2H), 2.97 -2.80 (m, 2H), 2.74 (s, 3H), 2.47 - 2.34 (m, J = 6.8 Hz, 1H), 1.10 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, MeOD) 5 174.4, 156.7, 152.9, 132.4, 123.2, 109.7, 107.4, 73.1, 64.4, 54.1, 36.4, 35.5, 28.3, 19.4, 18.6.HNRS> \H,J. (sd. / V-z"OH

[0533] Compound 12 was synthesized based on our previously described methodi of phenol alkylation using benzyl bromide as the alkylating at a 10 mg scale and 98% yield. 1H NMR (400 MHz, MeOD) 57.46 - 7.26 (m, 5H), 6.98 (d, J = 8.4 Hz, 1H), 6.74 (d, J = 2.5 Hz, 1H), 6.59 (dt, J = 8.4, 2.2 Hz, 1H), 5.05 (d, J = 2.7 Hz, 2H), 4.26 (s, 1H), 3.61 (dd, J = 10.9, 4.7 Hz, 1H), 3.54 -3.44 (m, 2H), 2.99 - 2.84 (m, 2H), 2.74 (d, J = 2.4 Hz, 3H), 2.47 - 2.34 (m, 1H), 1.09 (d, J = 6.6 Hz, 3 H), 0.92 (dd, J = 6.8, 1.5 Hz, 3H). 13C NMR (101 MHz, MeOD) 5 174.3, 158.5, 152.8, 137.5, 132.1, 128.1, 127.4, 127.2, 124.7, 108.8, 107.4, 72.7, 69.6, 64.4, 54.0, 36.3, 35.3, 28.2, 19.3, 18.6.

[0534] Compound 13 was synthesized based on our previously described method

[0013] of phenol alkylation using Mel as the alkylating agent at a 10 mg scale and 61% yield. 1HNMR (400 MHz, CDC13) 57.03 (d, J = 2.7 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.54 (d, J = 2.6 Hz, 1H), 6.44 (dd, J = 8.3, 2.6 Hz, 1H), 4.16 (s, 1H), 3.89 (d, J = 9.2 Hz, 1H), 3.79 (s, 3H), 3.68 (dd, J = 11.0, 3.8 Hz, 1H), 3.56 - 3.46 (m, 2H), 3.05 (dd, J = 16.8, 7.8 Hz, 1H), 2.78 (s, 3H), 2.76 - 2.70 (m, 1H), 2.43 (dp, J = 8.8, 6.5 Hz, 1H), 1.06 (d, J = 6.4 Hz, 3H), 0.88 (d, J = 6.7 Hz, 3H).13C NMR (101 MHz, CDC13) 5 174.3, 159.3, 152.6, 132.4, 123.3, 106.1, 105.8, 69.9, 65.8, 55.3, 54.6, 36.5, 35.1, 28.5, 20.5, 19.9.HAWCM_ ri, 3C mtn:'“0HN*-M 6 % ZS^NH ''-OHsa

[0535] Scheme S6. Synthesis of benzolactam activated acid S8. This intermediate is used for the synthesis of the corresponding group transfer azido (15), cy5.5 (16), and JQ1 (17) probes.

[0536] Activated benzolactam methylacrylic acid S8: 2-((7-((((2S,5S)-5-(hydroxymethyl)-2-isopropyl-l-methyl-3-oxo-l,2,3,4,5,6-hexahydrobenzo[e][l,4]diazocin-9-yl)oxy)methyl)-3,4-dihydroisoquinolin-2(lH) yl)methyl)acrylic acid. The alkylated compound was accessed as previously described using tertbutyl 7-(bromomethyl)-3,4-dihydroisoquinoline-2(lH)-carboxylate as the alkylating agent at 111 mg scale and 95% yield. The product was monitored by LCMS and used for the next step without further characterization. To access the desired analogs a desired amount of N-Boc compound (depending on the scale) was deprotected in TFA / DCM (30 %) at r.t. After the reaction completion (30 min) the volatiles are removed under reduced pressure. The resulting compound is then dissolved in DMF and DIPEA (5 equiv.). To this solution 2-(bromomethyl)acrylic acid (1 equiv.) is added and the resulting solution is stirred at r.t for 1 h. Product formation is monitored by LCMS, and upon completion, HATU is added. The resulting activated acid is used for the next steps without further analysis.

[0537] Compound 15: To a stirred solution of activated methacrylic acid S8 (synthesized as shown in scheme S6 at a 0.05 mmol scale) 5 -azidopentan- 1 -amine (2 equiv.) and DIPEA (2 equiv.) were added. The resulting mixture is stirred at r.t and product formation is monitored via LCMS. Upon reaction completion the crude mixture is purified on reverse phase HPLC using lEO / MeCN plus 0.1% formic acid as mobile phase and gradient of 10-100% MeCN, providing pure azidocompound (15) at 63% overall yield. 1H NMR (400 MHz, MeOD) 5 7.26 - 7.19 (m, 2H), 7.09 (dd, J = 8.2, 5.1 Hz, 1H), 6.98 (dd, J = 8.4, 3.0 Hz, 1H), 6.74 (t, J = 2.9 Hz, 1H), 6.57 (ddd, J = 8.1, 4.9, 2.5 Hz, 1H), 6.16 (d, J = 1.4 Hz, 1H), 5.64 (d, J = 1.5 Hz, 1H), 5.00 (d, J = 7.4 Hz, 2H), 4.25 (d, J = 15.4 Hz, 1H), 3.73 (s, 2H), 3.61 (ddd, J = 11.0, 4.7, 2.5 Hz, 1H), 3.55 - 3.44 (m, 4H), 3.31 - 3.22 (m, 2H), 2.94 (ddq, J = 26.3, 11.8, 6.2 Hz, 8H), 2.75 (d, J = 5.1 Hz, 3H), 2.40 (dtd, J = 13.8, 8.3, 5.3 Hz, 1H), 1.54 - 1.34 (m, 4H), 1.30 - 1.18 (m, 2H), 1.09 (dd, J = 6.6, 3.2 Hz, 3H), 0.92 (dd, J = 6.7, 4.3 Hz, 3H).13C NMR (101 MHz, MeOD) 8 174.2, 167.9, 158.5, 152.8, 138.1, 136.0, 133.6, 132.9, 132.1, 127.7, 126.4, 125.2, 124.7, 108.6, 107.5, 72.6, 69.4, 64.4, 60.0, 54.5, 54.0, 50.8, 49.7, 38.5, 36.3, 35.3, 28.4, 28.3, 28.2, 28.1, 23.9, 19.4, 18.7.

[0538] Scheme S7. Synthetic route for compound 16.

[0539] Compound 16: To a stirred solution of Cy5.5-NHS ester (25 mg, 0.04 mmol) in anhydrous DMF, tertbutyl (2-aminoethyl)carbamate (2 equiv.) and DIPEA (2 equiv.) were added. The resulting mixture was stirred at r.t. for 30 min, and product formation was monitored via LCMS. Upon completion, the product was purified on reverse-phase HPLC and used for the next step without further characterization. The resulting Cy5.5-Nboc- Amine is dissolved in TFA / DCM (20%) and stirred at r.t for 1 h. Upon complete deprotection the volatiles are removed under reduced pressure. The Cy5.5 is then transferred into a reaction via containing 1 equiv. of benzolactam-activated acid S8 (synthesized as shown in scheme 6.). The resulting mixture is then stirred at r.t for 1 h after which it was purified on reverse-phase HPLC using H2O / MeCN (+0.1% FA) as the mobile phase resulting 21 mg of pure product (47% overall yield). The product formation and isolation was monitored by HPLC. 1H NMR (400 MHz, MeOD) 8 8.47 (s, 1H), 8.39 - 8.27 (m, 2H), 8.23 (dd, J = 8.6, 3.7 Hz, 2H), 8.00 (q, J = 8.3 Hz, 4H), 7.69 - 7.44 (m, 5H), 7.19 - 7.09 (m, 2H), 7.03 (d, J = 7.8 Hz, 1H), 6.96 - 6.86 (m, 1H), 6.72 - 6.61 (m, 2H), 6.55 -6.46 (m, 1H), 6.32 (dd, J = 17.2, 12.7 Hz, 2H), 6.11 (d, J = 1.6 Hz, 1H), 5.63 - 5.58 (m, 1H), 4.88 (s, 2H), 4.18 (q, J = 9.0 Hz, 2H), 3.70 (d, J = 17.7 Hz, 5H), 3.58 (dt, J = 10.9, 5.4 Hz, 1H), 3.52 -3.44 (m, 4H), 3.33 (dq, J = 3.8, 1.9 Hz, 4H), 3.29 - 3.19 (m, 2H), 2.93 - 2.83 (m, 5H), 2.79 (q, J = 5.4 Hz, 2H), 2.67 (d, J = 3.8 Hz, 4H), 2.41 - 2.28 (m, 1H), 1.99 (d, J = 5.0 Hz, 12H), 1.88 - 1.78 (m, 2H), 1.59 (p, J = 7.1 Hz, 2H), 1.47 - 1.35 (m, 1H), 1.05 (dd, J = 10.7, 6.7 Hz, 3H), 0.88 (dd, J = 15.9, 7.6 Hz, 3H). 13C NMR (101 MHz, MeOD) 8 175.2, 174.7, 174.3, 174.1, 168.4, 167.4, 158.5, 152.9, 152.8, 140.2, 139.6, 138.6, 135.7, 133.8, 133.6, 133.5, 133.2, 132.1, 132.1, 132.0, 130.4, 130.3, 129.8, 128.1, 128.0, 127.6, 127.4, 127.4, 126.4, 125.2, 125.0, 124.7, 124.6, 122.0, 110.7, 110.6, 108.6, 107.4, 102.8, 102.5, 72.7, 69.4, 64.4, 59.9, 54.8, 53.9, 51.0, 49.6, 43.5, 39.0, 38.6, 38.5, 36.3, 35.4, 35.1, 30.5, 28.4, 28.2, 27.1, 26.3, 26.1, 25.9, 25.0, 19.4, 18.6.NHZ-PEG4-NHBOC HATU.DSPEA DMF. r.t, 2 h ClTFA / DCM r.t, t h *DMF. DIPEA r.t, 1h\Ho’

[0540] Scheme S8. Synthetic route for compound 17.

[0541] Compound 17: To a stirred solution of JQl-acid (40 mg, 0.1 mmol) in DMF (0.4 mL), HATU (1.5 equiv.), DIPEA (2 equiv.) and NH2-PEG4-NB0C (1.1 equiv.) were added. The resulting mixture is then stirred at r.t for 1 h. Upon completion, the reaction is then diluted with EtOAc and Brine. The organic layer is then collected, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting mixture is dissolved in TFA / DCM (50%), and upon completion, all volatiles are removed under reduced pressure. The resulting crude mixture is then purified on reverse-phase HPLC using FEO / MeCN (+0.1% FA) as the mobile phase and used for the next step without further characterization. To access the final product, the resulting JQ1-PEG4-NH2 is transferred to a stirred solution of activated benzolacatam acid S8 (1 equiv.) and stirred at r.t for 2 h. After the completion of the reaction, the product is purified on reverse-phase HPLC using H2O / MeCN (+0.1% FA) as the mobile phase, which provides 26 mg of pure product (23% overall yield). 1H NMR (400 MHz, MeOD) 87.49 - 7.43 (m, 2H), 7.41 -7.35 (m, 2H), 7.17 (d, J= 6.4 Hz, 2H), 7.03 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 2.5 Hz, 1H), 6.53 (dd, J = 8.4, 2.5 Hz, 1H), 6.14 (d, J = 1.7 Hz, 1H), 5.58 (d, J = 1.7 Hz, 1H), 4.96 (s, 2H), 4.62 (dt, J = 9.1, 4.8 Hz, 1H), 4.16 (s, 1H), 3.67 - 3.34 (m, 28H), 3.34 - 3.23 (m, 3H), 3.19 (dd, J = 6.1, 3.4 Hz, 2H), 2.88 (d, J = 5.9 Hz, 4H), 2.78 - 2.62 (m, 8H), 2.45 - 2.30 (m, 4H), 1.68 (d, J = 4.0 Hz, 3H), 1.05 (d, J = 6.5 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H).13C NMR (101 MHz, MeOD) 8 174.1, 171.4, 167.8, 164.6, 162.5, 158.5, 155.6, 152.8, 150.7, 138.3, 136.8, 136.5, 135.7, 134.0, 133.4, 132.2, 132.1, 131.8, 130.6, 130.6, 130.0, 128.4, 127.6, 126.4, 125.0, 124.8, 124.6, 108.5, 107.3, 72.4, 70.2, 70.2, 70.1, 70.1, 70.0, 69.9, 69.9, 69.4, 69.3, 69.1, 69.0, 64.5, 60.2, 54.8, 54.1, 53.8, 49.4, 39.2, 38.9, 37.6, 37.4, 36.4, 35.3, 28.6, 28.2, 19.4, 18.8, 13.2, 11.7, 10.3.References for Example 1

[0542] [1] G. Vandemoortele, S. Eyckerman, K. Gevaert, Trends in Biotechnology 2019, 37, 1078-1090.

[0543] [2] T. I. Oprea, C. G. Bologa, S. Brunak, A. Campbell, G. N. Gan, A. Gaulton, S. M. Gomez, R. Guha, A. Hersey, J. Holmes, A. Jadhav, L. J. Jensen, G. L. Johnson, A. Karlson, A. R. Leach, A. Ma’ayan, A. Malovannaya, S. Mani, S. L. Mathias, M. T. McManus, T. F. Meehan, C. von Mering, D. Muthas, D.-T. Nguyen, J. P. Overington, G. Papadatos, J. Qin, C. Reich, B. L. Roth, S. C. Schiirer, A. Simeonov, L. A. Sklar, N. Southall, S. Tomita, I. Tudose, O. Ursu, D. Vidovic, A. Waller, D. Westergaard, J. J. Yang, G. Zahoranszky-Kohalmi, Nature Reviews Drug Discovery 2018, 17, 317-332.

[0544] [3] aA. Keppler, S. Gendreizig, T. Gronemeyer, H. Pick, H. Vogel, K. Johnsson, Nat Biotechnol 2003, 21, 86-89; bA. Gautier, A. Juillerat, C. Heinis, I. R. Correa, Jr., M. Kindermann, F. Beaufils, K. Johnsson, Chem Biol 2008, 15, 128-136; cZ. Chen, C. Jing, S. S. Gallagher, M. P. Sheetz, V. W. Cornish, J Am Chem Soc 2012, 134, 13692- 13699; dN. George, H. Pick, H. Vogel, N. Johnsson, K. Johnsson, J Am Chem Soc 2004, 126, 8896-8897; eL. Vivero-Pol, N. George, H. Krumm, K. Johnsson, N. Johnsson, J Am Chem Soc 2005, 127, 12770-12771; fG. V. Los, L. P. Encell, M. G. McDougall, D. D. Hartzell, N. Karassina, C. Zimprich, M. G. Wood, R. Learish, R. F. Ghana, M. Urh, D. Simpson, J. Mendez, K. Zimmerman, P. Otto, G. Vidugiris, J. Zhu, A. Darzins, D. H. Klaubert, R. F. Bulleit, K. V. Wood, ACS Chem. Biol. 2008, 3, 373-382.

[0545] [4] aS. F. Banani, H. O. Lee, A. A. Hyman, M. K. Rosen, Nature Reviews Molecular Cell Biology 2017, 18, 285-298; bB. N. Manz, J. T. Groves, Nature Reviews Molecular CellBiology 2010, 11, 342-352; cM. F. Garcia-Parajo, A. Cambi, J. A. Torreno-Pina, N. Thompson, K. Jacobson, J Cell Sci 2014, 127, 4995-5005; dT. H. Tran, A. H. Chan, L. C. Young, L. Bindu, C. Neale, S. Messing, S. Dharmaiah, T. Taylor, J.-P. Denson, D. Esposito, D. V. Nissley, A. G. Stephen, F. McCormick, D. K. Simanshu, Nature Communications 2021, 12, 1176; eA. Singhal, B. T. Li, E. M. O’Reilly, Nature Medicine 2024, 30, 969-983; fV. P. Mysore, Z. W. Zhou, C Ambrogio, L. Li, J. N. Kapp, C. Lu, Q. Wang, M. R. Tucker, J. J. Okoro, G. Nagy-Davidescu, X. Bai, A. Pliickthun, P. A. Janne, K. D. Westover, Y. Shan, D. E. Shaw, Nat Struct Mol Biol 2021, 28, 847-857; gW. Li, X. Shi, C. Tan, Z. Jiang, M. Li, Z. Ji, J. Zhou, M Luo, Z. Fan, Z. Ding, Y. Fang, J. Sun, J. Ding, H. Lu, W. Ma, W. Xie, W. Su, Nat Chem Biol 2025; hM. J. Henley, A. N. Koehler, Nat Rev Drug Discov 2021, 20, 669-688.

[0546] [5] aS. I. Gould, A. N. Wuest, K. Dong, G. A. Johnson, A. Hsu, V. K. Narendra, O. Atwa, S. S. Levine, D. R. Liu, F. J. Sanchez Rivera, Nat Biotechnol 2024; bX. Ren, H. Yang, J. L. Nierenberg, Y. Sun, J. Chen, C. Beaman, T. Pham, M. Nobuhara, M. A. Takagi, V. Narayan, Y. Li, E. Ziv, Y. Shen, Mol Cell 2023, 83, 4633-4645. e4639; cM. Herger, C. M. Kajba, M. Buckley, A. Cunha, M. Strom, G. M. Findlay, bioRxiv 2024, 2024.2004.2001.587366; dA. Cirincione, D. Simpson, W. Yan, R. McNulty, P. Ravisankar, S. C. Solley, J. Yan, F. Lim, E. K. Farley, M. Singh, B. Adamson, Nat Methods 2025, 22, 92-101; eY. V. Serebrenik, S. E. Sansbury, S. S. Kumar, J. Henao- Mejia, O. Shalem, Genome Res 2019, 29, 1322-1328; fS. E. Sansbury, Y. V. Serebrenik, T. Lapidot, G. M. Burslem, O. Shalem, bioRxiv 2023, 2023.2007.2013.548611; gH. M. Sanchez, T. Lapidot, O. Shalem, bioRxiv 2024, 2024.2009.2016.613361; hY. V. Serebrenik, D. Mani, T. Maujean, G. M. Burslem, O. Shalem, Cell Genom 2024, 4, 100651.

[0547] [6] aJ. Shen, G. Zhou, W. Wang, Chemistry-Methods 2024, 4, e202300051; bS. Singh, W. Tian, Z. C. Severance, S. K. Chaudhary, V. Anokhina, B. Mondal, R. Pergu, P. Singh, U. Dhawa, S. Singha, A. Choudhary, Chemical Society Reviews 2023, 52, 5485-5515; cX. Liu, A. Ciulli, ACS Cent Sci 2023, 9, 1269-1284; dD. L. Buckley, K. Raina, N. Darricarrere, J. Hines, J. L. Gustafson, I. E. Smith, A. H. Miah, J. D. Harling, C. M. Crews, ACS Chem Biol 2015, 10, 1831-1837; eC. Jing, V. W. Cornish, Acc Chem Res 2011, 44, 784-792.

[0548] [7] aC. Y. Wu, K. T. Roybal, E. M. Puchner, J. Onuffer, W. A. Lim, Science 2015, 350, aab4077; bZ. B. Hill, A. J. Martinko, D. P. Nguyen, J. A. Wells, Nat Chem Biol 2018, 14, 112-117; cW. H. Leung, J. Gay, U. Martin, T. E. Garrett, H. M. Horton, M. T. Certo, B. R. Blazar, R.A. Morgan, P. D. Gregory, J. Jarjour, A. Astrakhan, JCI Insight 2019, 5; dG. Giordano-Attianese, P. Gainza, E. Gray-Gaillard, E. Cribioli, S. Shui, S. Kim, M. J. Kwak, S. Vollers, A. J. Corria Osorio, P. Reichenbach, J. Bonet, B. H. Oh, M. Irving, G. Coukos, B. E. Correia, Nat Biotechnol 2020, 38, 426-432; eC. U. Zajc, M. Dobersberger, I. Schaffner, G. Mlynek, D. Piihringer, B. Salzer, K. Djinovic-Carugo, P. Steinberger, A. De Sousa Linhares, N. J. Yang, C. Obinger, W. Holter, M. W. Traxlmayr, M. Lehner, Proc Natl Acad Sci U S A 2020, 117, 14926-14935; fM. Jan, I. Scarf'd, R. C. Larson, A. Walker, A. Schmidts, A. A. Guirguis, J. A. Gasser, M. Slabicki, A. A. Bouffard, A. P. Castano, M. C. Kann, M. L. Cabral, A. Tepper, D. E. Grinshpun, A. S. Sperling, T. Kyung, Q. L. Sievers, M. E. Birnbaum, M. V. Maus, B. L. Ebert, Sci Transl Med 2021, 13; gS. Carbonneau, S. Sharma, L. Peng, V. Rajan, D. Hainzl, M. Henault, C. Yang, J. Hale, J. Shulok, J. Tallarico, J. Porter, J. L. Brogdon, G. Dranoff, J. E. Bradner, M. Hild, C. P. Guimaraes, Cell Chem Biol 2021, 28, 583.

[0549] [8] aT. M. Nguyen, V. Sreekanth, A. Deb, P. Kokkonda, P. K. Tiwari, K. A. Donovan, V. Shoba, S. K. Chaudhary, J. A. M. Mercer, S. Lai, A. Sadagopan, M. Jan, E. S. Fischer, D. R. Liu, B. L. Ebert, A. Choudhary, Nat Chem 2024, 16, 218-228; bJ. A. M. Mercer, S. J. DeCarlo, S. S. Roy Burman, V. Sreekanth, A. T. Nelson, M. Hunkeler, P. J. Chen, K. A. Donovan, P. Kokkonda, P. K. Tiwari, V. M. Shoba, A. Deb, A. Choudhary, E. S. Fischer, D. R. Liu, Science 2024, 383, eadk4422.

[0550] [9] aM. Kawano, S. Murakawa, K. Higashiguchi, K. Matsuda, T. Tamura, I. Hamachi, J Am Chem Soc 2023, 145, 26202-26212; bR. N. Reddi, E Resnick, A. Rogel, B V. Rao, R. Gabizon, K. Goldenberg, N. Gurwicz, D. Zaidman, A. Plotnikov, H. Barr, Z. Shulman, N. London, J Am Chem Soc 2021, 143, 4979-4992; cR. N. Reddi, A. Rogel, E. Resnick, R. Gabizon, P. K. Prasad, N. Gurwicz, H. Barr, Z. Shulman, N. London, Journal of the American Chemical Society 2021, 143, 20095-20108; dT. Tamura, T. Ueda, T. Goto, T. Tsukidate, Y. Shapira, Y. Nishikawa, A. Fujisawa, I. Hamachi, Nature Communications 2018, 9, 1870; eH. R. Tsou, N. Mamuya, B. D. Johnson, M. F. Reich, B. C. Gruber, F. Ye, R. Nilakantan, R. Shen, C. Discafani, R. DeBlanc, R. Davis, F. E. Koehn, L. M. Greenberger, Y. F. Wang, A. Wissner, J Med Chem 2001, 44, 2719-2734; fT. Ueda, T. Tamura, M. Kawano, K. Shiono, F. Hobor, A. J. Wilson, I. Hamachi, Journal of the American Chemical Society 2021, 143, 4766-4774; gR. A. Ward, M. J. Anderton, S. Ashton, P. A. Bethel, M. Box, S. Butterworth, N. Colclough, C. G. Chorley, C. Chuaqui, D. A. Cross, L.A. Dakin, J. Debreczeni, C Eberlein, M. R. Finlay, G. B. Hill, M. Grist, T. C Klinowska, C. Lane, S. Martin, J. P. Orme, P. Smith, F. Wang, M. J. Waring, J Med Chem 2013, 56, 7025-7048; hJ. Zhuang, B. Zhao, X. Meng, J. D. Schiffman, S. L. Perry, R. W. Vachet, S. Thayumanavan, Chemical Science 2020, 11, 2103-2111; iN. London, Chemical Reviews 2025, 125, 326-368; jT. Tamura, M. Kawano, I. Hamachi, Chemical Reviews 2025; kR. Pergu, V. M. Shoba, S. K. Chaudhary, D. N. P. Munkanatta Godage, A. Deb, S. Singha, U. Dhawa, P. Singh, V. Anokhina, S. Singh, S. U. Siriwardena, A. Choudhary, ACS Central Science 2023, 9, 1558-1566; 1A. Birkholz, D. J. Kopecky, L. P. Volak, M. D. Bartberger, Y. Chen, C. M. Tegley, T. Arvedson, J. D. McCarter, C Fotsch, V. J. Cee, J Med Chem 2020, 63, 11602-11614.

[0551]

[0010] K. A. Donovan, J. An, R. P. Nowak, J. C. Yuan, E. C. Fink, B. C. Berry, B. L. Ebert, E. S. Fischer, Elife 2018, 7.

[0552]

[0011] aM. Mosior, A. C. Newton, Journal of Biological Chemistry 1995, 270, 25526- 25533; bS. S. Katti, I. V. Krieger, J. Ann, J. Lee, J. C. Sacchettini, T. I. Igumenova, Nature Communications 2022, 13, 2695; cJ. Das, G. M. Rahman, Chem Rev 2014, 114, 12108-12131.

[0553]

[0012] S. Kawamura, H. Chu, J. Felding, P. S. Baran, Nature 2016, 532, 90-93.

[0554]

[0013] V. M. Shoba, D. N. P. Munkanatta Godage, S. K. Chaudhary, A. Deb, S. U. Siriwardena, A. Choudhary, Angew Chem Int Ed Engl 2022, 61, e202202770.

[0555]

[0014] aT. M. Faraggi, C. Rouget-Virbel, J. A. Rincon, M. Barberis, C. Mateos, S. Garcia- Cerrada, J. Agejas, O. de Frutos, D. W. C. MacMillan, Organic Process Research & Development 2021, 25, 1966-1973; bE. R. Welin, C. Le, D. M. Arias-Rotondo, J. K. McCusker, D. W. C. MacMillan, Science 2017, 355, 380-385.

[0556]

[0015] N. J. Agard, J. A. Prescher, C. R. Bertozzi, Journal of the American Chemical Society 2004, 126, 15046-15047.

[0557]

[0016] X. Zhang, V. M. Crowley, T. G. Wucherpfennig, M. M. Dix, B. F. Cravatt, Nat Chem Biol 2019, 15, 737-746.

[0558]

[0017] P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, T. Keates, T. T. Hickman, I. Felletar, M. Philpott, S. Munro, M. R. McKeown, Y. Wang, A. L. Christie, N. West, M. J. Cameron, B. Schwartz, T. D. Heightman, N. La Thangue, C. A. French, O. Wiest, A. L. Kung, S. Knapp, J. E. Bradner, Nature 2010, 468, 1067-1073.

[0559]

[0018] A. V. Anzalone, X. D. Gao, C J. Podracky, A. T. Nelson, L. W. Koblan, A. Raguram, J. M. Levy, J. A. M. Mercer, D. R. Liu, Nat Biotechnol 2022, 40, 731-740.Example 2

[0560] Specific Aims. Chemogenetic tags, which are fused to protein-of-interest (POI), are genetically encoded sequences typically >150 amino acids (aa) that bind to small molecules, enabling modulating POI that lack small-molecule ligands. Since only ~2-5 % of the proteome[l] possesses small-molecule ligands, such tags have been immensely valuable, but emerging applications require chemogenetic tags that are miniature (< 50 aa), of human origin, and with drug-like ligands. Nanoscale clustering of membrane-associated proteins is a ubiquitous phenomenon and critical for their function. For example, HIV’s viral matrix protein and viral oncogene KRAS, upon myristoylation are translocated to the membrane to form “nanoclusters”. [2, 3] The receptor clustering is also observed in the immune synapse formed between cancer cells and immune cells (e.g., CAR T cells), where intimate contact is established between two cells. Large-size chemogenetic tags significantly disrupt these intimate clusters and immune cell recruitment strategies also require tags of human origin and ligands with drug-like attributes. Finally, CRISPR-based genome-wide screens are turbocharging functional genomics and prime editing technologies are enabling knock-in of ~50 aa sequences. The development of miniature chemogenetic tags compatible with prime editing will usher in a new era of functional chemogenomics. Applicants have develop a miniature chemogenetic tags of human origin that employ drug-like ligands and demonstrate their compatibility with cluster-biology systems and multiplexed prime editing.Development and application of Cl-domain Tag (cTag).

[0561] As noted above, Applicants have developed a cTag system consisting of a Cl domain (50 aa) containing a reactive cysteine and a benzolactam ligand bearing a group transfer linker that can react with that cysteine (Fig. 14A). By fusing cTag to POI, Applicants demonstrated efficient and dose-dependent labeling of POI in cells at low ligand concentration of 20 nM. Furthermore, by fusing cTag to ABL kinase and using a benzolactam ligand that can label cTag with BRD4 binder JQ1, Applicants induced proximity between ABL and BRD4 in cells, leading to the latter’sphosphorylation. Finally, cTag fused to KRASG12D, retained its ability to activate the MAPK pathway.

[0562] Applicants will optimize the on-target engagement, investigate off-targets, generate orthogonal cTags (Fig. 14B), and benchmark (Fig. 14C). Applicants will demonstrate its utility using POIs above and in multiplexed prime editing (Fig. 14C-D). Applicants will leverage extracellular compatibility of cTag by quantitating the impact of tag size on immune synapse formation using CAR T or NK cells and using HaloTag and FKBP12 as controls. Applicants envision these ultra small chemogenetic tags of human origin will find diverse applications in basic research and biomedicine, and in particular immunology.

[0563] Significance: Since ~ 5 % of proteome has small-molecule ligands (and most are enzyme inhibitors), [1] chemogenetic tags have played an outside role in research and biomedicine. Most used non-coval ent tags include eDHFR

[0014] and FKBP12,[1,15] while common covalent tags are HaloTag

[0016] and Snaptag.

[0017] Most of these tags are > 100 aa and are of non-human origin.

[0018] While these tags have been highly impactful, emergent biological discoveries and technologies described below point to the need for miniature tags (< 50 aa) of human origin and with drug-like ligands.Nanoscale receptor clustering and immune synapse

[0564] Receptor clustering is a crucial cellular mechanism that organizes receptors into groups on the cell surface, enabling rapid signal transduction and the activation of multiple pathways. [2,3] For example, the nanoclusters of the HIV protein Nef on the host cell's membrane are promoted via Nef s myristoylation and this clustering is vital for viral replication and downregulating host immune responses. [19-23] Similarly, the Gag protein's matrix domain forms clusters after myristoylation and membrane translocation that initiate HIV assembly and release. [24-27] KRAS clustering at the membrane is also important for its function; its activation through EGFR signaling allows for membrane localization through its polybasic domain and myristoylation, and results in nanocluster formation that allows efficient recruitment of effector proteins. [28,29] Attaching large chemogenetic tags to proteins can disrupt these clusters. For instance, appending HaloTag to KRAS disrupted it localization and function (MAPK pathway activation) whereas cTag, developed in this study, did not, pointing to the importance of size. T-cell activation, in the context of contemporary and emerging immunotherapies, is tightly regulated involving receptor clusteringand fine-tuning of the T cell response after the T cell receptor (TCR) binds to an antigen-loaded MHC molecule. [30,31] Both helper T cells and cytotoxic T cells need extra signals (CD28-B7.1 or B7.2 interactions) to be activated.

[0032] Survival signals, including ICOS,33 4-1BB34, and 0X4035 further enhance immune response. To prevent overactivation and ensure a controlled response, cells utilize CD28- CTLA-4 competition for B7 interactions.

[0036] Thus, a balance between stimulatory and inhibitory signals in clustered receptors is crucial and large tags can impact this delicate tuning of T cell activation.Genome-wide chemogenetic tag knock-in screen using prime editing

[0565] Pooled genome-wide CR1SPR knockout screens have revolutionized functional genomics[37,38] and loss-of-function[39-41] studies by uncovering novel gene functions and disease-relevant targets. These screens involve generation of a pool of cells with each cell having a unique gene knockout that is barcoded. There is a growing need for pooled genome-wide knock-in screening approaches where each cell in the pool will have a unique knock-in at a particular genomic locus. Such knock-in screens can help delineate the impact of disease-associated mutations, gain-of-function mutations, and exploring the functional consequences of tagging or labeling. [42,43] A genome-wide knock-in screen using miniature chemogenetic tags could enable, for example, proximity -based screens.

[0044] Here, one can systematically examine the consequences inducing proximity between two proteins on a genome wide scale (e.g., one ubiquitin ligase against entire genome). However, current prime editing technologies are limited to small insertions (~ 50 aa) and even then the editing efficiencies are low, [45,46] requiring enrichment of edited cells. Here, a miniature chemogenetic tag that covalently links to fluorophore will allow facile enrichment of tagged cells via FACS sorting, a workflow Applicants propose to optimize in the context of multiplexed prime editing.Induced-proximity modalities beyond protein degradation

[0566] Halotag has been immensely useful in induced proximity field (e.g., PROTACs). [47,44] However, the large size of the tag poses challenges while studying induced proximity for protein editing with post-translational modifications (PTMs). The lack of allosteric non-inhibitory binders for the enzymes that regulate these modifications has led many to explore chemogenetic tags for effective manipulation strategies. [47,44] Applicants,

[0048] alongside others,

[0049] have reported that when large chemogenetic tags are used, PTM editing often occurswithin the tag itself, complicating our understanding of its biological consequences. For example, while developing a platform for targeted tyrosine phosphorylation, Applicants found that the HaloTag was being phosphorylated.

[0048] This suggests that larger tags may interfere with desired modifications by competing for PTM induction and smaller tags could minimize unwanted editing and enhance accuracy in studying the biological implications of PTM modifications. Overall, most biological processes occur involve intricate protein regulation in highly condensed systems. Here large tags are disruptive, pointing to the need for miniature tags. Applicants built cTag with druglike ligands.

[0567] Innovation. Applicants propose developing first-in-class miniature chemogenetic tags with drug-like ligands to meet needs in functional biology. These tags, consisting of less than 50 amino acids, can be integrated into proteins without disrupting their activity, eve...

Claims

CLAIMSWhat is claimed is:

1. A chimeric small molecule according to a formula:A- Li-E-T, A-E- Li-T, or A-L1-E-L2-T;wherein A is a protein-tag binding moiety;T is a transfer moiety;Li and L2 are each a linker; andE is an electrophilic reactive group,wherein the chimeric small molecule undergoes a group transfer reaction with the protein-tag resulting in electrophilic transfer of the transfer moiety to the protein-tag and elimination of the protein-tag binding moiety.

2. The chimeric small molecule of any of the preceding claims, wherein the protein-tag bound by the protein-tag binding moiety is derived from a Cl domain of Protein Kinase C (PKC).

3. The chimeric small molecule of claim 2, wherein the Cl domain of PKC is a human Cl domain of PKC.

4. The chimeric small molecule of any of the preceding claims, wherein the protein-tag binding moiety is 12-O-Tetradecanoylphorbol- 13 -acetate (TP A) or a benzolactam analog.

5. The chimeric small molecule of any of the preceding claims, wherein the protein-tag binding moiety is:

6. The chimeric small molecule of any of the preceding claims, wherein the transfer moiety binds a substrate of interest.

7. The chimeric small molecule of claim 6, wherein the substrate of interest is a protein.

8. The chimeric small molecule of claim 7, wherein the protein is BRD4, BRD2, BRD3, FKBP12F36V, tau, alpha-synuclein, HSP27, alphaAC, alphaBC, NF-L, CREB, DDX3X, PFK1, PFKFB3, PGK1, G6PD, KRAS, PKM2, MDH1, FH, KRT18, RRM1, PRPS1, Pol eta, AND-1, FEN1, TOP2A, RAD18, PARG, NRF1, MTA1, YTHDC1, YTHDF1, YTHDF2, MITF, FBL, YAP, LATS2, GLI2, RACK1, HDAC1, M0RC2, STAT3, SLC7A11, FTH, TRFC, c-Jun, ZEB1, TAB3, MEK2, CHK2, PLK1, HGS, SKP2, p27, ZNF263, 0TX2, BMI1,SOX2, FOXA1, DOT1L, p65, STAT5, FOXK1, PDLIM7, FOXO1, CRTC2, PGC-lalpha, ERRgamma, ChREBP, p53, CaMKIdelta, AKT, SAMHD1, STING, IRF5, MAVS, vimentin, STAT6, IKKB, S6K1, RIPK1, RIPK3, GSDMD, or streptavidin.

9. The chimeric small molecule of claim 8, wherein the transfer moiety is:i" >s- ;~o;oJ, ..Ci, or analogs thereof.

10. The chimeric small molecule of any of claims 1 to 9, wherein the transfer moiety is a detectable label or an affinity label.

11. The chimeric small molecule of any of claims 1 to 9, wherein the transfer moiety is an azide, alkyne, biotin, or a cyanine dye.

12. The chimeric small molecule of any of the preceding claims, wherein LI and L2 are independently selected from alkane, alkene, alkyne, amine, ether, thiol, sulfone, carbonyl, acyl, ketone, carboxylate ester, amide, enone, anhydride, imide, PEG, and combinations thereof.

13. The chimeric small molecule of any of the preceding claims, wherein LI and L2 are rigid molecules.

14. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group is selected from N-acyl-N-alkyl sulfonamide (NASA), dibromophenyl benzoate, orN-sulfonyl pyridone.

15. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group is selected from:

16. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group has the formula:wherein Ri is selected from C-O, SO2, Me-C-O, or Me-SCh, R2 is selected from H, alkane, alkene, alkyne, amine, nitrile, nitro, ether, alcohol, thiol, sulfone, sulfonate, halogen, carbonyl, acyl, ketone, carboxylate ester, amide, enone, anhydride, imide, cyclic hydrocarbon, an unsaturated cyclic hydrocarbon, a heterocycle, one or more fused rings thereof; an aliphatic halide such as -OCF2CI or any combination thereof, and the benzene ring is optionally substituted at any position.

17. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group is selected from the group consisting of:O, ,O OxK A N' Me I CNMe*'18. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group is a cysteine reactive electrophilic group selected from the group consisting of:

19. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group is a lysine reactive electrophilic group selected from:Ov ZOxszJ-LR< "N Mewherein Ri is selected from the group consisting of:wherein R2 is selected from the group consisting of:

20. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group is a lysine reactive electrophilic group selected from the group consisting of:21s~2:ll32a-W 23K-i;id Zfla-Sflc «$*. m3a»~sae * 31 a, 3t b 32a S2i 34S. 34L!21. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group iswherein X is selected from the group consisting of:HN-S HO~P=i -0 OiRj R2wherein Rl, R2, R3 each independently comprise of an alkyl group, aryl group, or a heteroatom optionally O, N, or S.

22. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group is23. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group isN O L N A MeI O S^Oior an analog thereof.

24. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group is25. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group isL2 , wherein R is selected from the group consisting of: '■" M " y ’ N ’ ( H O=P-OMe 0=5=0 ,,-^v CR, N S i I O’ 7:>xs^s Ax0''’< ; : XS" o=s=o °Z0 -S' O 6!CF326. The chimeric small molecule of any of the preceding claims, wherein the electrophilic reactive group ishl / ■O~S=0, or an analog thereof.

27. The chimeric small molecule of any of the preceding claims, wherein the protein-tag binding moiety, the transfer moiety, or at least one of LI and L2 comprises a bio- orthogonal group.

28. The chimeric small molecule of claim 27, wherein the bio-orthogonal group is selected from:I T N,artd29. The chimeric small molecule of any one of claims 1 to 9, wherein the chimeric small molecule is:

30. An engineered protein-tag, comprising a Cl domain of Protein Kinase C, wherein the Cl domain comprises a benzolactam binding pocket comprising a cysteine residue.

31. The engineered protein-tag of claim 30, wherein the cysteine residue is located on a surface of the benzolactam binding pocket.

32. The engineered protein-tag of claims 30 or 31, wherein the Cl domain comprises an L254C mutation.

33. The engineered protein-tag of any of claims 30 to 32, wherein the protein-tag comprises no more than 150 amino acids.

34. The engineered protein-tag of claim 33, wherein the protein-tag comprises about 150 amino acids, 145 amino acids, 140 amino acids, 135 amino acids, 130 amino acids, 125 amino acids, 120 amino acids, 115 amino acids, 110 amino acids, 105 amino acids, 100 amino acids, 95 amino acids, 90 amino acids, 85 amino acids, 80 amino acids, 75 amino acids, 70 amino acids, 65 amino acids, 60 amino acids, 55 amino acids, 50 amino acids, 45 amino acids, 40 amino acids, 35 amino acids, 30 amino acids, 25 amino acids, or 20 amino acids.

35. The engineered protein-tag of claim 34, wherein the protein-tag comprises about 50 amino acids.

36. The engineered protein-tag of any of claims 30 to 35, wherein the protein-tag comprises an amino acid sequence of SEQ ID NO: 1.

37. The engineered protein-tag of any of claims 30 to 35, wherein the protein-tag is encoded by a nucleic acid sequence of SEQ ID NO: 2.

38. The engineered protein-tag of any of claims 30-37, wherein the cysteine residue is capable of undergoing group transfer reaction with a ligand comprising a protein-tag binding moiety, an electrophilic linker, and a transfer moiety, whereby the transfer moiety is electrophilically transferred to the protein-tag and the protein-tag binding moiety is eliminated.

39. The engineered protein-tag of claim 38, wherein the ligand is the chimeric small molecule of any one of claims 1 to 29.

40. A protein comprising the engineered protein-tag of any one of claims 30-39, wherein the engineered protein-tag is connected to the protein by chemogenetic fusion or chemical conjugation.

41. The protein of claim 40, wherein the protein is a kinase, a methyl transferase, an acetyltransferase, a glycosyltransferase, an aminotransferase, a phosphatase, a peptidase or protease, a glycosidase, a lipase, a nuclease, an esterase, an amylase, a phosphodiesterase, a dehydrogenase, an oxidase, a reductase, a peroxidase, a hydroxylase, a monooxygenase, a catalase, a decarboxylase, an aldolase, a dehydratase, a synthase, a hyaluronate lyase, an epimerase, a racemase, a mutase, a topoisomerase, a protein disulfide isomerase, a ligase, an aminoacyl -tRNA synthetase, a carboxylase, a synthetase, or a ubiquitin ligase.

42. The protein of claim 41 , wherein the engineered protein-tag does not alter the native functions of the protein.

43. A method of labeling a protein-tag comprising:delivering the chimeric small molecule of any one of claims 1-29 to the proteintag; andtransferring the transfer moiety to the protein-tag via a group transfer reaction that results in elimination of the protein-tag binding moiety,whereby the protein-tag is labeled with the transfer moiety.

44. The method of claim 43, wherein the group transfer reaction occurs between the chimeric small molecule of claim 1 and a cysteine or lysine residue of the engineered protein-tag.

45. A method of modifying a protein comprising:a. expressing a protein comprising the engineered protein-tag of any one of claims 30 to 39;b. delivering a chimeric small molecule comprising a protein-tag binding moiety capable of binding the protein-tag, an electrophilic linker, and a transfer moiety; andc. labeling the engineered protein-tag with the transfer moiety via a group transfer reaction that results in elimination of the protein-tag binding moiety.

46. The method of claim 45, wherein the protein-tag is connected to the protein via chemogenetic fusion or chemical conjugation of the protein.

47. A method of modifying a target substrate in a cell comprising:a. expressing a protein comprising the protein-tag of any one of claims 30 to 39 in a cell;b. delivering a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker, and a substrate binding moiety;c. labeling the protein with the substrate binding moiety and eliminating the proteintag binding moiety via a group transfer reaction;d. inducing proximity between the protein and a target substrate via binding of the substrate binding moiety to the target substrate; ande. modifying the target substrate by the protein.

48. The method of claim 47, wherein the protein is a kinase, a methyltransferase, an acetyltransferase, a glycosyltransferase, an aminotransferase, a phosphatase, a peptidase or protease, a glycosidase, a lipase, a nuclease, an esterase, an amylase, a phosphodiesterase, a dehydrogenase, an oxidase, a reductase, a peroxidase, a hydroxylase, a monooxygenase, a catalase, a decarboxylase, an aldolase, a dehydratase, a synthase, a hyaluronate lyase, an epimerase, a racemase, a mutase, a topoisomerase, a protein disulfide isomerase, a ligase, an aminoacyl-tRNA synthetase, a carboxylase, a synthetase, or a ubiquitin ligase.

49. A method for site-specific protein labeling comprising:a. expressing a protein comprising the protein-tag of any one of claims 30 to 39 in a cell or cell population;b. delivering a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker, and a detectable label or affinity label;c. labeling the protein with the detectable label or affinity label and eliminating the protein-tag binding moiety via a group transfer reaction;d. detecting the labeled protein in the cell or cell population using microscopy or affinity-based detection.

50. A method for endogenous protein degradation screening comprising:a. inserting a nucleic acid encoding the protein-tag of any one of claims 30 to 39 into one or more genomic loci encoding an endogenous protein(s) in a cell or cell population;b. delivering a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker, and a degradation-inducing moiety;c. labeling the endogenous protein(s) with the degradation-inducing moiety and eliminating the protein-tag binding moiety via a group transfer reaction;d. exposing the cell or cell population to a selective pressure;e. identifying cells displaying a phenotype change under the selective pressure; f. sequencing the cell or cell population to determine which tagged endogenous protein(s), when degraded, are associated with the phenotype change.

51. A method for functional screening of induced protein -substrate interactions comprising:a. inserting a nucleic acid encoding the protein-tag of any one of claims 30 to 39 into one or more genomic loci encoding an endogenous protein(s) in a cell or cell population;b. delivering to the cell or cell population a chimeric small molecule comprising a protein-tag binding moiety, an electrophilic linker, and a substrate binding moiety;c. labeling the endogenous protein(s) with the substrate binding moiety and eliminating the protein-tag binding moiety via a group transfer reaction, thereby inducing proximity between the tagged endogenous protein(s) and the substrate;d. identifying cells displaying a phenotype change resulting from the induced proximity;e. sequencing the cell or cell population to determine which tagged endogenous protein are associated with the phenotypic change.

52. A method for functional screening of post-translational modifications comprising: a. inserting a nucleic acid encoding the protein-tag of any one of claims 30 to 39 into one or more genomic loci encoding an endogenous protein(s) in a cell or cell population;b. delivering to the cell or cell population a ligand comprising a protein-tag binding moiety, an electrophilic linker, and an enzyme binding moiety;c. labeling the endogenous protein(s) with the enzyme binding moiety and eliminating the protein-tag binding moiety via a group transfer reaction, thereby inducing proximity between an enzyme capable of catalyzing a post-translational modification and the endogenous protein(s);d. identifying cells displaying a phenotypic change resulting from the induced proximity;e. sequencing the cell or cell population to determine which tagged endogenous protein(s), when modified, are associated with the phenotypic change.

53. The method of any one of claims 44-52, wherein the chimeric small molecule or ligand is the chimeric small molecule of any one of claims 1 to 29.

54. A kit for protein-tagging and proximity-induced molecular transfer comprising: a. a nucleic acid encoding a protein-tag of any one of claims 30 to 39, or one or more nucleic acids encoding one or more proteins comprising the protein-tag;b. a chimeric small molecule comprising a protein-tag binding moiety capable of binding the protein-tag, an electrophilic linker, and a transfer moiety; andwherein the chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety.

55. A kit for conducting programmable nuclease-based protein-tagging screens comprising:a. a vector encoding an RNA-guided programmable nuclease;b. a library of guide RNA templates or vector system for expressing guide RNAs targeting a set of genomic loci encoding endogenous proteins;c. a donor template comprising a nucleic acid sequence encoding a protein-tag of any one of claims 30 to 39;d. a chimeric small molecule comprising a protein-tag binding moiety capable of binding the protein-tag, an electrophilic linker, and a transfer moiety; andwherein the chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety.

56. The kit of claim 55, wherein the RNA-guided programmable nuclease is a CRISPR-Cas, a prime editor, an OMEGA system, a CAST system, a TIGR system, or a non-LTR retrotransposon system.

57. A modular kit for protein-tagging and molecular transfer comprising: a. a nucleic acid encoding a protein-tag of any one of claims 30 to 39, or one or more nucleic acids encoding one or more proteins comprising the protein-tag;b. a set of precursors comprising:i. at least two protein-tag binding moieties;ii. at least two electrophilic linkers;iii. at least two transfer moieties;c. reagents for conjugating the precursors to form chimeric small molecules, wherein each chimeric small molecule comprises:i. a protein-tag binding moiety;ii. an electrophilic linker; andiii. a transfer moiety;wherein the chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety.

58. A kit for cell-based phenotypic screening comprising:a. one or more cell lines stably expressing one or more proteins comprising a protein-tag of any one of claims 30 to 39;b. a library of chimeric small molecules, each chimeric small molecule comprising i. a protein-tag binding moiety;ii. an electrophilic linker; andiii. a transfer moiety;wherein each chimeric small molecule is configured to bind the protein-tag and facilitate transfer of the transfer moiety to the protein-tag with elimination of the protein-tag binding moiety.

59. The kit of any one of claims 54-58, wherein each chimeric small molecule is independently the chimeric small molecule of any one of claims 1 to 29.

60. An electrophilic reactive linker according to the formula Li-E, E-Li, or L1-E-L2, wherein E is an electrophilic reactive group and wherein Li and L2 are linking molecules.

61. The electrophilic reactive linker of claim 60, wherein E reacts with a nucleophilic reactive group.

62. The electrophilic reactive linker of claim 60, wherein E is configured to facilitate attachment of the electrophilic reactive group and all or a portion of Li or L2 to a Cysteine, Serine, Threonine, Tyrosine, Glutamic Acid, Aspartic Acid, Lysine, Arginine, Histidine, or a Methionine amino acid on a polypeptide.

63. The electrophilic reactive linker of claim 60, wherein the linking molecules Li and L2 are independently selected from alkane, alkene, alkyne, amine, ether, thiol, sulfone, carbonyl, acyl, ketone, carboxylate ester, amide, enone, anhydride, imide, PEG, or any combination thereof.

64. The electrophilic reactive linker of claim 63, wherein the linking molecules Li and / or L2 comprise rigid molecules.

65. The electrophilic reactive linker of claim 60, wherein the electrophilic reactive group is selected from:o |..£” 9M'' " >■ / "''N ’TF" ", or analogs thereof.

66. The electrophilic reactive linker of claim 60, wherein E is configured to facilitate attachment of all or a portion of Li or L2 to a cysteine, and wherein E is:! H67. The electrophilic reactive linker of claim 60, wherein E is configured to facilitate attachment of all or a portion of Li or L2 to a lysine, and wherein E is:EiC68. The electrophilic reactive linker of claim 60, wherein the electrophilic reactive linker further comprises a bio-orthogonal group.

69. The electrophilic reactive linker of claim 68, wherein the bio-orthogonal group is selected from tetrazines, triazines, cyclooctenes, cyclopropenes and diazo.

70. The electrophilic reactive linker of claim 68, wherein the bio-orthogonal group is selected from the group consisting of:

71. The electrophilic reactive linker of claim 60, wherein the electrophilic reactive linker is capable of covalently labeling a target polypeptide.

72. The electrophilic reactive linker of claim 71, wherein the covalent labeling comprises covalently bonding to a nucleophile disposed on the target polypeptide.